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Preface 
 
On a molecular level protein – ligand interactions are central to a number of biological 
processes, but its investigation was inherently difficult due to several problems, especially for 
membrane proteins. Usually NMR spectroscopy is valued for its ability to shed light on molecular 
structure, but actually its greatest potential lies in the information that can be provided about 
molecular interactions at an atomic level.1 In the past ten years, a huge amount has been 
published on NMR ligand interactions including numerous reviews.2,3,4,5,6  
In this thesis, we present NMR spectroscopy as a powerful tool for the study of small 
molecule – biomolecule complexes, with a focus on ligand – based strategies. The analysis of this 
type of interactions produces a whole set of challenges, including the characterization of the 
dynamic behaviour and the conformational properties of the ligands in complex with the target 
macromolecules. Membrane proteins change their conformation if extracted from their 
environment. Therefore it is important to work in the biophysical neighbourhood of the 
membrane itself and not in an isotropic extracellular medium.2 
Membrane proteins, in fact, cause problems for the application of NMR-based ligand-
screening methods because of the need to maintain the proteins in a membrane environment. For 
this reason, studies were conducted directly with the proteins embedded in liposomes or micelles. 
This environment can interact with ligands non-specifically and can overlap with ligand signals, 
where the ligand is the observable of our experiments. We, in particular, worked with intact 
tumour cells overexpressing the proteins of interest; also in this case, many experimental 
problems have raised, such as maintaining the cells in suspension, verifying that the interaction is 
not aspecifically, verifying that the protein is in its activate form etc.. Even though the use of NMR 
spectroscopy is highly underdeveloped in the area of drug discovery for membrane proteins and 
                                                           
1 Potenza, D.; Vasile, F. Seminars in Organic Synthesis, “A. Corbella” Summer School, 37th, Gargnano, Italy, June 18-22 
2012, 225 – 248. 
2 a) Meyer, B.; Peters, T. Angew. Chem. Int. Ed. 2003, 42, 864 – 890; b) Mayer, M. and Meyer, B. J. Am. Chem. Soc. 
2001, 123, 6108 – 6117; c) Johnson, M. A. and Pinto, B. M. Carbohydrate research 2004, 339, 907 – 928. 
3 Angulo, J.; Nieto, P. M. Eur. Biophys. J. 2011, 40, 1357 – 1369. 
4 Calle, L. P.; Canada, F. J.; Jimenez-Barbero, J. Nat. Prod. Rep. 2011, 28, 1118 – 1125. 
5 Bhunia, A.; Bhattacharjya, S.; Chetterjee, S. Drug Discov. Today 2012, 17, 505 – 513. 
6 Carlomagno, T. Annu. Rev. Biophys. Biomol. Struct. 2005, 34, 245 – 266. 
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only a few papers treated these systems in their natural environment, these proteins constitute 
the most important class of drug targets, demonstrating the necessity to gain insight into their 
interactions with potential ligands.7 Most of the biomedically relevant proteins as well as about 
30% of the proteins in mammalian systems are membrane bound or integrated proteins and the 
interactions of peptides with these membranes are fundamental to a number of biological 
processes, such as the insertion and folding of peptides in membranes, the rupturing of 
membranes by toxins, the membrane-mediated mechanism of peptide-receptor interactions.7  
A variety of biophysical methods have been developed, such as Surface Plasmon 
Resonance (SPR), isothermal titration calorimetry, fluorescence polarization assay, fluorescence 
resonance energy transfer, enzyme-linked immunosorbent assay etc., but none of them gives 
insight into the binding epitope of the ligand at an atomic level with proteins in their natural 
environment and X-ray, that could theoretically provide this information, can find difficulties to 
crystallize this kind of receptors in an active form.2,8,9 
NMR spectroscopic techniques have emerged as powerful methods to identify and 
characterize the binding activity of ligands with receptor proteins; transferred-NOE (tr-NOE) and 
Saturation Transfer Difference (STD) have gained momentum. Among the ligand-based NMR 
techniques, STD and transferred-NOE focus on the NMR signals of the ligand and utilize NOE 
effects between protein and ligand. These methods do not require labelled protein, since only the 
ligand NMR signals are detected and only a small amount of protein is required. These techniques 
are particularly useful in the medium–low affinity range, therefore they have been adopted to 
detect ligand interactions in various systems. In particular, they are used for: i) the definition of 
the bioactive conformation of the ligand in the bound state (tr-NOESY), ii) the identification and 
characterization of the binding mode of the ligand in membrane proteins with epitope mapping of 
the ligand itself (STD).1,2 These techniques will be better described in Chapter 1.  
In particular, our group is interested in the study of the interaction between membrane 
proteins and small peptidomimetic ligands. Only a few reviews10,11 treated the study of 
                                                           
7 Yanamala, N.; Dutta, B. B. et al. Chem. Biol. Drug Des 2010, 75, 237 – 256. 
8 Cala, O.; Guillière, F.; Krimm, I. Anal. Bioanal. Chem. 2014, 406, 943 – 956. 
9 Dalvit, C. Drug Discov. Today 2009, 14, 1051 – 1057. 
10 Claasen, B.; Axmann, M.; Meinecke, R and Meyer, B. J. Am. Chem. Soc. 2005, 127, 916 – 919. 
11 Meinecke, R. and Meyer, B. J. Med. Chem. 2001, 44, 3059 – 3065. 
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peptidomimetics - membrane proteins interactions in their natural environment. In spite of the 
difficulties, some groups12,13,14,15 have focused their research on biologically relevant transient 
protein - ligand interactions, obtaining significant results in the field and inspiring other groups to 
a further improvement of the methods applied to these complex systems. 
During my PhD, I had the highly qualifying opportunity to grasp these new potent NMR 
methods, trNOE and STD,1,2 and to apply them for assessing small molecule ligand interactions 
with intact tumour cells and isolated proteins. Specifically, two main topics have been addressed: 
1) One part of my PhD thesis was developed within the framework of a PRIN project 
(MIUR PRIN project 2010NRREPL “Synthesis and Biomedical Applications of Tumour-Targeting 
Peptidomimetics”) involving different research units and aimed at the design, synthesis, structural 
analysis and biological evaluation of new peptidomimetic integrin ligands. Integrins are the main 
cell surface receptors mediating cell adhesion to extracellular matrices and one of the best known 
aspects for the inhibition of integrins is their ability to recognize endogenous ligands characterized 
by short RGD (Arg-Gly-Asp) sequences.16 On the base of these information and due to the 
presence of some RGD cyclic ligands in clinical phases, our group developed a small library of 
peptidomimetics containing diketopiperazine scaffolds, known to be a -turn inducer, and the 
recognition RGD sequence. My contribution to the project concerned the application of NMR and 
computational techniques aimed at obtaining a detailed conformational study of the 
diketopiperazine peptidomimetic ligands containing the Arg-Gly-Asp (RGD) and isoDGR sequence, 
but overall a detailed investigation of ligand-receptor interactions with live cells overexpressing 
integrins on their membrane, e. g. platelets and tumour cells. In particular, I set up live cell NMR 
methodologies by using human platelets and investigating the interaction of some RGD 
peptidomimetic ligands with the platelet-specific integrin IIb3. The results of these experiments 
are discussed in the first part of Section 2-Chapter 2. Then, I expanded the live cell NMR study by 
                                                           
12 Mari, S.; Serrano-Gomez, D.; Canada, F. J.; Corbì, A. L.; Jimenez-Barbero, J. Chem . Int. Ed. 2005, 44, 296 – 298. 
13 Meyer, B.; Weimar, T.; Peters, T. Eur. J. Biochem. 1997, 246, 705 – 709. 
14 Bernardi, A.; Arosio, D.; Manzoni, L.; Monti, D.; Posteri, H.; Potenza, D.; Mari, S.; Jimenez-Barbero, J. Org. Biomol. 
Chem. 2003, 1, 785 – 792. 
15Airoldi, C.; Giovannardi, S.; La Ferla, B.; Jimenz-Barbero, J.; Nicotra, F. Chemistry - A European Journal 2011, 17, 
13395 – 13399. 
16 a) Shimaoka, M.; Springer, T. A. Nature Rev. Drug Discov. 2003, 2, 703 – 716; b) Hynes, R. O. Cell 2002, 110, 673 – 
687. 
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using human tumour cells and gaining insight into the interaction of the small library of ligands 
with the tumour-associated integrins V3 and 51 (second part of the Section 2-Chapter 2). The 
NMR results were supported by docking calculations of the ligands in the active site of the 
different integrins and were compared to the results of competitive receptor binding assays and 
competitive cell adhesion experiments.  
2) The second part of my PhD was mainly focused on cadherins, a class of adhesive 
proteins that promotes homophilic interactions. This project, part of a FIRB project coordinated by 
Dr. M. Civera (Computer-aided design, synthesis and biological evaluation of peptidomimetics 
targeting N-cadherin as anticancer agents, MIUR-FIRB “Futuro in Ricerca” RBFR088ITV), benefits 
from different collaborations and aimed at obtaining a thorough understanding of the 
peptidomimetics - cadherin interactions and a full comprehension of their binding mechanism.17 
Our group set out to rationally design and synthesize small peptidomimetic molecules aimed at 
providing partial or total inhibition of the cadherin - cadherin interaction. The rational design of 
mimics of the tetrapeptide sequence Asp1-Trp2-Val3-Ile4 (DWVI), which is the initial part of the 
adhesion arm,18 has been performed by replacing the central dipeptide Trp2-Val3 unit of the DWVI 
adhesive motif with several scaffolds developed in our laboratories.19 An initial computational 
study led to the selection of some promising candidates to be synthesized. Due to the difficulties 
to crystallize small molecule - cadherin complexes, NMR has proved to be a useful method of 
investigation. The NMR study of the interactions was conducted with three ligands and the 
isolated proteins, that a recent paper demonstrates to have a role in tumour progression either if 
embedded in the membrane or free in solution.20 In particular, the interactions between the EC1-
EC2 domain of the two cadherins, E- (epithelial) and P- (placental) and three ligands were 
                                                           
17 Doro, F.; Colombo, C.; Alberti, C.; Arosio, D.; Belvisi, L.; Casagrande, C.; Fanelli, R.; Manzoni, L.; Parisini, E.; Piarulli, 
U.; Luison, E.; Figini, M.; Tomassetti, A.; Civera, M. “Computational design of novel peptidomimetic inhibitors of 
cadherin homophilic interactions” European Journal of Medicinal Chemistry (submitted). 
18 Parisini, E.; Higgins, J. M. G.; Liu, J.-H.; Brenner, M. B.; Wang, J.-H. J. Mol. Biol. 2007, 373, 401 – 411. 
19 a) Manzoni, L.; Arosio, D.; Belvisi, L.; Bracci, A.; Colombo, M.; Invernizzi, D.; Scolastico, C. J. Org. Chem. 2005, 70, 
4124 – 4132; b) Ressurreição, A. S. M.; Bordessa, A.; Civera, M.; Belvisi, L.; Gennari, C.; Piarulli, U. J. Org. Chem. 2008, 
73, 652 – 660; c) Arosio, D.; Belvisi, L.; Colombo, L.; Colombo, M.; Invernizzi, D.; Manzoni, L.; Potenza, D.; Serra, M.; 
Castorina, M.; Pisano, C.; Scolastico, C. ChemMedChem 2008, 3, 1589 – 1603; d) Manzoni, L.; Belvisi, L.; Arosio, D.; 
Civera, M.; Pilkington-Miksa, M.; Potenza, D.; Caprini, A.; Araldi, E. M. V.; Monferini, E.; Mancino, M.; Podestà, F.; 
Scolastico, C. ChemMedChem 2009, 4, 615 – 632; e) Marchini, M.; Mingozzi, M.; Colombo, R.; Guzzetti, I.; Belvisi, L.; 
Vasile, F.; Potenza, D.; Piarulli, U.; Arosio, D.; Gennari, C. Chem. Eur. J. 2012, 18, 6195 – 6207. 
20 Brouxhon, S. M.; Kyrkanides, S.; Teng, X.; Athar, M.; Ghazizadeh, S.; Simon, M.; O’Banion, M. K.; Ma, L. Oncogene 
2014, 33, 225 – 235. 
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examined. The aim of the project, however, is not only the analysis of the ligand epitope, but 
further studies should be done. NMR studies using labeled protein constructs and molecular 
dynamics simulations allowing both ligand and protein flexibility will significantly improve the 
structural understanding of the binding of peptidomimetic ligands to the extracellular domains of 
the cadherins. The combined use of NMR and computational approaches will permit to increase 
the affinity of our ligands for specific cadherins, by optimization of the interactions with the 
receptor. The results obtained for this part of the project are well described in Chapter 3. 
 
The research activities described in the thesis have led to the following publications and 
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Section 1: NMR methods 
 
Drug discovery is a complex and costly endeavor, where few drugs that reach the clinical 
testing phase make it to market. High-throughput screening (HTS) is the primary method used by 
the pharmaceutical industry to identify initial lead compounds. Unfortunately, HTS has a high 
failure rate and is not particularly efficient at identifying viable drug leads. These shortcomings 
have encouraged the development of alternative methods to drive the drug discovery process.1 
Specifically, NMR spectroscopy and molecular docking are routinely being employed as important 
components of drug discovery research; moreover, NMR has demonstrated its utility in fragment-
based drug design, a novel and increasingly popular strategy for lead discovery that provides an 
alternative to conventional high-throughput screening.2,3,4  
NMR spectroscopy and molecular docking are perfectly complementary techniques, and 
were essential for our research. Mono- and bidimensional experiments were useful for the 
attribution and for the conformational studies of the peptidomimetics: 
 TOCSY (TOtally Correlated SpettroscopY),5,6 a method developed specifically for peptides 
that permits to identify protons of the same spin system. 
 NOESY (Nuclear Overhauser Effect SpectroscopY),5,6 useful for the identification of dipolar 
couplings between protons. 
 HSQC (Heteronuclear Single-Quantum Correlation spectroscopy),5 heteronuclear sequence 
1H-13C useful for the identification of proton – carbon coupling (1J). 
For the study of ligand-protein interactions, two are the methods used and these will be 
described in detail in the next paragraphs, tr-NOESY (transferred NOE) and STD (Saturation 
Transfer Difference). 
For the computational studies, the programs and methods used, all based on molecular 
mechanics, are: 
 MacroModel,7,8 with its graphical interface Maestro, used both for the conformational analysis 
(MC/MM) and for molecular dynamics simulations (MC/SD). 
8 
 
 Glide (Grid-based ligand docking with energies),9 used for the identification of the binding 
modes (docking) and for the prediction of the binding affinity (scoring) of the ligands to the 
receptor. 
 
1.1.1 Protein – ligand interactions by NMR 
Nuclear Magnetic Resonance (NMR) spectroscopy has long been a favourite tool of 
chemists interested in host-guest systems because it permits access to a wealth of information 
about the molecular recognition reaction. NMR has evolved dramatically in the last 20 years and, 
in parallel with the development of NMR methods for the determination of protein structure, a 
variety of tools aimed at detecting protein - ligand interactions have been proposed and are being 
now used both in industrial and academic laboratories as valuable tools for structure-based drug 
discovery.10 
Solution-state NMR has become an accepted method for studying the structure of small 
proteins in solution. This has resulted in over 3000 NMR-based co-ordinate sets being deposited in 
the Protein Data Bank. It is becoming increasingly apparent, however, that NMR is also a very 
powerful tool for accessing interactions between macromolecules and various ligands. These 
interactions can be assessed at a wide variety of levels, e.g. qualitative screening of libraries of 
pharmaceuticals, “chemical shift mapping”, dissociation constants, the complete three-
dimensional structure determination of a protein-ligand complex.11 
In the past ten years, a huge amount has been published on NMR investigations of protein 
- ligand interactions, including numerous reviews.12-16 The binding process is regarded as an 
equilibrium condition which results from a balance between association and dissociation events. 
NMR spectroscopy is based on the study of simple parameters such as chemical shift and the 
dipole interactions, which allow to determine both the structure and conformation of the 
molecules examined. These same parameters may be employed to deduce key features of ligand - 
receptor molecular recognition processes. NMR-based methods, in addition, can be applied to 
weak and transient protein - protein or protein - ligand complexes that are difficult to study by 
other structural methods. Theoretically, all NMR spectroscopic parameters can be useful for 
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assessing the binding activity of a ligand to a protein. Actually, only parameters with high 
sensitivity are used: chemical shift, relaxation times, diffusion constants, NOEs, or saturation serve 
as measures of binding.2 
The binding of a ligand to a protein is depicted below. The ligand, L, a small molecule (such 
as a peptide or oligosaccharide) binds reversibly to a protein P. 
 
 
Figure 1.1.1. Ligand - protein equilibrium in a intermolecular exchange process.2 
 
The binding of ligands to macromolecules is an intermolecular exchange process that can 
be evaluated by an association constant, KA or by a dissociation constant, KD, that, for a protein 
with a single binding site, are defined as: 
 
KA = kon / koff = [PL]/[P][L]         Equation 1 
 
KD = [L][P]/[PL] = koff / kon              Equation 2  
 
where [L], [P] and [PL] are the equilibrium concentrations of “free” ligand, “non-bonded” 
protein and complexed state, respectively (Figure 1.1.1.).   
The association constants of typical binding reactions of biomolecules range from 102 to 
1012 M-1. Values for protein - carbohydrate and protein - peptide interactions are typically weaker. 
Since the association rate is usually rapid, limited only by molecular diffusion, dissociation rates 
are also rapid, leading to fast exchange of the ligand between free and bound states.17 These 
conditions, with a KD between >10
-3 and <10-7M, are the typical ones where NMR techniques can 
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be applied. In fact, an advantage of using NMR to measure protein - ligand interaction is that the 
NMR method extends the range of measurable interactions into the mM range, a region not well 
covered by traditional biochemical binding assays. 
The NMR properties of free and bound states are different. The NMR signals from free and 
bound states can be in the “fast” (one averaged signal), “slow” (two non-averaged signals) or 
intermediate exchange regime (broad lines). If KD > 10
-5 M the exchange regime is normally fast, 
while if KD < 10
-6 M, the exchange rate is often slow. koff and (f – b) are key parameters in 
deciding the exchange regime (Figure 1.1.2.).11 As already mentioned, the interaction protein - 
ligand is a dynamic system for which the rate of exchange between free and bound forms is 
decisive for the quantitative NMR assessment of species in solution.  
Chemical exchange in NMR refers to any process in which a nucleus exchanges between 
two or more environments in which its NMR parameters (chemical shift, scalar coupling, dipolar 
coupling, relaxation rate) differ. It is worth remembering that it is considered a very slow exchange 
process that which occurs within seconds, while a fast process is included in the scale between 
micro-and nano-seconds. Figure 1.1.2. shows the time scale related to the NMR parameters and 
to the dynamic processes of the molecules.2 
 
 
 
Figure 1.1.2. Exchange rate relative to chemical shift and constant coupling (top). Time scale in 
NMR dynamics (bottom).2  
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For a system in slow exchange (lifetime is long) on the chemical shift time scale, the 
frequency (or chemical shift) of each environment is sampled before exchange so, solved and 
integrated signals may be expected for the free and bound state (Figure 1.1.2.). In practice, a 
situation of this type is very rare to achieve because of the extreme difficulty to detect and 
integrate μM signals into a complex and crowded spectrum. More generally, systems in fast 
exchange are studied. For these systems the observed NMR response of a ligand (or protein) is the 
mole fractions weighted average of the NMR parameters of the free and bound states.  
 
Mobs = XLML + XPLMPL           Equation 3 
 
Where Mobs is any NMR observable (chemical shift, scalar coupling, dipolar coupling, 
relaxation rate) characteristic of the equilibrium system, XL and XPL are the mole fractions of the 
free and bound ligand, and ML and MPL are the NMR parameters of the ligand in the free and 
bound state, respectively. The mole fractions are defined as:    XL+XPL= 1     and        XP + XPL = 1. 
As mentioned above, this equation is applicable if the exchange is fast on the relaxation 
and chemical shift timescales of the system, namely if koff is larger than the chemical shift 
difference between the free and the bound forms of the ligand (Figure 1.1.3.). Under this 
conditions, only one NMR line is observed (Figure 1.1.3.). The NMR observable Mobs, grown on the 
ligand molecule in the bound state, is transferred to the free ligand and vice versa; this transfer 
process is mediated by a rapid exchange between MPL and ML during the time necessary to 
measure Mobs. The individual populations XL and XPL depend on the KD value and on the 
concentrations of L and P. From equation 3 it is evident that the resonances of the ligand in a 
ligand-target mixture can only be observed if the ligand is in excess with respect to the target.2 
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Figure 1.1.3. In the fast exchange, the frequency domain contains a single signal whose chemical 
shift is a weighted average of the chemical shifts of the two states. 
 
The object of the NMR observation might be the ligand or the protein. Protein – ligand 
complexes are analyzed using the so-called protein-observed and ligand-observed NMR 
experiments in which the NMR parameters of the protein and the ligand, respectively, are 
compared in their free and bound states.2,18  
In protein-observed methods, the most typical parameter and the easiest to follow is the 
chemical shift. Chemical shift perturbations of the protein resonances observed on ligand addition 
are identified to localize the ligand binding site. This enables one to immediately distinguish 
specific from non-specific binding. The 3D structure of the protein – ligand complex can be 
resolved via heteronuclear experiments performed on isotopically labeled (13C, 15N, 2H) protein 
samples. The structure resolution requires molecular dynamics calculations with experimental 
NMR restraints resulting from chemical shifts, scalar couplings, nuclear Overhauser effects (NOEs), 
paramagnetic interactions or dipolar couplings. The major drawbacks of protein-observed 
methods are the experimental time and the need for highly stable and soluble protein. In addition, 
these methods are limited in routine practice to proteins with low molecular masses (less than 30 
kDa) to avoid great effort with regard to both labeling strategies and resonance assignment.19 
Ligand-based methods do not require labelled protein, since only the ligand NMR signals 
are detected and only a small amount of protein is required. These techniques are particularly 
useful in the medium–low affinity range, therefore they have been adopted to detect ligand 
interactions in various systems. Among the ligand-based NMR techniques, Saturation Transfer 
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Difference (STD)  and transferred-NOE focus on the NMR signals of the ligand and utilize NOE 
effects between protein and ligand. Therefore, the STD technique can be used as an epitope 
mapping device to describe the target-ligand interactions, while the trNOE offers easy detection of 
binding events, additionally producing information on the bound conformation of the ligands. In 
addition to tr-NOESY and STD, there are other NMR experiments, based on the Overhauser effect, 
able to screen potential leads from a compound library. WaterLOGSY20 and INPHARMA21 represent 
an example, even if they are less widespread NMR techniques. 
 
1.1.2 tr-NOESY (transferred-NOE) 
The fundamentals of the NOE were described very early in the history of NMR, in a classic 
paper by Solomon published in 1955.22a Solomon’s work then lay almost dormant for some years 
until the advent of double resonance techniques led to the more widespread availability of 
spectrometers having a decoupler. The first paper to demonstrate the power of the NOE in 
structural problems was by Anet and Bourne in 1965.22b In 1972, Balaram et al.22c observed a 
negative NOE enhancement between a protein and a peptide binding to it, and they showed that 
negative enhancements are a general property of large molecules. The second major advance was 
the introduction of the two dimensional NOE experiment, largely by Ernst’s group. These advances 
could not have had the impact they did without developments in instrumental techniques. The 
availability of the first FT spectrometers around 1970, the development of superconducting 
magnets that allow more stability and the advent of dedicated computer permit the diffusion of 
NOE experiments.22  
In order to understand the tr-NOESY experiment, it is important to know the theory of the 
nuclear Overhauser effect (NOE). The nuclear Overhauser effect (NOE) is defined as the change in 
intensity of a certain resonance after perturbation of the population of a spin in close spatial 
proximity (by saturation or inversion). The interaction through space of the dipoles of 
neighbouring nuclei, or cross-relaxation, gives rise to the NOE.17  
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Figure 1.1.4. Nuclear Overhauser effect between two protons closed to space. 
 
The cross-relaxation rate, , governs the magnitude and sign of the NOE. For an isolated 
two-spin system, the change in intensity of spin I after perturbation of spin S is described by 
Solomon (Figure 1.1.5.) equation:  
 
 
Figure 1.1.5. Solomon diagram. 
 
dIZ/dt = - (IZ – IZ0) (W0IS + 2W1I + W2IS) – (SZ-SZ0) (W2IS – W0IS)         Equation 5 
 
where the W factor are transition probabilities (rate constants) for zero-, single-, and 
double-quantum transitions between energy levels of the two-spin system, as shown in Figure 
1.1.5., and IZ and SZ are the longitudinal components of the magnetization of spins I and S. 
Transitions between the energy levels are stimulated by transient local magnetic fields induced by 
the dipoles of the spins tumbling past each other. The W transition probabilities (rate constants) 
therefore depend on the rate of molecular tumbling. The term W2IS is the rate constant for double-
quantum transitions and is stimulated by local magnetic fields fluctuating at frequencies of 20 
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(the frequency difference between the  and  energy levels); therefore, it is greatest if the 
rate of molecular tumbling is rapid. This term gives rise to positive NOE enhancements. The term 
W0IS describes zero-quantum transitions, and is stimulated by fields fluctuating at very low 
frequencies (I – S ~ 0); this term gives rise to negative NOE enhancements. The term (W2IS – W0IS) 
in the Solomon equation is the overall rate constant for dipole-dipole transitions giving rise to the 
NOE, or cross-relaxation; this term is known as the cross-relaxation rate constant, IS. The term 
(W0IS + 2W1I + W2IS) is the dipolar longitudinal relaxation rate constant of spin I, or IS. An 
expression for the steady-state nuclear Overhauser effect (NOE), the change in I spin intensity on 
saturation of spin S (abbreviated fI{S}), may be derived by setting dIZ/dt = 0 and SZ = 0. Since S0Z = 
(S/I)I0Z, 
 
fI{S} = (IZ – I0Z)/I0Z = (S/I) * ((W2IS – W0IS)/(W0IS+2W1I+W2IS)) = (S/I)*(IS/IS)         Equation 6 
 
When the dependence of the W rate constants on the precession frequencies of the spins 
() and on the molecular tumbling rate (defined by the rotational correlation time, C), is 
incorporated into the above expression, the result is, 
 
fI{S} = (S/I) * ((5 + 
2c
2 – 4 4c
4)/(10 + 232c
2 + 44c
4))         Equation 7 
 
which reduces to 0.5 *(S/I) for small molecules tumbling rapidly (C << 1); and to -1 * 
(S/I) for large molecules tumbling slowly (C >> 1). NOE enhancements are expected to be 
positive for small molecules, and negative for large molecules. In practice, the most useful 
information is obtained from transient NOE experiments, rather than from steady-state NOE 
experiments. From transient NOE experiments, NOE buildup rates, governed by IS, are measured. 
The initial rate of NOE buildup is directly proportional to IS. In addition, the relative values of IS 
provide a measure of internuclear distances, because the dipole-dipole interaction, which gives 
rise to cross-relaxation, has a strong dependence on distance (r-6).17 
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Transferred NOE is a transient NOE experiments.12,23-26 In this experiment, the system is 
excited by high frequency pulses. During this mixing time the intra- and intermolecular 
transferred-NOEs build up where the intermolecular trNOEs are usually much larger than 
intramolecular effects. Tipically, the 2D-NOESY experiment is used to detect transient NOEs and 
consequently the tr-NOESY. trNOE has the potential to offer easy detection of binding events, 
additionally producing information on the bound conformation of the ligands. This approach 
provides key information on the ligands’ binding mode in the natural environment and allows to 
deduce information on the structural requirements of the ligand in the bound state. Transferred 
intramolecular NOEs are well established as unique sources of structural information on bound 
ligand. 
The observation of trNOEs relies on different tumbling times τc of free and bound 
molecules. Low- or medium-molecular-weight molecules (MW<1000–2000) have a short 
correlation time τc and, as a consequence, such molecules exhibit positive NOEs, no NOEs, or very 
small negative NOEs depending on their molecular weight, shape, and the field strength. Large 
molecules, however, exhibit strongly negative NOEs.27 When a small molecule (ligand) is bound to 
a large-molecular weight protein (the protein receptor molecule) it behaves as a part of the large 
molecule and adopts the corresponding NOE behavior, that is, it shows strong negative NOEs, so-
called trNOEs. These trNOEs reflect the bound conformation of the ligand. Binding of a ligand to a 
receptor protein can thus easily be distinguished by looking at the sign and size of the observed 
NOEs. Furthermore, the discrimination between trNOEs originating from the bound state and 
NOEs of the ligand in solution can also be achieved by the build-up rate, that is, the time required 
to achieve maximum intensity, which for trNOEs is in the range of 50 to 100 ms, whereas for 
nonbinding molecules it is four- to ten-times as long (Figure 1.1.6.). 
Critical parameters for this experiment are: 
a) Mixing time. The mixing time must be short enough so that the contribution of the free ligand is 
negligible and long enough to allow visualization of the signal in the spectrum.  
b) The molar ratio of ligand to receptor. It should be emphasized that the tr-NOESY experiment 
works well for ligands that have KD in the M - mM range. 
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c) Spin diffusion. Although the intermolecular spin diffusion is present in every system, it is smaller 
in magnitudo than intramolecular spin diffusion and should not affect the determination of 
peptide ligand structure.28 In addition, spin-diffusion-mediated cross-peaks can be detected by 
employing tr-ROESY experiments, due to the alternation of sign between direct and indirect 
effects.29 
tr-NOESY is a robust complement to the STD method. Initially, tr-NOESY experiment was 
used for screening mixtures of carbohydrates that had potential binding affinity for a lectin, 
Aleuria aurantia agglutinin (AAA).23 Then, the tr-NOESY method was also successfully applied to 
characterize the conformation of natural products bound to different proteins.30 
 
 
Figure 1.1.6. Schematic view of the tr-NOESY experiment. NOESY technique shows slow NOE build-
up with weak positive maxima for free small ligands (left, cross-peaks with the opposite sign of the 
diagonal). tr-NOESY shows strong negative maxima for the bound state (medium, cross-peaks with 
the same sign of the diagonal). The analysis of these negative cross-peaks provides information on 
the bound geometry of the ligand. The tr-NOESY has the potential to offer easy detection of 
binding events, additionally producing information on the bound conformation of the ligands. On 
the right, the graphic of NOE % as a function of the correlation time is reported. 
 
In conclusion, for a small molecule ligand binding reversibly to a protein, fast exchange on 
the “relaxation time scale” implies that koff is greater than s, in both the free and bound states of 
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the ligand. This condition leads to averaging of the cross-relaxation rate, and therefore of the 
observed NOE, between the ligand free and bound states: 
 
OBS = pB*B + pF*F,         Equation 8 
 
where pB and pF are the fractions of bound and free ligand. This leads to the phenomenon 
of the transferred nuclear Overhauser effect, which allows the determination of bound-ligand 
conformations. The transferred nuclear Overhauser effect (trNOE) refers to the observation of 
negative NOE effects, representative of the bound conformation, for a small-molecule ligand in 
solution with a protein, in contrast to the positive NOE effects normally expected for a small 
molecule in the absence of protein. Since B is much greater than F, OBS is dominated by B even 
with an excess of free ligand: 
pBB >> pFF 
OBS ≈ pBB 
The large, negative NOE effects which develop when the ligand is bound to the protein are 
transferred from the bound to the free state of the ligand by chemical exchange. This allows 
transferred NOE effects to be measured on smaples containing a mixture of the protein and an 
excess of free ligand.17  
The sequence used for our experiments is the so-called “noesyesgpph”; it is a gradient-
based phase-sensitive 2D NOESY with excitation sculpting.31 
 
Figure 1.1.7. noesyesgpph sequence used for our experiments; d1 corresponds to the relaxation 
delay (typically few second, 1- 5 times than T1), d0 is an increment delay, d8 is the mixing time 
(usually fixed at 200 ms or 700 ms), sp1 is the shape pulse for selective excitation.  
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1.1.3 STD (Saturation Transfer Difference)2 
Saturation transfer NMR was a pioneering technique developed in 1979 by Wuthrich’s 
group32 to obtain resonance assignments of the heme group in oxidized cytochrome c-557 from 
Crithidia oncopelli. After twenty years, in 1999, Mayer and Meyer33 proposed the same STD 
technique to elucidate ligand binding to the receptor. STD-NMR is one of the most widespread 
NMR methods to study the interactions between small ligands and macromolecular receptors.  
 
 
Figure 1.1.8. Illustration of the 1D STD-NMR experiment applied to a sample containing a protein 
receptor in the presence of small ligands in molar excess. The experiment provides for the 
acquisition of two 1D NMR spectra: a standard 1H-NMR (off resonance) spectrum (top), and a 1H-
NMR (on resonance) spectrum with selective saturation of receptor proton signals (medium). If 
protein–ligand 1H–1H distances are short enough, the magnetization of protein proton can be 
transferred to a small molecule by intermolecular NOE. The difference spectrum (STD) will only 
show the signals of the ligand protons which have been in intimate contact with the receptor 
(bottom). 
 
Originally proposed as a technique for the rapid screening of compound libraries, its scope 
has been extended to determine the ligand regions in contact with the receptor (epitope 
mapping).34 The method is based on the transfer of saturation from the protein to the bound 
ligand which in turn, by exchange, is moved into solution where it is detected (Figure 1.1.8.). 
During the period of saturation, the magnetization gradually moves from the protein to the 
protons of the ligand when the ligand binds to the target. This saturation process is very efficient, 
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so the modulation of the ligand signal induced by the protein is readily detected, even in the 
presence of a large excess of ligand. The ligand protons nearest to the protein are most likely to be 
saturated to the highest degree, and therefore have the strongest signal in the mono-dimensional 
STD spectrum. The ligand protons located further away are saturated to a lower degree, and their 
STD intensities are weaker. Therefore, the degree of saturation of individual ligand protons 
(expressed as absolute-STD percent)  reflects their proximity to the protein surface and can be 
used as an epitope-mapping method to describe the target-ligand interactions (Figure 1.1.8.). 
Moreover, the sensitivity to discriminate between binders and non binders is excellent, and this 
experiment has been successfully used to identify ligands with binding activity from multi-
component mixtures.12 The STD experiment is implemented as a difference experiment (Figure 
1.1.8.). Two mono-dimensional spectra are acquired: one with selective excitation of the protein 
turned on, and one where the selective excitation is moved to an empty spectral region. If the 
irradiation conditions are adequately chosen, it is possible to saturate very efficiently only protons 
of the protein, but not those of the ligand. In this situation, if binding occurs, magnetization from 
the receptor protons will be transferred to ligand protons that are close in space in the bound 
state. For transient interactions with rapid exchange, the ligand polarization in the bound state is 
transferred to the free state where the saturation accumulates during the irradiation time of the 
experiment. In fact, the enthalpic relaxation of a molecule of low molecular weight, is much slower 
than the kinetic constant koff of the binding process. The difference spectrum will show only the 
signals of ligands that were at some time associated with the protein. For non binding molecules, 
the intensity of the two spectra (on- and off-resonance) is the same and their difference spectrum 
cancels out.  
Figure 1.1.9. shows the STD pulse sequence associated with the sequence Watergate for 
water suppression. The subtraction of the spectra can be obtained by the phase cycling after every 
scan. The saturation of the protein is obtained by a selective pulse, usually a Gaussian pulse is 
used because it reduces the side band problem and excites uniformly the region of signals. In 
addition, it is preferred to apply a train of pulses of the duration of 50 ms each with intervals of 1 
ms, instead of using a long selective pulse. The times of saturation are in the range of 1-3 seconds. 
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Figure 1.1.9. Pulse sequence for 1D-STD experiment associate with Watergate sequence (water 
suppression).2 
 
In STD NMR experiments, a sample should contain the ligand (in a large molar excess, from 
10:1 to 100:1) and the receptor (large molecules with MW > 15 KDa). Generally, the sample 
containing the protein is irradiated in the area of the aromatic protons or in the area of the 
spectrum between -2 and 1 ppm (valine, leucine and isoleucine residues), then the radiation is 
spread on all the protein residues exploiting the spin diffusion phenomenon. Once chosen the 
frequency of radiation, the protocol provides for the acquisition of an STD experiment on a sample 
containing only the ligand. In this way, the presence of artifacts due to Overhauser effects 
between the protons of the ligand can be excluded. 
STD experiments have enormous potential, they have been used to select, with success, 
libraries of both natural and synthetic compounds, also using immobilized receptors.35 The STD 
NMR technique may be applied to a large variety of systems, from medium-size receptors to large 
entities, such as viruses,36 bacteria and even intact cells.37-39  
In the first STD experiments, the interactions between a protein receptor and 
carbohydrates were studied.23,29,38 These systems are characterized by low binding affinities (the 
dissociation rate constant KD was in the micro-molar range) and generate a substantial saturation 
transfer. Among others, the groups of Jimenez-Barbero and Meyer23,24,25,33,34 have focused their 
research on biologically relevant transient protein – carbohydrate interactions. 
The STD technique was also applied to study the interaction between protein receptors 
and peptide ligands.34,39 Usually, a set of compounds is screened with a target receptor, in other 
cases the ability of a ligand to interact with similar binding sites within a single protein is studied. 
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Often, peptide ligands show a dissociation constant (KD) in the nM range. Then, the study of these 
systems becomes difficult with NMR-STD technique because it is the limits of the detection. 
Furthermore, in our cases the proteins of interest are proteins whose function is strongly related 
to their conformation (for example, the proteins expressed on the cell membrane). So, the STD 
experiments must be directly recorded on samples containing a suspension of living cells without 
having to isolate the receptor protein. In this respect, a second generation of STD, termed STDD 
(saturation transfer double difference) has become a tool in the epitope mapping of drug 
molecules. In STDD, a STD spectrum of a cell plus ligand system is recorded. Then another 
spectrum containing only the cell is recorded at the same concentration as the previous spectrum. 
Next, a difference spectrum of these two systems is computed to perform the epitope mapping of 
drug, bound to the cell.  
The intensity of the STD signals depends, among other things, on the irradiation 
time/saturation time and on the excess of ligand molecules used. The more ligand that is used and 
the longer the irradiation time the stronger the STD signal is.  The ligand protons nearest to the 
protein are most likely to be saturated to the highest degree, and therefore have the strongest 
signal in the STD spectrum; whereas the ligand protons located further away are saturated to a 
lower degree, and their STD intensities are weaker. Therefore, the degree of saturation of 
individual ligand protons (expressed as absolute-STD percent)12,33 reflects their proximity to the 
protein surface and can be used as an epitope-mapping method to describe the target–ligand 
interactions.  
All STD intensities depend on the duration of radiofrequency irradiation of the protein 
(saturation time), and the extent of saturation transferred to the ligand protons generally 
increases with this time.33 The ligand group epitope mapping by STD intensities is typically 
obtained for a given saturation time (normally of the order of seconds). Ideally, epitope 
information would not depend on the chosen saturation time. However different relaxation rates 
of the ligand protons can produce artifacts in the epitope definition. Because all artifacts are 
consequences of differences in the ability to accumulate saturation in the free state, a way to 
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cancel them is to derive STD intensities close to zero saturation time, or to calculate the initial 
slope of a curve builded up at different saturation time.13 
 
Determination of binding constants 
The dissociation constant (KD) (Equation 2) which describe protein–ligand interaction can 
be obtained from STD NMR spectra. At equilibrium, the fraction of proteins bound to the ligand fp’ 
is given by  
  
fp’= [PL]/([PL]+[P])        Equation 9 
 
The combination of equations (2) and (9) yields 
 
fp’= [L]/([L]+KD)         Equation 10 
 
Equation 10 is one of the fundamental equations that elucidate the outcome of the NMR 
experiment. It shows that increasing the ligand concentration [L] increases the fractional 
occupation fp’ of the receptor-binding site according to a hyperbolic function of [L]. In the limit [L] 
<< KD, the fractional population of the ligand is directly proportional to its concentration. In the 
opposite limit [L] >> KD, the protein receptor is completely saturated by the ligand (fp’ = 1). The 
interesting situation occurs when [L] ≈ KD and the receptor is half-saturated; that is, half of the 
receptor molecules exist in a one-to-one complex with the ligand. Therefore, ligands with weaker 
affinity have larger KD and require the addition of more ligand to saturate the receptor-binding 
site. Thus, by adjusting the receptor and ligand concentrations, it is possible to “select” the 
maximum KD to obtain an optimum observable NMR signal. Such a tuning of the detection 
threshold is very useful in ligand-based screening experiments and in particular in STD 
experiments for screening large compound libraries. At equilibrium, the transient presence of the 
ligand molecule at the protein site is responsible for chemical exchange, a parameter that is used 
only by NMR methods in ligand-screening experiments. 
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STD can be used for KD ranging from 10
-3 to 10-8M. Operatively, the value of KD can be 
obtained from the initial growth rate of the STD amplification factor. Since the STD-NMR intensity 
reflects the concentration of ligand-receptor complex in solution,12,33 Mayer and Meyer34 
proposed a conversion rule from the observed experimental intensities (I0-Isat/I0) to the STD 
amplification factors (STD-AF), that is by multiplying the observed STD by the molar excess of 
ligand over protein (). 
STD-AF = (I0-Isat)/I0=STD         Equation 11 
This converts the STD intensity, which depends on the fraction of bound ligand, into a 
factor (STD-AF) that is function of the fraction of bound protein. Thus, the evolution of the STD-AF 
along a ligand titration series enables construction of a saturation curve in the form of an 
association isotherm. These curves can be adjusted by means of Equation 10 and the value of KD 
results from the mathematical fit of the experimental curve. In various cases, however, apparent 
KD values obtained from STD NMR titrations have been shown to depend strongly on experimental 
conditions (e.g., saturation time, relative concentration of species, monitored proton).  
Angulo et al.40 showed that the origin of such discrepancies can be found to be the fast 
ligand rebinding in solution, where a previously saturated ligand molecule returns to the complex 
(bound state) before its perturbed polarization (i.e. saturation) has completely relaxed back to 
equilibrium. This means that the strongest effect will be observed for low ligand-to-protein ratios, 
as typically found during the initial steps of a titration series (starting at the lowest ligand 
concentration). This dependence on the fraction of bound ligand also explains why such artifacts 
in KD determination are stronger for systems with larger affinity (the biases typically increase from 
mM to nM interactions), and for titrations with larger protein concentrations. After careful study 
of the artifacts introduced by the different experimental conditions of the STD NMR experiment, 
Angulo et al.40 concluded that: 
1. STD data overestimate KD, and so its value is always grater (or equal) than true 
thermodynamic value. 
2. the protons with largest STD intensities give greater discrepancy. 
3. the discrepancy is higher for largest protein concentration (low ligand/protein ratio) 
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The accurate determination of dissociation constants requires the removal of all effects 
from fast protein – ligand rebinding in solution. Because these effects are related to the 
accumulation of saturated ligand in the bulk solution, they are minimized as sat approaches 0. As 
for determination of ligand epitopes, this requires determination of the initial slopes of the build-
up curves of STD-AF values with the saturation time. The procedure for exact KD determination
30 
involves the initial slopes of a curve recorded with sat-dependent STD-AF for each ligand 
concentration (instead of just one STD NMR experiment at a single saturation time, as suffices for 
epitope mapping). 
 
1.1.4 Water suppression sequences 
The experiments conducted during my thesis were performed both in a H2O/D2O 9:1 and in 
a phosphate buffer solutions. So, we need pulse sequences that permit to eliminate the effects of 
the huge water resonance on the quality of the spectrum.  
The solvent signal suppression technique can be divided into:  
a) Saturation based methods: discrimination by frequency or by relaxation times. 
b) Methods avoiding solvent saturation 
c) Magnetization Destruction-Based Methods 
d) Coherence Selection 
e) Postacquisitional Methods 
The proton signals of the water solvent fall at around 4.7 ppm, overlapping at all the signals 
that fall in the range between 4.5 and 4.9 ppm. For the STD experiments we used the suppression 
sequence called WATERGATE (Water suppression by GrAdient Tailored Excitation),41 while for the 
mono- and bidimensional experiments (TOCSY, NOESY) we used the Excitation Sculpting technique 
(DPFGSE, Double Pulse Field Gradient Spin Echo);42 this last is an improvement of the WATERGATE 
sequence where a second spin echo sequence with gradients is added to cancel phase errors. 
One of the simplest and widely used ways to eliminate a strong water signal is to use 
presaturation.43 
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Figure 1.1.10. Solvent suppression by presaturation. 
 
In this technique, the transmitter is set to the water resonance; a very long (seconds) low 
power (mW) pulse is given. The excitation profile of this pulse is very narrow due to its length and 
it saturates the water resonance at the transmitter frequency. A non-selective hard 90° pulse is 
then given to place all remaining spin in the transverse plane for detection. 
WATERGATE43 is widely used in many complicated pulse sequences. Unlike presaturation 
which irradiates the water resonance with a long low power pulse, this method is based on the 
gradient spin echo technique. 
 
 
Figure 1.1.11. Water suppression with WATERGATE. 
 
The transmitter frequency is set on the water resonance. A non-selective hard 90° pulse is 
applied followed by a 1-2 msec gradient pulse. The gradient pulse dephases all of the resonances. 
A composite pulse (consisting of 6 hard pulses separated by a delay, ) is then applied which acts 
as a 180° pulse for everything except peaks on resonance (i.e. water) and any peaks at frequencies 
n/ away from the transmitter, where n is an integer. t is chosen such that 1/ lies outside of the 
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spectral width (typically several hundred sec). The second gradient pulse (equal in magnitude, 
duration and sign, to the first) further dephases the water resonance at the center of the spectrum 
which was unaffected by the composite pulse, but rephases everything else which was inverted by 
the composite pulse. The gradients and composite pulse act as a gradient spin echo for all. The FID 
is then collected with the water resonance suppressed by the two dephasing gradients. 
 
Section 2: Computational methods 
 
1.2.1 Molecular Mechanics (MM) 
In a quantum mechanical description of a molecule, electrons need to be included. Thus a 
very large number of particles must be considered in order to fully describe the system. 
Calculations performed at a quantum mechanical level are very time consuming and a different 
approach is needed when dealing with molecules bigger than a few tens of atoms. Molecular 
mechanics is then invariably used in this case. Molecular mechanics is based on the validity of two 
main assumptions: 
 the Born-Oppenheimer approximation and the Potential Energy Surface 
 Force fields 
While the Born-Oppenheimer approximation enables the possibility of writing the potential 
energy of the system as a function of the nuclear coordinates, discarding the electrons, the force 
fields give a functional form to the description of the potential energy. 
The Born-Oppenheimer approximation is the basis of all methods of molecular modeling. It 
states that the electronic and nuclear motions can be separated, because the mass of the 
electrons is much smaller and hence they can rapidly adjust to any change in the nuclear position. 
This allows to calculate the energy of a molecule as a function of the nuclear coordinates only.  
Energy changes that are associated to a variation of the nuclear position can be considered 
as movements on a multidimensional surface, which is called the Potential Energy Surface (PES).44 
Each point on the PES represents a molecular conformation characterized by its structure and 
energy. Stationary points on the PES are points where the first derivative of the energy is zero with 
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respect to the coordinates. Minimum points are one type of stationary point and correspond to 
stable conformations of the molecule. Defining the shape of a molecule implies locating all the 
accessible minima and assigning them a relative energy, and hence a probability factor.  
A molecular mechanics (MM) program uses a Force Field (FF) to define a PES for each 
molecule and to calculate an energy value for every combination of the system coordinates. 
In the approach of molecular mechanics (MM) a molecule is seen as a collection of atoms, 
held together by forces. The forces acting between atoms have the classical form of a potential 
energy function and contain parameters which are determined empirically. The collective action of 
the interatomic forces generates the force field which describes the molecule’s potential energy.  
The overall potential energy of a molecule, its steric energy, is obtained as a linear 
combination of independent terms originating from interatomic interactions, and its qualitative 
formulation is as follows: 
 
Equation 1 
The various terms reflect the origin of the model in vibrational spectroscopy and are defined as: 
 Estretch = Stretch energy over all bonds 
 Ebend = Bending energy over all angles 
 Etorsion = Torsional (dihedral) energy (over all dihedral angles) 
 EVdW = Van der Waals energy (over all atom pairs ≥ 1,4) 
 Eelectrostatic = Electrostatic energy (over all charged atom pairs ≥ 1,4) 
Mixed terms, such as stretch-bend or torsion-stretch energies may also be included. The 
VdW term and the electrostatic term act between atom pairs which are separated by at least 
three bonds, and hence are often called the non-bonded interaction terms. Thus, a MM force field 
is a collection of parametric potential energy functions that describe interatomic interactions. The 
different force fields are defined by the functional form chosen for the energy functions and by 
the values of their parameters. It must be stressed that there is no such thing as “the best form” of 
a FF: force fields are empirical, and are evaluated exclusively on the basis of their performance. 
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Furthermore, different force fields have often been developed with different molecular properties 
or different types of molecules in mind, and their performance will vary accordingly. 
A typical form of a force field is shown in Equation 2, where the various terms represent 
the different forces acting between pairs of nuclei:44 
 
Equation 2 
 
The first two terms, the stretching and bending forces, are the simplest to visualize. They 
correspond to the familiar IR stretching and bending vibrations and act to return the related 
structural parameters, bond length and bond angles, to their equilibrium values I0and Ө0. Thus, 
the equilibrium value of the structural parameter, for instance the equilibrium bond length I0, is 
seen as the “natural” value for that specific bond and each deviation from this ideal state, caused 
by perturbations from the rest of the molecule, will increase the overall energy of the molecule. 
The size of the increase will be determined by the value of the associated force constant k and will 
be returned by the MM calculations as the stretch energy for the conformation been calculated. 
Both the force constant k and the equilibrium values of bond length and angles, l0 and Ө0, are 
parameters of the FF. Depending on the FF, the values of l0 and Ө0 can be derived from 
experimental data (X-ray, electron diffraction, MW spectroscopy etc.) or from high-level molecular 
orbital calculations and the values of the force constants can be optimized by trial and error and 
by least square methods. 
The fourth term is the non-bonded term and is calculated between all pair of non-bonded 
atoms, i.e. all the atoms that are separated by more than two bonds. This term is usually modeled 
using a Lennard-Jones potential for van der Waals interactions and a Coulomb potential term for 
the electrostatic interaction. As expected for a model which ignores the existence of electrons in 
molecules, the electrostatic term is particularly difficult to handle. In general, a Coulomb potential 
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is used and is calculated by assigning to each atom or atom type a partial atomic charge, which is 
often obtained by fitting to the electrostatic molecular potential obtained from QM calculations. 
The third term is a torsional potential, that models how the energy changes as a bond 
rotates. Physically, the rotation barriers about chemical bonds are generated by attractive or 
repulsive interactions which, in principle, could be accounted for by the non-bonded interaction 
terms. However, most FF do include explicit torsional potential terms, which are used to model 
correctly the known energy profiles for rotation about a given type of bond. 
The different FF may vary in the way the parameters are obtained and optimized, as well as 
in the form of some of the potential terms. In all cases, it is assumed that the value of the 
parameters is transferable, that is that a given atom or combination of atoms will behave similarly 
in different molecules. 
The best known FF are MM2, MM3 and MM4 (Allinger et al.), parameterized for many 
functional groups and for modeling hydrocarbons, AMBER (Kollman),45 OPLS_AA (or OPLS_2001, 
Jorgensen)46 and CHARMM, parameterized for proteins and nucleic acids and used to model 
molecular dynamics of biomolecules. They mainly differ in: 
 Force Field of the first class, mainly developed for the treatment of extended systems 
(proteins or DNA). Armonic functions are used for the stretching or bending terms and the cross-
interaction terms were implicitly kept into consideration. 
 Force Field of the second class, mainly developed for the treatment of small/medium 
molecules with high accuracy. These FF explicit the cross-interaction terms, use exponential terms 
for the Van der Waals energy and expansion of third or fourth degree for the bending and 
stretching terms. 
In particular, OPLS_2001 and OPLS_2005, both belonging to the first class Force Field, were used in 
the thesis. 
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1.2.2 Solvation Models: the implicit water GB/SA solvation model44 
Most chemical processes occur in solution, and, although many molecular modeling studies 
are still carried out without including solvation models, the solvent medium can have a major 
effect on molecular structures and energies. This is particularly important for the study of 
biological interactions which take place between polar molecules in the presence of water. 
The simplest and crudest way of including solvent-related effects in molecular mechanics 
calculation is to increase the dielectric constant in the coulombic electrostatic term of the 
potential energy. In vacuum, the value of ε0 is 1. Polar solvents, like water, dampen the 
electrostatic interactions and their effect can be modeled by assigning to ε0 the value of the 
solvent’s dielectric constant (e.g. for water ε0= 80). More realistic solutions are provided by so-
called explicit or implicit solvation models. 
In the most detailed microscopic approach, solvent molecules are treated explicitly, and 
the electrostatic properties of both solvent and solute are obtained by averaging over a very large 
number of configurations of the system. In the most widely used explicit model, TIP3P, the water 
molecule is considered as a rigid molecule having three interaction sites, corresponding to its 
three atoms. The partial positive charges on the hydrogen atoms are exactly balanced by an 
appropriate negative charge located on the oxygen atom. The van der Waals interaction between 
two water molecules is computed using a Lennard-Jones function with just a single interaction 
point per molecule centered on the oxygen atom; no van der Waals interactions involving the 
hydrogen atoms are calculated. 
Explicit solvation calculations of this kind run slowly because hundreds of explicit solvent 
molecules need to be included. Furthermore, convergence can be a problem, since different 
solvent starting configurations often give different final energies, and hence simple energy 
minimization is not useful in an explicit solvent. 
This prompted interest in models which incorporate the influence of the solvent in an 
implicit fashion.47 There are two main types of implicit solvation models: empirical models and 
models based on continuum electrostatics.  
32 
 
Solvent models based on continuum electrostatics define the solute interior and the 
solvent as regions with different dielectric constants, and the electrostatic solvation free energy is 
computed by solving the Poisson-Boltzmann equations.48 These methods represent a rigorous 
treatment of continuum electrostatics, which takes into account solvation of single charges as well 
as screening effects (charge-charge and charge-dipole interactions). However, the calculations are 
too time-consuming to be performed routinely. Often one also encounters convergence problems, 
which may depend on the resolution of the solute-solvent boundary, on the partial charge 
representation, and on the difficulty in mapping forces related to the dielectric boundary onto 
individual atoms.  
 
The implicit model GB/SA (Generalized Born/Solvent-Accessible Surface Area) was used in 
the calculations of the thesis. As for the other empirical models, GB/SA dissects the solvation free 
energy, that is the free energy change to transfer a molecule from vacuum to solvent, in three 
components, an electrostatic component, a van der Waals component and one component 
associated with creating the solute cavity within the solvent (Eq. 3). The last two terms depend on 
the solvent-accessible surface area of the solute, the first term is usually derived either by the 
Onsager or the Born model. 
 
Gsol = Gcav+ GVdW + Gpol              Equation 3 
The contribution of each group to the GVDW and Gcav terms is often approximated by a 
linear function of its solvent-accessible surface area. The GB/SA system does not show 
convergence problems and allows simple minimizations and conformational searches to be 
performed in all the solvents that have been parameterized (water and chloroform). 
 
1.2.3 Conformational analysis 
Conformational search methods are used to sample the PES, i.e. to locate all the accessible 
minima and their associated relative energies. Distance geometry methods can be used to derive 
molecular conformations from experimental data; Metropolis Monte Carlo and molecular 
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dynamics simulation methods can be used to explore the entire conformational space of 
molecules. Methods which use a search algorithm coupled with an energy minimization are used 
to identify the preferred conformations of a molecule, i.e. the conformations localized at minimum 
points on the energy surface. Such conformational searches can be performed using either 
systematic search or random search algorithms.  
The simplest type of systematic search is called a grid search, and it contains various steps. 
First, all rotatable bonds are identified and systematically rotated through 360° using a fixed 
increment. Every conformation so generated is subjected to energy minimization to locate the 
closest (downhill) minimum conformation. The search stops when all the possible combination of 
torsion angles have been generated and minimized. After elimination of duplicates (duplicates are 
defined as molecular structures that do not differ by more than a defined threshold), the resulting 
minima are yielded as the search output. It can readily be seen that the number of conformations 
generated by a grid search is much larger than the number of minima on the surface and that 
many starting conformations will end up in the same minimum energy structure. Many of the 
initial conformations will be very high in energy, and some of them, for instance those containing 
major steric clashes of atoms, may be discarded even before the minimization. Nonetheless, the 
number of structures to be generated and minimized increases combinatorially with the number 
of rotatable bonds. 
A random search method moves from one region of the PES to a completely unconnected 
region in a single step by performing a random change of coordinates. Although the change can be 
made both in Cartesian coordinates or in internal coordinates, it has been shown that the latter 
method is much more efficient at exploring the conformational space of molecules, because it 
greatly reduces the number of degrees of freedom to be.49 After the random change has been 
made, the structure is refined using energy minimization. If the minimized conformation has not 
been found before, and falls within a predefined energy window above the instant global 
minimum of the search, it is stored. A conformation is then selected to be used as the starting 
point for the next iteration, and the cycle starts again. The procedure continues until a given 
number of iterations have been performed or until the user decides that no new conformations 
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can be found. A flow chart of the steps is given in Figure 1.2.1. There are many ways in which the 
structure for input to the next iteration can be selected, and this choice will influence the 
efficiency of the method. It has been shown that low-energy final conformers are favored by 
selecting low-energy starting geometries at each Monte Carlo step.50 The rational for such an 
empirical finding is that low-energy full structures are composed of low-energy substructures and 
a limited number of random variations of internal coordinates leaves many of the energetically 
favorable substructures intact. 
 
 
Figure 1.2.1. Flow chart of the processes conducted by an MC/MM simulation. 
There is not a “natural” endpoint of a random search procedure and the choice has to be 
made by the user. Generally the search is stopped after a predefined number of steps (1000 steps 
for rotatable bond is cited in the literature as a reasonable initial guess) and the results are 
analyzed for convergence. The usual strategy is to generate conformations until no new 
structures, or no low-energy new structures, are obtained. This generally requires each structure 
to be generated many times, so the number of times each minimum has been found is also used 
as a convergence criterion. However, one can never be absolutely sure that all of the minimum 
energy conformations have been found. If a run shows poor convergence, a common strategy is to 
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restart a new search from the instant minimum. The output of the two independent searches can 
then be merged to improve the coverage of the PES. 
An alternative method of conformational analysis is constituted by the simulation of the 
motion of the molecule. 
Although most of these simulations are conducted using the technique of molecular 
dynamics, it is possible use stochastic simulation methods (such as Metropolis Monte Carlo 
algorithm) or mixed methods (such as MC/SD, Metropolis Monte Carlo/stochastic Dynamics). 
 
1.2.4 Molecular dynamics simulations 
Molecular Dynamics (MD)51 simulations are based on the calculation of the time 
dependent behaviour of molecular systems, giving a detailed description of the variation from one 
conformation to another of the system studied. Simulations generate ensembles of representative 
configurations in such a way that accurate values of thermodynamic and structural properties can 
be obtained with a reasonable amount of computation. In particular, statistical analysis links 
microscopic and macroscopic properties providing the fundamental principles for the description 
of biomolecular systems. 
In the molecular dynamics it is not possible/necessary to specify the internal coordinates 
because the entire molecule is constantly modified and monitored. In the molecular dynamics 
approach a trajectory (conformations in function of the time) of the molecular system is generated 
through the simultaneous integration of the Newton equations of the motion; it goes to simulate 
the thermal motion of the molecule along the PES. 
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with 
ri = position of the i atom 
t = time 
Fi = force acting on the i atom. 
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The integration is done in a reduced time step, generally between 1 and 10 femtoseconds. 
In the stochastic dynamics (SD), instead, the Langevin equation52,53,54 of motion for the Brownian 
motion is integrated in time, thus simulating the coupling of the atomic motions to a thermal bath 
or to the effect of a solvent (Equation 5). 
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with: 
RI = stochastic force; 
I = frictional coefficients. 
i represents how much the system is coupled to the heat bath; it assumes an universal 
value, in function of the Force Field, to represent the effect of the solvent. The stochastic term 
introduces energy, while the frictional term removes kinetic energy from the system.  
At the end of a dynamic simulation is obtained:  
• A number of intermediate conformations (if required) from which you can obtain 
information about the dynamics of the system  
• Molecular data specifically required averaged over time 
• Thermodynamic data (potential and kinetic energy) averaged over time  
• Geometric information about the PES explored  
• kinetic information  
The fundamental problem of molecular dynamics simulations is their convergence. The simulation 
should be conducted for a period long enough to cover the PES thermally accessible so as to allow 
its efficient sampling and reliable results. The convergence of a simulation is evaluated through 
the analysis of convergence of the parameters obtained during the simulation itself, checking if 
the parameters converge to the desired accuracy at a fixed value, or carrying out the same 
simulation starting from different conformers and verifying that the results are similar.  
The problem of convergence is related to the difficulty of molecular dynamics to overcome 
the energy barriers. This means that if the PES contains holes separated by relatively high energy 
37 
 
barriers (higher than RT), these may never be overcome during the simulation. In this case, the 
convergence is apparently good because the potential hole is well sampled, but the data cannot 
be considered reliable because only part of the PES was sampled. 
A method to overcome the latter problem is the coupling of the molecular dynamics, or 
better of the stochastic dynamics, with the Metropolis Monte Carlo method, which, through a 
random variation of molecular coordinates, allows a more complete sampling of the 
conformational space.  
The combined method is called Mixed-Mode Metropolis Monte Carlo/Stochastic Dynamics 
(MC/SD) and it was used for all calculations in the thesis. This approach combines the method 
Metropolis Monte Carlo (MC), which has the ability to interconvert conformations separated by 
large energy barriers, with the stochastic dynamics (SD) that samples effectively local 
conformational space. The molecular dynamics is not used since it generates a microcanonical 
ensemble (at constant energy), while Metropolis Monte Carlo and stochastic dynamics generate 
canonical ensembles of Gibbs (at constant temperature) and, therefore, can be used in 
combination.  
In particular, the Monte Carlo Metropolis algorithm compares the energy of each new 
conformation, obtained by a random change of a coordinate of the previous conformation, with 
the energy of its predecessor. The method consists of the following steps:  
1. Random selection of a coordinate of the molecule and its random variation  
2. Calculation of the resulting change in the potential energy V  
3. If V <0 then the new configuration is accepted; if V≥0 then the new configuration is 
accepted if the Boltzmann factor e -[E(new) - E(old)/kT] is greater than a random number chosen 
between 0 and 1, otherwise the previous configuration is taken. The term e -[E(new) - E(old)/kT] is the 
probability to accept or reject the new conformation generated. 
4. It iterates through this cycle until it reaches a number Ntrial of iterations. 
In this way a large number of energetically accessible system configurations, called states, 
are explored; this set of states (ensemble) allows the calculation of the thermodynamic properties 
of the system, including the entropic term. The method is less efficient than the molecular 
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dynamics for the calculation of thermodynamic properties and obviously does not produce direct 
information on the dynamics of the system.  
The combined method MC/SD differs from other procedures designed for the same 
purpose, in two points: 
 It assigns equal importance to the dynamics and to the Metropolis Monte Carlo. 
 During the simulation, there is a continuous alternation between the two methods.  
It is a protocol that allows calculation through a dynamic simulation to evolve the 
conformation generated by a Monte Carlo step. The latter introduces large changes in a few 
degrees of freedom, making the sampling of the PES faster.  
The algorithm used by the combined method is the following:  
1. It assigns a starting structure (already minimized), the duration of the simulation, the 
torsion angles to vary, the maximum number of these to be changed at every step.  
2 It carries out a step of Metropolis Monte Carlo changing the torsion angles (randomly 
from one to the maximum number specified in point 1).  
3 The structure obtained is evaluated according to the criteria of Metropolis Monte Carlo; 
if it satisfies the cycle continues, otherwise it is discarded, taking the previous structure, and 
skipping to step 5.  
4 A short equilibration through SD is made, to minimize the error of numerical integration 
which results from the discontinuity inserted in the trajectory by Metropolis Monte Carlo.  
5. It performs the dynamics for the equivalent of a time step, during which the desired data 
are collected and mediated.  
6 The intermediate structure and the data are passed to step 2, until it reaches the end of 
the simulation.  
A problem that can plague even this type of method is the dependence on the starting 
structure and, in general, the convergence, which, as for the dynamics simulations, must be 
carefully evaluated. In the thesis the convergence has been verified by running different MC/SD 
simulations for each compound with different starting conformations of the molecule. 
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1.2.5 Docking calculations (Glide) 
Docking is a computational procedure extremely important for virtual screening and 
identification of new drugs. Technically, the docking is the placement of a molecule in a region of 
interest, such as the binding site of a macromolecule, and the assessment of this pose with a 
"score", which theoretically should reflect the affinity between the two interacting partners, in 
terms of complementarity of shape and properties. The protein - ligand interaction is dictated by 
complementary features between the two molecules, mainly based on Van der Waals forces, 
hydrogen bonds and electrostatic forces. A good complementarity indicates that the molecule is 
potentially a good binder.  
The docking programs on the market are numerous and differ in the type of algorithm used 
for the generation of new poses, for the function used for the calculation of the "score", or for the 
evaluation of the flexibility of the protein and the ligand.  
Routinely a default region of the macromolecule is selected; in this region, the docking 
program places the ligand in all possible positions, until reaching a maximum value of favourable 
interactions, which corresponds to the best "fit".  
The program Glide (Grid-based Ligand Docking with Energies) used in this research builds a 
grid (equally spaced points) of the entire binding region (bounding box) and defines a larger 
volume containing all the atoms, called enclosing box.  
Glide uses a series of filters to search for possible locations of the ligand in the active site, 
and then to generate the best ligand binding poses through a coarse screening. The filter examines 
steric complementarity of the ligand to the protein and evaluates various ligand – protein 
interactions with the empirical Glide Score function. Next, the ligand binding poses selected by the 
initial screening are minimized in situ with the OPLS force field. Finally the score is used to rank the 
resulting ligand binding poses.56 
The empirical score function calculated is: 
 
Gscore = 0.065vdW + 0.130Coul + Lipo + Hbond + Metal +BuryP + RotB +Site     Equation 6 
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with  
vdW = Van der Waals interaction energy 
Coul = Coulomb interaction energy 
Lipo = favourable hydrophobic interaction energy 
Hbond = term relative to the hydrogen bond 
Metal = term relative to metal interactions 
BuryP = penalty terms for bulky polar groups 
RotB = penalty terms for freezing rotatable bonds 
Site = polar interactions in the binding site. 
 
The "Glide score" is given, then, by the sum of different contributions related to non-
covalent interactions and the weight assigned to each of these terms is derived from the "fitting" 
to known binding energies obtained experimentally in a variety of different receptor - ligand 
complexes. 
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Section 1: Introduction 
 
In recent years, the enormous achievements made in modern molecular and 
cellular biology have enabled the complex network of biological targets and their different 
functional properties to be unveiled, along with the possible pathogenic deviations. Of the 
possible biological targets, surface cell receptors (e.g. integrins) constitute points of 
intervention in the pharmacology of many pathologies.1,2 In addition, fast progresses have 
been achieved in the study of protein-protein and ligand-protein interaction, that became 
possible also on an atomic level due to the development of new potent NMR spectroscopic 
techniques (Chapter 1).3 
This part of my PhD thesis, that was the main focus of the three-year project, was 
developed within the framework of a PRIN project (MIUR PRIN project 2010NRREPL 
“Synthesis and Biomedical Applications of Tumor-Targeting Peptidomimetics”) involving 
different research units and aimed at the design, synthesis, structural analysis and 
biological evaluation of new peptidomimetic integrin ligands.  
My PhD project benefits from collaborations with the research groups of Prof. 
Gennari and Dr. Belvisi from University of Milan (Department of Chemistry) and of Prof. 
Piarulli (University of Insubria) for the design and development of new peptidomimetics 
targeting integrins, particularly with the group of Dr. Belvisi for the computational part, and 
with Prof. Gennari’s and Piarulli’s groups for the synthesis. The project also benefits from 
the collaboration with Dr. Arosio (Consiglio Nazionale delle Ricerche) for the in vitro 
binding assays and with the research group of Dr. Tringali for the cell cultures and the in 
vitro adhesion assays.  
 
My contribution to the project concerned the application of NMR and 
computational techniques aimed at obtaining: 
 a detailed conformational study of diketopiperazine peptidomimetic ligands 
containing the Arg-Gly-Asp (RGD) and isoDGR sequence by NMR techniques (VT-NMR and 
NOESY) in acqueous solution and by computational methods, such as Monte Carlo-
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Stochastic Dynamics (MC/SD) simulations. The results of this task are discussed in this 
Section 1. 
 a detailed investigation of ligand-receptor interactions by new potent NMR 
spectroscopic techniques3 applied to live cells overexpressing integrins on their membrane, 
e. g. platelets and tumour cells.5,6 In particular, I set up live cell NMR methodologies by 
using human platelets and investigating the interaction of some RGD peptidomimetic 
ligands with the platelet-specific integrin IIb3. The results of these experiments are 
discussed in the first part of Section 2. Then, I expanded the live cell NMR study by using 
human tumour cells and gaining insight into the interaction of the small library of ligands 
with the tumour-associated integrins V3 and 51 (“Interaction with ECV-304” and 
“Interaction with MDA-MB-231”). The NMR results were supported by docking 
calculations of the ligands in the active site of the different integrins and were compared to 
the results of competitive receptor binding assays and competitive cell adhesion 
experiments.  
 
In this section an overview on integrins and on their role in many common diseases, 
in particular thrombosis and cancer, will be shortly presented. A more detailed discussion 
can be found in some published reviews.8,9 
 
2.1.1 Integrins 
The “integrin” terminology was applied in a 1987 review article (Hynes, R. O. Cell) to 
describe a family of structurally, immunochemically and functionally related cell-surface 
heterodimeric receptors, which integrated the extracellular matrix with the intracellular 
cytoskeleton to mediate cell migration and adhesion.9b In fact, integrins are a large family 
of transmembrane non-covalently linked heterodimeric receptors composed of an - and 
-subunit. Until now at least 24 such heterodimers have been identified, comprising 18 -
subunits and 8 -subunits that formed specific, but diverse heterodimers (Figure 2.1.1.).8
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Figure 2.1.1. Integrin subfamilies; in green are reported different types of -chains, in light green 
-chains except for V, in fact it can associate with many different -subunits, whereas other -
subunits are singular in their choice of -subunit partner. 
 
Initially, integrin subfamilies were defined by their -subunit, between them the most 
important are 1, 2, and 3; however, the -subunit seemed to be important in defining the 
ligand binding properties of the integrin, and, consequently, defining integrin subfamilies required 
a more flexible system that takes into consideration also integrin ligand-binding properties and 
functions.8 
The subunits are type-I transmembrane proteins equipped with an extensive extracellular 
domain (amino-terminal) and a small cytoplasmic tail (carboxy-terminal) connected by a single 
transmembrane chain (Figure 2.1.2.).  
 
 
Figure 2.1.2. Subunits structure; -I domain = Interactive Domain, I-EGF domain = Integrin-
Epidermal Growth Factor-like domain, PSI = Plexin Semaphorin Integrin. 
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 chain has a molecular weight varying between 120 and 200 kDa and consists of about 
1100 amino acids, while  chain varies between 90 and 100 kDa (800 amino acids).  
The extracellular part of the  subunit is characterized by three or four regions close to the 
terminal nitrogen, which contain from 12 to 15 amino acids capable of binding divalent cations 
such as Ca2+ or Mg2+. Both subunits have a transmembrane region of about 20 - 30 residues and an 
intracellular region comprising from 15 to 80 residues. While the amino-terminal portion of both 
chains form a globular head that contributes to their association and formation of the ligand 
pocket, the carboxy-terminal portion of  subunit connects integrins with actin filaments of the 
cytoskeleton through intracellular proteins such as talin, vinculin and -actin.10 The various 
components of the two subunits and their interaction partners are shown schematically in Figure 
2.1.3.. 
 
 
Figure 2.1.3. Interactions with extracellular matrix proteins (Ligand-binding region) and with 
cytoskeleton (cytoplasm). 
 
The cytoplasmic domain interacts with components of the cytoskeleton, allowing the 
adhesion of the extracellular domains to different ligands, such as glycoproteins of the 
extracellular matrix (i.e., fibronectin, fibrinogen, collagen and vitronectin) or proteins on the 
surface of other cells. 
Therefore, integrins are constituted by a complex "integral" transmembrane which has the 
task of modulating the association between the extracellular matrix and the cytoskeleton.11 This 
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connection regulates the activity of all the cells, leading integrins to play an essential role in 
cellular functions.  
Both extracellular domains of the  and  chains contain sites with metal ions that allow 
interaction with the ligand; the most important of these sites is called "Metal-Ion-Dependent 
Adhesion Site" (MIDAS) (Figure 2.1.4.).8 
 
 
Figure 2.1.4. Receptor site with the three metal ions (Ca2+ or Mg2+); MIDAS, Adjacent to MIDAS = 
ADMIDAS, Ligand-associated-Metal-Binding-Site=LIMBS.8 
 
The two main functions of integrins are: 
1) Structural functions: attachment of the cell to other cells and to the ECM (Extracellular 
Matrix); in fact, integrins are often described as the “glue of life”. This means that the major 
function of these receptors is to maintain the proper structure of tissues by organization of cell-
cell and cell-ECM tethering. 
2) Signal transduction from the ECM to the cell and vice versa. The signals involve: cell 
growth, cell migration, cell division, cell survival, cellular differentiation, apoptosis (programmed 
cell death). Integrins transduce information from the ECM (extracellular matrix) to the cell as well 
as reveal the status of the cell to the outside, allowing rapid and flexible responses to changes in 
the environment.8,12 
Integrins display three distinct conformations: a resting inverted V-shaped conformation; 
an intermediate partially activated extended state; and a fully activated open, ligand-binding 
conformation (Figure 2.1.5.). 
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Figure 2.1.5. Swichtblade like opening of integrins. Three major integrin states: a) bent (with a 
closed headpiece), b) extended with a closed headpiece, and c) extended with an open headpiece. 
A number of intermediates exists between these three main activation states due to outside-in 
signaling and inside-out signaling (“switchable model”). 
 
Some integrins can bind their ligands in a resting state, whereas others require activation 
before binding. Activation is mediated by signaling events leading to alterations in the intracellular 
domains, also known as “inside-out signaling”. Ligand binding results in transmission of a signal 
into the cell, which is known as “outside-in signaling” (Figure 2.1.5.). Their participation in signal 
transduction results in cytoskeleton reorganization (shape change, adhesion, migration), 
regulation of cell proliferation, cell survival and apoptosis, as previously said. On the whole, the 
ability of integrins in mediating stable adhesion to the ECM or to other cells, in participating in the 
assembly of an ECM, in controlling migration, and in regulating signaling cascades, explains their 
prominent role for the correct development and function of various tissues. Absence of functional 
integrins is associated with aberrant development of tissues and their functions, ultimately 
resulting in the initiation and prolongation of many diseases such as thrombosis and related 
pathologies, tumor formation and metastasis spread, tumor angiogenesis, vascular damage 
brought about by osteoporosis.13,14,15  
However, although integrins are known to be involved in various disorders, identifying the 
specific integrin involved and their precise role is difficult because many diseases are multifactorial 
and integrins are only one of many types of receptors involved. Moreover, many cells express 
multiple integrins that exhibit complementary binding properties.8  
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A brief overview of the two disorders in which integrins are known to have an important 
role and that are the main focus of this thesis is presented. 
Thrombosis: the first-disease-related process to be clearly associated with integrins was 
thrombosis - the formation of a blood clot inside a blood vessel, which occurs when platelets 
adhere to damaged blood vessels and become activated. These activated platelets recruit other 
platelets, resulting in the formation of a haemostatic plug. This is an essential mechanism for 
preventing blood loss, but inappropriate thrombus formation can lead to a stroke or to a heart 
attack. In the 1970s, it was noted that some patients with a severe bleeding disorder known as 
Glanzmann’s thrombasthenia lacked two functional glycoproteins (GPIIb and GPIIIa) on their blood 
platelets, which are now known as the integrin IIb3. It was subsequently found that the platelet – 
platelet interaction that mediates thrombus formation is facilitated by fibrinogen binding to the 
platelet-specific integrin IIb3 following platelet activation caused by thrombotic stimuli. This 
knowledge provided the basis for the development of the first three integrin-targeted drugs to be 
approved, which were introduced in the 1990s (see “Integrin ligands”).8,16 
Cancer: During carcinogenesis, the growth of the tumour and its subsequent metastasis is 
highly dependent on tumor cells being able to regulate their attachment to the extracellular 
matrix and to adjacent cells. Given that integrins have important roles in cell attachment, survival, 
migration, invasion and angiogenesis, which are all critical for carcinogenesis, they have attracted 
considerable attention as potential anticancer targets. Many different integrins have been 
implicated in carcinogenesis, in particular V3, V5 and 51 play a key role in modulating cancer 
development. These may be important in angiogenesis, in which endothelial cell survival is 
crucial.8 They also have a key role in metastasis, and its expression in melanoma is associated with 
highly metastatic disease. Integrin 51 is a major cellular receptor for the extracellular matrix 
protein fibronectin and plays a fundamental role during mammalian development.17 Potentially, 
blocking integrin function could interfere with tumor growth and metastasis. 
 
The ectodomain of the V3 and of 51 receptors has been crystallized in the resting state, 
while the ligand-binding domain of IIb3 has been crystallized in both the inactive and activated 
conformations.16,17,18,19 
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In addition, from a structural point of view, V3, 51 and IIb3 are all characterized by 
the lack of the -I-domain. 
Compared with other cell adhesion receptor classes, integrin’s ligand recognition 
mechanism is highly unique in three aspects. First, the ligand recognition specificity of each 
integrin heterodimer is determined combinatorially, in that both the  and the  subunits 
contribute to the selective ligand binding of the resultant heterodimeric receptor, and even the 
same  (or ) subunit will bind different ligands when paired with a different  (or ) subunit. 
Second, in contrast to other divalent cation-dependent cell adhesion molecules such as cadherins 
in which metals do not directly bridge two molecules across the cell-cell junction, the core 
mechanism of integrin-ligand recognition involves a direct coordination bond between a Mg2+ ion 
bound on the integrin (called MIDAS) and a carboxylate oxygen from the ligand. Lastly, the ligand-
binding affinity of integrins can be modulated allosterically via conformational changes that take 
place outside the binding pocket.17 
 
2.1.2 Integrin ligands 
Over the last decade, it has been identified a wide variety of potent integrin antagonists, 
with low molecular weight, whose biological targets are V3 IIb3 or 51 integrins. One of the 
best known aspects for the inhibition of -I-domain lacking integrins is their ability to recognize 
endogenous ligands characterized by short RGD (Arg-Gly-Asp) sequences (Figure 2.1.6.). 
 
N
H
H
N
N
H
O
O
O
COOH
NH
NH2
HN
AspGlyArg
..........
 
Figure 2.1.6. RGD sequence of integrin endogeneous ligands. 
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In fact, despite the great variability of the receptors, only a few integrins recognize a single 
endogenous ligand; most of them is able to bind to a wide variety of ligands, which are also 
recognized by other adhesion receptors of the cell surface.20 Among the natural ligands of 
integrins we find laminin, fibronectin, vitronectin, fibrinogen and fibrin. Therefore, the first phase 
in the planning and development of synthetic antagonists of these receptors was focused on 
creating a series of low molecular weight peptides where various amino acid residues flank the 
RGD consensus sequence. This sequence was used as template for the development of potent and 
selective monomeric ligands, both linear and conformationally constrained by cyclization, 
characterized by a peptide, pseudopeptide or not peptide sequence. It was shown that linear 
ligands containing the RGD sequence have, however, low specificity toward integrins, while 
homologous peptides having a cyclic structure generally show higher activity and selectivity. These 
efforts leads to the design and synthesis of effective, conformationally constrained cyclic (pseudo) 
peptides, such as the inhibitor Cilengitide (Figure 2.1.7.), which proved to be one of the most 
potent and selective antagonists of the integrin V3,
21 reached phase III clinical trials for the 
treatment of glioblastoma multiforme and now is in phase II studies for head and neck cancer as 
well as lung cancer. 
 
N
N
N
O
O
CH3
N
O
HO
O
H
H
H
N
N
O
H
O
H NH
NH2
Cilengitide  
Figure 2.1.7. Structure of the inhibitor Cilengitide (cyclo-[Arg-Gly-Asp-D-Phe-N(Me)-Val]) 
developed by Kessler in the early 90s. 
 
In addition, a crucial step forward in this important area arose from the crystal structure 
determination of the extracellular segment of vitronectin receptor V3 and of its complex with 
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Cilengitide,18 and from the resolution of the crystallographic structure of integrin IIb3
19 in 
complex with a synthetic antagonist in use as antithrombotic, called Eptifibatide or Integrilin, 
whose structure is shown in Figure 2.1.8.. 
 
 
 
 
 
 
 
 
Figure 2.1.8. Structure of the inhibitor Integrilin developed by Robert M. Scarborough e David 
Phillips (COR Therapeutics). 
 
Recently, in 2012, the crystal structure of the 51 integrin headpiece fragment bound by 
an allosteric inhibitory antibody was determined both in the absence and presence of a ligand 
peptide containing the RGD sequence.17 The structure, solved as a complex with a Fab fragment of 
the anti-1 inhibitory antibody SG/19, revealed high similarity to the ligand-unbound form of V3 
and IIb3 integrins. Like integrin V3, 51 integrin was crystallized in its resting conformation. It 
was particularly important to obtain structural information about 1 integrins because they 
constitute the largest and probably the most ancient integrin subclass. 
The specific recognition of RGD peptide by three different integrins is reported in Figure 
2.1.9.. A more detailed explanation of the single domain will be given in the next Sections. 
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Figure 2.1.9. Specific recognition of RGD peptide by three different integrins: 51, V3 and IIb3. 
Hydrogen and coordination bonds are shown in clashed lines. Metal ions in the I-domain are 
shown in spheres.17 
 
Capitalizing on these fundamental results, numerous cyclic peptidomimetics containing the 
RGD sequence and pseudopeptide scaffolds of different nature were introduced. 
These include ligands incorporating unnatural 6,5- and 7,5- fused 1-aza-2-oxobicycloalkane 
amino acids (ST1646, ST2605, DB58) (Figure 2.1.10.),22,23,24 or diketopiperazinic scaffold-containing 
-amino acids (AV98),25 RGD peptidomimetics containing -aminocyclopentane carboxylic acid26 
(PRGC008) or 4-aminoproline residue27 (PRGC021)28 and RGD-Morpholine peptides (c-[RGDf-D-
Morph]).29 
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Figure 2.1.10. Structure of some cyclic ligands based on a RGD sequence and various scaffolds. 
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However, up to now, a large number of linear or cyclic peptidic and peptidomimetic ligands 
have been developed, which are all related to the common recognition motif RGD28,30 and a few 
potent ligands are presently in different stages of clinical trials for cancer therapy, or in clinical use 
for antithrombotic therapy. Notwithstanding these recent achievements, the discovery of new 
ligands displaying high activity and selectivity together with an optimal pharmacological profile still 
remains a challenge. 
During my thesis work, studies have been focused on hybrid cyclic ligands containing a 
diketopiperazinic scaffold and the recognition sequence RGD (see AV98 in Figure 2.1.10.). These 
scaffolds affect the spatial arrangement of the pattern, locking it in various conformations, 
described in the paragraph below.  
 
2.1.3 DKP-RGD peptidomimetic ligands 
New bifunctional diketopiperazine (DKP) scaffolds [DKP-1 (cis) and DKP-2/DKP-7 (trans)], 
which are formally derived from aspartic acid and 2,3-diaminopropionic acid and bear a carboxylic 
acid and an amino functionality, were recently developed and their stereochemistry and 
substitution patterns were varied (Figure 2.1.11.). In particular the scaffolds differ in: 1) the 
relative stereochemistry, namely cis (DKP-1) or trans (DKP-2 – DKP-7); 2) the absolute 
stereochemistry of the trans scaffolds [3R,6S (DKP-2, DKP-4, DKP-5) or 3S, 6R (DKP-3, DKP-6, DKP-
7)]; 3) the substitution at the endocyclic nitrogen atoms, which can be either hydrogen or benzyl 
(DKP-2,DKP-3, DKP-4, DKP-6) or dibenzyl (DKP-5, DKP-7). 
 
 
 
 
 
Figure 2.1.11. Bifunctional DKP scaffolds. 
 
These bifunctional diketopiperazines were introduced into the 17-membered cyclic RGD 
peptidomimetics Cyclo-[DKP-1-RGD] – Cyclo-[DKP-7-RGD] (Figure 2.1.12.). 
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6
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Figure 2.1.12. Cyclic RGD peptidomimetics containing bifunctional DKP scaffold. 
 
The configuration of the two amino acids may affect the spatial arrangement of the RGD 
motif, while the different nature of the nitrogen substitutes can influence the affinity for the 
receptor for steric repulsion or lipophilic interactions. The context of the RGD sequence (flanking 
residues, 3D presentation, and individual features of the integrin binding pockets) determines the 
specificity and efficacy of interaction. 
In the case of the N-dibenzyl derivative Cyclo-[DKP-7-RGD], the molecule can exist as two 
different separable conformers (diastereomers) due to hindered rotation of one ring around the 
other, in a way reminiscent of the ansa-cyclopeptides (i.e., the DKP N-benzyl group cannot pass 
inside the macrolactam ring). So, for this compound two diastereomers (P1 – P2) were formed in 
the macrolactamization step and were isolated in a 2(A):1(B) ratio. 
 
2.1.4 NMR characterization and conformational studies4 
During the period of my thesis, I have contributed to the characterization of the 
conformations adopted by these RGD ligands, where diketopiperazine scaffolds were introduced 
in order to induce -turn motifs and stabilize the structure of the cycle. Natural peptides or 
proteins most frequently form -helices, -sheets, as well as reverse-turns.27 A turn is defined as a 
site where the peptide backbone reverses the direction of propagation by adopting a U-shaped 
conformation. 
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The terms -turns and -turns have more restricted definitions and describe turns of four 
or three consecutive residues, respectively. These turns can be stabilized by intramolecular H-
bonding. In the -turn, the carbonyl of the first residue i may be hydrogen bonded to the NH of 
the fourth residue (i+3), producing a ten-membered cycle. In -turns, the C=O of the first residue 
(i) may be hydrogen bonded to the NH of the third residue (i+2), giving rise to a seven-membered 
ring.  
For this reason, conformational studies in the free-state of these cyclic conformationally 
constrained RGD peptidomimetics were conducted by 1H-NMR experiments (VT-NMR and NOESY) 
in aqueous solution and by computational methods, such as mixed-mode Metropolis Monte 
Carlo/Stochastic Dynamics (MC/SD) simulations. Monodimensional 1H-NMR experiments were 
conducted to detect intramolecular hydrogen bonds, by measuring the chemical shift of the N–H 
protons and their temperature coefficients (/T), while NOESY spectra were recorded to 
investigate both sequential and long-range NOE's that provide evidences of preferred 
conformations. These NOE contacts were used as constraints (see ∗Supplementary Information∗) 
for the MC/SD simulations,31 performed using the implicit water GB/SA solvation model32 and the 
OPLS_2001 force field,33 chosen for its capability to better parameterize the diketopiperazine 
scaffolds of our compounds.  
The structure and connectivity of ligands Cyclo-[DKP-1-RGD] and Cyclo-[DKP-2-RGD] to 
Cyclo[DKP-7-RGD] were unambiguously assigned by means of mono- and bidimensional 1H- and 
13C-NMR spectra (see ∗Supplementary Information∗). The relevant NMR data are summarized in 
Table 2.1.1.. 
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Structure (ppm) (ppb/K) Significant NOE contacts 
NH1 NH4 NH10 NHArg NHGly NHAsp NH1 NH4 NH10 NHArg NHGly NHAsp 
cyclo[DKP-1-RGD] 8.35 - 7.46 8.40 8.75 8.10 -7.3 - -2.0 -7.0 -8.0 -3.7 NHAsp-NH10; NHAsp-NHGly 
cyclo[DKP-2-RGD] 8.35 - 8.78 8.57 8.18 8.29 -8.7 - -10.7 -7.0 -5.7 -7.7 NHArg-NHGly 
cyclo[DKP-3-RGD] 8.10 - 8.28 8.80 8.00 7.85 -5.7 - -8.5 -6.0 -4.5 -3.5 NHArg-NHGly 
cyclo[DKP-4-RGD] - 8.17 7.59 8.29 8.27 8.88 - -9.1 -0.7 -9.3 -8.2 -9.3 -- 
cyclo[DKP-5-RGD] - - 8.58 8.48 8.23 8.42 - - -11.0 -7.5 -4.7 -8.2 NHArg-NHGly 
cyclo[DKP-6-RGD] - 8.07 7.90 8.32 8.35 8.80 - -4.9 -5.1 -7.6 -6.7 -8.0 NHAsp-NH10; NH4-NH10 
cyclo[DKP-7-RGD]-A - - 8.04 8.66 7.93 7.76 - - -7.5 -5.0 -3.0 -1.0 NHArg-NHGly; NHAsp-NHGly 
cyclo[DKP-7-RGD]-B - - 7.72 8.34 8.45 8.55 - - -4.0 -7.0 -7.0 -5.0 NHAsp-NH10 
Table 2.1.1. 1H-NMR and NOE data of cyclic RGD peptidomimetics in water. 
 
On the basis of spectroscopic data and computational simulations, different preferred 
conformations featuring specific intramolecular H-bonding patterns and turn motifs were 
identified for the different ligands, depending on configuration and substitution of the DKP 
scaffold. In particular, five distinct types of conformations were recognized and classified as 
follows: Type I-cis (-turn at Gly-Asp), Type I-trans (-turn at Gly-Asp), Type II (-turn at Arg-Gly), 
Type III (-turn at DKP-Arg) and Type IV (-turn at Asp-DKP). As shown below, these conformations 
are characterized by various values of the distance between the Cb atoms of Asp and Arg residues, 
a key parameter for the RGD fitting into the active site of integrins.18 In particular, an extended 
conformation of the RGD motif displaying a distance of about 9 Å is required to allow the 
carboxylate and guanidinium groups to properly interact with the receptor acting as an 
electrostatic clamp. 
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Compound Cyclo-[DKP-1-RGD]25 exists as an equilibrium of two different preferred 
conformations. The NOESY spectrum shows two mutually exclusive long-range NOE contacts. The 
cross peak between DKP-NH10 and NHAsp (strong) is indicative of a -turn conformation at Gly-Asp 
stabilized by a hydrogen bond between DKP-NH10 and Arg-C=O (referred as Type I H-bonding 
pattern, Figure 2.1.13.A). The chemical shift value (7.46 ppm) and the /T value (-2 ppb/K) of 
the amide proton DKP-NH10 indicate that this proton is strongly locked in an intramolecularly H-
bonded state. The cross peak between NHGly and NHAsp (medium) is indicative of an alternative -
turn conformation at Arg-Gly, stabilized by a hydrogen bond between Asp-NH and C(8)=O 
(referred as Type II H-bonding pattern, Figure 2.1.13.B). 
 
 
Figure 2.1.13. Preferred intramolecular hydrogen-bonded patterns proposed for compound DKP-1 
on the basis of spectroscopic data. The arrows indicate significant NOE contacts. A) Type I H-
bonding pattern, Gly-Asp β-turn motif. B) Type II H-bonding pattern, Arg-Gly β-turn motif. 
 
Three-dimensional structures satisfying long-range NOE contacts were generated for 
compound Cyclo-[DKP-1-RGD]25 performing two 10 ns restrained MC/SD simulations and applying 
the DKP-NH10/NHAsp or the NHAsp/NHGly distance restraint derived from the NOESY spectra. More 
than 90% of the conformations sampled during the first simulation adopted a non-extended 
arrangement of the RGD sequence characterized by a -turn at Gly-Asp and the presence of the 
corresponding hydrogen bond between DKP-NH10 and Arg-C=O. In addition, the formation of a -
turn at Gly stabilized by the hydrogen bond between NHAsp and Arg-C=O was observed for 40% of 
the simulation. A C(Arg)–C(Asp) average distance of 7.4 Å was obtained during this MC/SD 
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calculation. A representative energy minimized conformation selected by cluster analysis and 
featuring both H-bonds is shown in Figure 2.1.14.A (Type I-cis H-bonding pattern).  
 
 
Figure 2.1.14. Structures of Cyclo-[DKP-1-RGD] as obtained by restrained MC/SD simulations 
based on experimental distance information, after energy minimization. A) Type I-cis H-bonding 
pattern, -turn at Gly and II’-turn at Gly-Asp [CArg)–C(Asp)=7.9 Å]. B) Type II H-bonding 
pattern, -turn at Arg and II’-turn at Arg-Gly [C(Arg)–C(Asp)=6.6 Å]. Tube representation: O, N 
in dark gray, C in light gray and N-H hydrogens in white; for the sake of clarity, all H atoms bound 
to carbon are omitted. 
 
Approximately 60% of the conformations sampled during the simulation of Cyclo-[DKP-1-
RGD] featuring the NHAsp/NHGly distance restraint, adopted a non-extended arrangement of the 
RGD sequence characterized by a -turn at Arg-Gly and the corresponding hydrogen bond 
between NHAsp and C(8)=O. In addition, the formation of a -turn at Arg stabilized by the hydrogen 
bond between NHGly and C(8)=O was observed for 40% of the simulation. The C(Arg)–C(Asp) 
average distance in this MC/SD calculation was 6.8 Å. A representative energy minimized 
conformation selected by cluster analysis and featuring both H-bonds is shown in Figure 2.1.14.B 
(Type II H-bonding pattern). 
 
The similarity of the NMR data of compounds Cyclo-[DKP-2-RGD] and Cyclo-[DKP-3-RGD] 
and, hence, of the conformation of these two ligands is quite surprising, considering the opposite 
configuration of the diketopiperazine scaffold [DKP-2 (3R,6S); DKP-3 (3S,6R)] which should impart 
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a different stereochemical orientation to the two side arms of the diketopiperazine. This 
conformational similarity can be interpreted in terms of a quasi-enantiomeric structure of the two 
ligands (excluding the configuration of the remote RD amino acid side chains, Figure 2.1.15.). Both 
the compounds are apparently characterized by conformational mobility, as suggested by the 
values of chemical shifts and Δδ/ΔT reported in Table 2.1.1.. The only exception is proton NH-Asp 
of Cyclo-[DKP-3-RGD] (7.85 ppm, /T = -3.5 ppb/K), which might be involved in a Type II H-
bonding pattern (for definition of Type II H-bonding pattern, see Figure 2.1.13.B above). This last 
conformation, however, is less important due to the lack of an associated NOE contact and we will 
not report in the other analysis. On the other hand, the presence in both cases of a NOE contact 
between NHGly and NHArg suggests the formation of a -turn motif at DKP-Arg, stabilized by a 
hydrogen bond between NHGly and C(5)=O (referred to as Type III H-bonding pattern, Figure 
2.1.15.).  
 
 
Figure 2.1.15. Preferred intramolecular hydrogen-bonded pattern proposed for compound DKP-2 
(left) and DKP-3 (right) on the basis of spectroscopic data. The arrows indicate significant NOE 
contacts. The DKP-Arg β-turn motif is referred to as Type III H-bonding pattern. 
 
The presence of this H-bond is also supported by the rather upfield chemical shift value of 
NHGly in these two ligands (8.18 and 8.00 ppm for DKP-2 and DKP-3, respectively) and the 
relatively low temperature dependence (-5.7 and -4.5 ppb/K, respectively).  
Ligand Cyclo-[DKP-5-RGD], with the dibenzylated diketopiperazine, shows NMR features 
similar to ligand Cyclo-[DKP-2-RGD] (for definition of Type III H-bonding pattern, see Figure 2.1.15. 
above): a NOE contact between NHGly and NHArg and a rather shielded NHGly (8.23 ppm) with a 
relatively low temperature coefficient (-4.7 ppb/K). 
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The distance restraint corresponding to the NOE contact between NHGly and NHArg was 
applied in the 10 ns MC/SD simulations of compounds Cyclo-[DKP-2-RGD], Cyclo-[DKP-3-RGD] and 
Cyclo-[DKP-5-RGD]. More than 90% of the conformations sampled during each of these 
simulations adopted an extended arrangement of the RGD sequence characterized by a pseudo -
turn at DKP-Arg and the formation of the corresponding hydrogen bond between the NHGly and 
C(5)=O. Interestingly, only for compound Cyclo-[DKP-3-RGD], the additional formation of a -turn 
at Arg-Gly stabilized by the hydrogen bond between NHAsp and C(8)=O was observed for 15% of 
the simulation. These results and the NMR data (showing  7.85 ppm and /T -3.5 ppb/K for 
NHAsp of Cyclo-[DKP-3-RGD]) suggest the contribution of a Type II/Type III H-bonding pattern to 
the conformational equilibrium of Cyclo-[DKP-3-RGD] (mainly populated by a Type III H-bonding 
pattern). C(Arg)-C(Asp) average distances of 9.3, 8.8, and 9.1 Å were obtained during the MC/SD 
calculations of Cyclo-[DKP-2-RGD], Cyclo-[DKP-3-RGD] and Cyclo-[DKP-5-RGD], respectively. A 
representative energy minimized conformation selected by cluster analysis and featuring the H-
bond between the Gly-NH and C(5)=O (Type III H-bonding pattern) is shown in Figure 2.1.16 for 
RGD peptidomimetic Cyclo-[DKP-2-RGD]. 
 
 
Figure 2.1.16. Structures of Cyclo-[DKP-2-RGD] as obtained by restrained MC/SD simulations 
based on experimental distance information, after energy minimization. Compound Cyclo-[DKP-2-
RGD], Type III H-bonding pattern, distorted inverse -turn at Asp and pseudo -turn at DKP-Arg 
[CArg)–C(Asp)=9.4 Å]. Tube representation: O, N in dark gray, C in light gray and N-H hydrogens 
in white; for the sake of clarity, all H atoms bound to carbon are omitted. 
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Ligands Cyclo-[DKP-4-RGD] and Cyclo-[DKP-6-RGD], featuring the diketopiperazine 
scaffolds DKP-4 (3R,6S) and DKP-6 (3S,6R) respectively (with the benzyl substitution at the 
endocyclic nitrogen N-1, instead of N-4), show a different NMR pattern. 
Ligand Cyclo-[DKP-4-RGD] is characterized by the absence of relevant NOE contacts, a very 
low temperature dependence (-0.7 ppb/K) and a quite upfield chemical shift value (7.59 ppm) for 
proton NH10. These two features suggest a Type I H-bonding pattern (for definition of Type I H-
bonding pattern, see Figure 2.1.18.A below), notwithstanding the apparent lack of NOE contact 
between NHAsp and NH10. 
Due to the absence of relevant long-range NOE contacts, several 10 ns runs of 
unconstrained MC/SD simulations were performed for high affinity ligand Cyclo-[DKP-4-RGD] 
(containing N-1-benzylated DKP-4, 3R,6S) starting from different 3D structures. Most of the 
conformations sampled during these simulations adopted an extended arrangement of the RGD 
sequence [C(Arg)-C(Asp) average distance of 8.8 Å] and approximately 40% of them are 
characterized by a -turn at Gly-Asp and the presence of the corresponding hydrogen bond 
between DKP-NH10 and Arg-C=O. These results provide a structural model in agreement with NMR 
data showing a low temperature dependence (-0.7 ppb/K) and an upfield chemical shift value 
(7.59 ppm) for proton NH10. 
A representative energy minimized conformation selected by cluster analysis and featuring 
the H-bond between DKP-NH10 and Arg-C=O (Type I-trans H-bonding pattern) is shown in Figure 
2.1.17 for RGD peptidomimetic Cyclo-[DKP-4-RGD].  
 
 
Figure 2.1.17. Structure of Cyclo-[DKP-4-RGD] as obtained by MC/SD simulations, after energy 
minimization. Compound Cyclo-[DKP-4-RGD], Type I-trans H-bonding pattern, inverse -turn at 
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Asp and distorted II’-turn at Gly-Asp [CArg)–C(Asp)=9.0 Å]. Tube representation: O, N in dark 
gray, C in light gray and N-H hydrogens in white; for the sake of clarity, all H atoms bound to 
carbon are omitted. 
 
It is worth noting how the combination of the trans DKP-4 scaffold with the Gly-Asp -turn 
occurs by generating an extended RGD arrangement, while the combination of the cis DKP-1 
scaffold with the same secondary motif resulted in a non-extended RGD disposition (see above, 
Figure 2.1.14.A). Accordingly, two Type I H-bonding patterns have been defined (Type I-cis and 
Type I-trans), depending on the cis or trans relative stereochemistry of the diketopiperazine 
scaffold. 
On the other hand, ligand Cyclo-[DKP-6-RGD] is characterized by a rather strong NOE 
contact between NHAsp and NH10 and a moderate one involving NH4 and NH10. These two contacts 
are mutually exclusive and hence indicative of an equilibrium between two different 
conformations, respectively Type I and Type IV binding modes (Figure 2.1.18.A and B). The 
hydrogen bonded status of the two amide protons NH4 and NH10, as indicated by their rather low 
temperature dependence (-4.9 and -5.1 ppb/K, respectively) and quite upfield chemical shift 
values (8.07 and 7.90 ppm, respectively), corroborate this assumption. The Type IV H-bonding 
pattern could feature a pseudo -turn at Asp-DKP stabilized by a hydrogen bond between NH4 and 
Gly-C=O (NOE contact between NH4 and NH10). 
 
Figure 2.1.18. Preferred intramolecular hydrogen-bonded pattern proposed for compound Cyclo-
[DKP-6-RGD] on the basis of spectroscopic data. A) Type I H-bonding pattern, Gly-Asp -turn 
motif. B) Type IV H-bonding pattern, pseudo -turn at Asp-DKP. The arrows indicate significant 
NOE contacts. 
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Three-dimensional structures satisfying long-range NOE contacts were generated for 
compound Cyclo-[DKP-6-RGD] (containing N-1-benzylated DKP-6, 3S,6R) performing two 10 ns 
restrained MC/SD simulations and applying the DKP-NH10/NHAsp or the NH4/NH10 distance restraint 
derived from NOESY spectra (Table 2.1.1., Figure 2.1.18.). 
Most of the conformations sampled during the first simulation adopted an extended 
arrangement of the RGD sequence [C(Arg)-C(Asp) average distance of 9.0 Å] and approximately 
40% of them are characterized by a -turn at Gly-Asp and the corresponding hydrogen bond 
between DKP-NH10 and Arg-C=O. A representative energy minimized conformation selected by 
cluster analysis and featuring this H-bond is shown in Figure 2.1.19.A (Type I-trans H-bonding 
pattern). Approximately 70% of the conformations sampled during the simulation of Cyclo-[DKP-6-
RGD] featuring the NH4/NH10 distance restraint adopted an extended arrangement of the RGD 
sequence [C(Arg)-C(Asp) average distance of 8.8 Å] characterized by a pseudo -turn at Asp-DKP 
and the corresponding hydrogen bond between NH4 and Gly-C=O. In addition, the formation of a 
-turn at Asp stabilized by the hydrogen bond between NH10 and Gly-C=O was observed for 50% of 
the simulation. A representative energy minimized conformation selected by cluster analysis and 
featuring these H-bonds is shown in Figure 2.1.19.B (Type IV H-bonding pattern). 
 
 
Figure 2.1.19. Structures of Cyclo-[DKP-6-RGD] as obtained by restrained MC/SD simulations 
based on experimental distance information, after energy minimization. A) Type I-trans H-bonding 
pattern, inverse -turn at Asp and distorted II’-turn at Gly-Asp [CArg)–C(Asp)=9.0 Å]. B) Type 
IV H-bonding pattern, inverse -turn at Asp and pseudo -turn at Asp-DKP [C(Arg)–C(Asp)=8.8 
Å]. Tube representation: O, N in dark gray, C in light gray and N-H hydrogens in white; for the sake 
of clarity, all H atoms bound to carbon are omitted. 
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The dibenzylated diketopiperazine containing peptidomimetic Cyclo-[DKP-7-RGD] was 
eventually studied. Compound Cyclo-[DKP-7-RGD] was obtained as a mixture of two 
diastereomers Cyclo-[DKP-7-RGD]-A and Cyclo-[DKP-7-RGD]-B due to hindered rotation of one 
ring around the other (see Figure 2.1.20.), whose conformations in solution were studied 
separately.  
 
 
Figure 2.1.20. Compounds Cyclo-[DKP-7-RGD]-A and Cyclo-[DKP-7-RGD]-B, diastereomers of 
Cyclo-[DKP-7-RGD] due to hindered rotation.  
 
In particular, compound Cyclo-[DKP-7-RGD]-A displays two mutually exclusive NOE 
contacts between NHArg and NHGly and between NHAsp and NHGly. These three protons, on the 
other hand, show also a rather strong hydrogen bonded status, as indicated by their low 
temperature dependence and, at least for NHAsp and NHGly, their upfield chemical shift (Table 
2.1.1.). These data indicate an equilibrium between two different conformations: one displaying a 
Type III H-bonding pattern (β-turn at DKP-Arg, see Figure 2.1.15.) and a second one showing a 
Type II H-bonding pattern (-turn at Arg-Gly, see Figure 2.1.14.), like Cyclo-[DKP-1-RGD]. Finally, 
ligand Cyclo-[DKP-7-RGD]-B shows a single NOE contact between NHAsp and NH10 and a hydrogen 
bonded status for NH10 ( 7.72 ppm and /T -4 ppb/K, see Table 2.1.1.). These values are 
indicative of a Type I H-bonding pattern (see Figure 2.1.17.A above). 
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Three-dimensional structures satisfying long-range NOE contacts were generated for RGD 
peptidomimetic Cyclo-[DKP-7-RGD] performing three 10 ns restrained MC/SD simulations and 
applying the distance restraints derived from NOESY spectra of diastereoisomers Cyclo-[DKP-7-
RGD]-A and Cyclo-[DKP-7-RGD]-B (Table 2.1.1.): in the first simulation NHArg/NHGly relevant in 
Cyclo-[DKP-7-RGD]-A, in the second simulation NHAsp/NHGly also relevant in Cyclo-[DKP-7-RGD]-A, 
and in the third simulation DKP-NH10/NHAsp relevant in Cyclo-[DKP-7-RGD]-B. 
All the conformations sampled during the first two simulations adopted a non-extended 
arrangement of the RGD sequence [C(Arg)-C(Asp) average distance of 6.6 Å] characterized by 
the simultaneous presence of different turn motifs (pseudo -turn at DKP-Arg, -turn at Gly and 
pseudo -turn centered at the DKP unit). The structural models provided by these restrained 
MC/SD simulations differ from the conformations hypothesized on the basis of NMR data of Cyclo-
[DKP-7-RGD]-A [equilibrium between Type III (pseudo -turn at DKP-Arg) and Type II (-turn at 
Arg-Gly) H-bonding patterns, see the previous section]. However, also the calculated structures 
are able to provide an explanation for the NOE contacts and the NMR temperature coefficients 
observed for compound Cyclo-[DKP-7-RGD]-A. 
The distance restraint corresponding to the NOE contact between DKP-NH10 and NHAsp 
(observed in the NOESY spectrum of high affinity ligand Cyclo-[DKP-7-RGD]-B) was applied in the 
third 10 ns MC/SD simulation of compound Cyclo-[DKP-7-RGD]. Most of the conformations 
sampled during this simulation adopted an extended arrangement of the RGD sequence [C(Arg)-
C(Asp) average distance of 9.0 Å] and approximately 50% of them are characterized by a -turn 
at Gly-Asp and the corresponding hydrogen bond between DKP-NH10 and Arg-C=O (Type I-trans H-
bonding pattern). 
Contrary to what observed for the other cyclic RGD peptidomimetics containing DKP 
scaffolds, rotation of the DKP ring cannot be observed during the simulations performed on 
compound Cyclo-[DKP-7-RGD], confirming Cyclo-[DKP-7-RGD]-A and Cyclo-[DKP-7-RGD]-B as two 
different separable conformers (diastereomers) due to hindered rotation of one ring around the 
other. 
In conclusion, we identified five types of conformation, namely Type I-cis (-turn at Gly-
Asp), Type I-trans (-turn at Gly-Asp), Type II (-turn at Arg-Gly), Type III (-turn at DKP-Arg) and 
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Type IV (-turn at Asp-DKP). The most populated ones are the Type III, adopted by the compounds 
Cyclo-[DKP-2-RGD], Cyclo-[DKP-3-RGD], Cyclo-[DKP-5-RGD], and Cyclo-[DKP-7-RGD]-A and the 
Type I-trans, adopted by Cyclo-[DKP-4-RGD], Cyclo-[DKP-6-RGD] and Cyclo-[DKP-7-RGD]-B (Figure 
2.1.21.). 
A)                                                                                 B) 
 
Figure 2.1.21. Representation of the two most populated conformations; A) Example of a Type III 
H-bonding pattern, B) Example of a Type I-trans H-bonding pattern. Red arrows indicate NOE 
contacts, while dashed black line the H-bonds. 
 
2.1.5 isoDGR peptidomimetics 
Recent biochemical studies have shown that a spontaneous post-translational 
modification, occurring at the Asn – Gly – Arg (NGR) motif of the extracellular matrix protein, 
fibronectin, leads to the isoAsp-Gly-Arg (isoDGR) sequence.34 This rearrangement, which involves 
the attack of the protein backbone NH on the primary amide side chain of asparagines and ring 
opening of the succinimide, is a known side reaction normally leading to loss of biological 
activity.35 In this case, however, the result is a gain of protein function and the creation of a new 
adhesion binding site for integrins. Subsequent biochemical, spectroscopic and computational 
investigations have shown that the isoDGR sequence can fit into the RGD-binding pocket of V3 
integrin, establishing the same electrostatic clamp as well as additional polar interactions. Then, 
rapid NGR- to isoDGR- sequence transition in fibronectin generates V3 inhibitors (named 
“isonectins”) that competitively bind RGD binding sites. Given the structural and functional 
similarities between RGD and isoDGR, it is conceivable that peptides containing the isoDGR motif 
could also be exploited for the generation of integrin antagonists.36,37,38 
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In fact, in 2010, Kessler et al. created different libraries of head-to-tail-cyclized 
pentapeptides containing the isoDGR amino acid motif (i.e., c(GisoDGRG), c(FisoDGRG)), and 
studied these constrained isoDGR peptides for their affinities for integrin subtypes. The first 
approach was to synthesize a small library of peptides based on the retrosequence of the highly 
active integrin-binding cyclic peptide c(-RGDfV-), for example, c(-VfisoDGR-).38 
Based on these observations, a few conformationally constrained cyclopeptides containing 
the isoDGR sequence have been synthesized by our group. 
Two cyclic isoDGR peptidomimetics were synthesized containing the bifunctional 
diketopiperazine scaffolds mentioned above (Figure 2.1.22.) and we investigated their 
conformation in solution.37 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.22. Cyclic isoDGR peptidomimetics containing the bifunctional diketopiperazine 
scaffolds. 
 
Although isoDGR- and RGD- containing ligands can share the same binding site on 
integrins, their effects on integrin function are not necessarily identical for the following reasons. 
It is well established that the interaction between integrins and ligands is regulated by 
conformational changes. Conformational changes and integrin activation can be transmitted 
bidirectionally across the membrane through interactions with intracellular molecules (“inside-out 
signaling”) and with extracellular ligands (outside-in signaling”). It has been suggested that 
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different RGD-containing ligands induce different signaling pathways. Thus, it is possible that RGD 
and isoDGR ligands induce differential conformational changes and signaling in vivo.34 Notably, 
isoDGR docks onto V3-integrin in an inverted orientation compared with RGD docking to V3-
integrin. This orientation allows isoDGR to bind the integrin - and -subunits through the isoAsp 
and Arg residues. The acidic and basic side chains of these residues are at the correct distance and 
orientation to engage stabilizing interactions with the polar regions of the integrin, thus 
reproducing the canonical interactions between RGD and V3-integrin. Therefore, isoDGR is a 
natural fit for the RGD-binding pocket of V3 integrin.
36 
It appears, therefore, that isoDGR, like RGD, can differentially recognize integrins 
depending on its molecular scaffold. 
 
2.1.6 NMR characterization and conformational studies of isoDGR compounds37 
The structure and connectivity of compounds 8 and 9 were unambiguously assigned from 
the mono- and bidimensional 1H and 13C NMR spectra (see ∗Supplementary Information∗). The 
preferred conformations of 8 and 9 were investigated by 1H NMR spectroscopy of dilute H2O/D2O 
9:1 solutions and by computational methods. One-dimensional 1H-NMR spectroscopy experiments 
were conducted to detect intramolecular hydrogen bonds, by measuring the chemical shift of the 
amide N-H protons, their temperature coefficients (Δδ/ΔT) and their chemical exchange rate in the 
presence of D2O. The results are reported in the Table 2.1.2.. 
 
Ligand 8 9 
Structure Cyclo[DKP2-isoDGR] Cyclo[DKP3-isoDGR] 
 (ppm) 
T 
(ppb/K) 
Chemical Exchange 
rates 
(ppm) 
T 
(ppb/K) 
Chemical Exchange 
rates 
NH1 8.34 -6.99 0 min 7.60 -1.70 0 min 
NH10 8.43 -8.57 20 min 8.46 -8.02 1h27min 
NHAsp 8.23 -4.90 0 min 8.63 -7.03 12 min 
NHGly 7.88 -4.76 0 min 8.16 -7.20 7 min 
NHArg 8.26 -6.87 5-10 min 8.27 -6.92 12-17 min 
Table 2.1.2. List of the temperature coefficients, chemical shifts and chemical exchange rates of 
the two cyclo[DKP-isoDGR] peptidomimetics. 
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NOESY spectra were also recorded to investigate both sequential and long-range NOE 
signals that provide evidences of preferred conformations. Three-dimensional structures satisfying 
long-range NOE contacts were generated by restrained mixed-mode Metropolis Monte 
Carlo/stochastic dynamics (MC/SD) simulations,31 using the implicit water GB/SA solvation 
model.32 The data obtained from the NMR experiments show that compound 8 (Figure 2.1.23.) is 
characterized by a high conformational flexibility. In fact, the Δδ/ΔT values range from −4.7 ppb K−1 
(Gly-NH) to −8.5 ppb K−1 (DKP-NH10) and the N-H chemical shifts indicate that the amide protons 
of 8 are all solvent exposed. However, the strong NOE contact between isoAsp-NH and Gly-NH 
(Figure 2.1.23., structure on the left) indicates a preferred folding through the formation of a 
pseudo-β-turn stabilized by an intramolecular hydrogen bond between Gly-NH and DKP-C(5)=O. 
 
 
Figure 2.1.23. Left: preferred intramolecular hydrogen-bonded pattern proposed for the cyclic 
isoDGR peptidomimetic 8, on the basis of spectroscopic data. The arrow indicates the NOE 
contact. Right: 3D structure of 8 as obtained by restrained MC/SD simulations based on 
experimental distance information, after energy minimization [pseudo-β-turn at DKP-isoAsp, 
Cβ(Arg)-COO−(Asp) distance=8.8 Å]. 
 
The distance restraint corresponding to the NOE contact between isoAsp-NH and Gly-NH 
was applied in the MC/SD simulations of Compound 8. Approximately 50 % of the conformations 
sampled during the simulations adopted an extended arrangement of the isoDGR sequence 
characterized by a pseudo-β-turn at DKP-isoAsp and the formation of the corresponding hydrogen 
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bond between Gly-NH and C(5)=O. A Cβ(Arg)-COO−(Asp) average distance of 8.6 Å was obtained 
during the MC/SD calculations. A representative energy minimized conformation featuring the 11-
membered ring hydrogen bond between Gly-NH and C(5)=O is shown in Figure 2.1.23. (structure 
on the right). 
NMR spectroscopy experiments performed on the isoDGR peptidomimetic 9 suggest a 
different conformational preference. In fact, compound 9 exists in two preferred conformations 
(Figure 2.1.24.a and b). The NOESY cross-peak between DKP-NH10 and Arg-NH (strong) is 
indicative of a β-turn conformation stabilized by a hydrogen bond between DKP-NH10 and isoAsp-
C=O (Figure 2.1.24.a), whereas the NOESY cross-peak between Gly-NH and isoAsp-NH (weak) is 
indicative of a pseudo-β-turn motif (Figure 2.1.24.b) similar to that observed for compound 8. 
 
 
Figure 2.1.24. Preferred intramolecular hydrogen-bonded patterns proposed for the cyclic isoDGR 
peptidomimetic 9, on the basis of spectroscopic data. The arrows indicate the NOE contacts. a) β-
turn at Gly-Arg; b) pseudo-β-turn at DKP-isoAsp.  
 
Only the distance restraint corresponding to the strong NOE contact between DKP-NH10 
and Arg-NH (Figure 2.1.24.b) was applied in the MC/SD simulations of compound 9. It is worth 
noting that approximately 80 % of the conformations sampled during the simulations adopted an 
extended arrangement of the isoDGR sequence, characterized by a pseudo-β-turn at DKP-isoAsp 
and the formation of the corresponding hydrogen bond between Gly-NH and C(5)=O (Figure 
2.1.25.). In addition, the formation of a distorted β-turn at Gly-Arg (Figure 2.1.25.), characterized 
by hydrogen bond distances of about 3.5 Å between DKP-NH10 and isoAsp-C=O, was observed for 
10 % of the simulations. A Cβ(Arg)-COO−(Asp) average distance of 10.7 Å was obtained during the 
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MC/SD calculations of compound 9. Two representative energy-minimized conformations 
featuring the two hydrogen bond patterns compatible with the strong NOE contact between DKP-
NH10 and Arg-NH are shown in Figure 2.1.25.. 
 
 
Figure 2.1.25. The 3D structures of compound 9 as obtained by restrained MC/SD simulations 
based on experimental distance information, after energy minimization. a) Distorted β-turn at Gly-
Arg, populated for 10 % of the simulation, Cβ(Arg)-COO−(Asp) distance=10.7 Å; b) pseudo-β-turn at 
DKP-isoAsp, populated for 80 % of the simulation, Cβ(Arg)-COO−(Asp) distance=10.8 Å. 
 
Cyclic isoDGR peptidomimetics 8 and 9 were examined in vitro for their abilities to 
compete with biotinylated vitronectin for binding to the purified V3 receptor (Table 2.1.3.). 
Screening assays were performed by incubating the immobilized integrin V3 with increasing 
concentrations (10-12 – 10-5 M) of the two isoDGR ligands in the presence of biotinylated 
vitronectin (1 mg mL-1), and measuring the concentration of bound vitronectin in the presence of 
the competitive ligands.  
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Table 2.1.3. Inhibition of biotinylated vitronectin binding to V3 receptor. [a] IC50 values were 
calculated as the concentration of compound required for 50% inhibition of biotinylated 
vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean ± 
SD of triplicate determinations. [b] Determined by a solid phase binding assay by using supported 
vitronectin, soluble V3 integrin, specific primary and secondary antibodies. [c] Calculated as the 
concentration of compound required for 50 % inhibition of biotinylated vitronectin binding. 
 
The IC50 values of compounds 8 and 9 reported in Table 2.1.3. compare favorably with 
other isoDGR ligands, such as the cyclopentapeptide cyclo[GisoDGRphg]38a recently published by 
Kessler and co-workers, as well as with known RGD ligands, such as the cyclic peptidomimetic 
cyclo[(3S, 6R)DKP-RGD],4,25 cyclopentapeptides cyclo(RGDfV) and Cilengitide.21b In particular, 
ligand 9 is ten-times more potent in binding integrin V3 than cyclo[GisoDGRphg], only 2-3 times 
less potent than the RGD ligands cyclo[(3S,6R)DKP-RGD] and cyclo(RGDfV), and fifteen-times less 
potent than the powerful RGD ligand Cilengitide. 
In order to rationalize, on a molecular basis, the affinity of compounds 8 and 9 for the αvβ3 
receptor, docking studies were performed starting from the representative conformations 
obtained from the restrained MC/SD simulations. The crystal structure of the extracellular 
segment of integrin αvβ3 complexed with the cyclic pentapeptide Cilengitide (PDB ID: 1L5G) was 
taken as a reference model for the interpretation of the docking results in terms of ligand – 
protein interactions. In the X-ray complex, Cilengitide binds to the interface of the α and β units 
forming specific electrostatic interactions. The acid and basic pharmacophoric groups and their 
orientation are essential for binding to αvβ3, because they act like an electrostatic clamp and 
interact with charged regions of the receptor binding site. 
Ligands V3 IC50 [nM] 
8 46.7 ± 18.2 
9 9.2 ± 1.1 
cyclo[GisoDGRphg] 89 ± 19[b] 
cyclo[(3S,6R)DKP-RGD] 4.5 ± 1.1 
cyclo[RGDfV] 3.2 ± 1.3 
cyclo[RGDf(N-Me)V] (Cilengitide) 0.6 ± 0.1[c] 
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Docking calculations starting from the pseudo-β-turn DKP-isoAsp geometries of compound 
8 (Figure 2.1.23., right) and from the distorted β-turn Gly-Arg conformations of compound 9 
(Figure 2.1.25., left), produced top-ranked poses conserving the key electrostatic interactions but 
lacking further stabilizing hydrogen bond interactions with the β subunit (e.g., hydrogen bonds of 
ligand carboxylate oxygen with the backbone amides of Asn215 and Tyr122, and hydrogen bonds 
between ligand backbone N-H and protein backbone carbonyl groups). 
On the contrary, docking calculations starting from the pseudo-β-turn DKP-isoAsp 
geometries of Compound 9 (Figure 2.1.25., right) produced top-ranked poses conserving all the 
important interactions of the X-ray complex (Figure 2.1.26.). 
 
Figure 2.1.26. Best pose of compound 9 (atom color tube representation, pseudo-β-turn at DKP-
isoAsp) into the crystal structure of the extracellular domain of αvβ3 integrin (α unit red and β unit 
blue wire representation) overlaid on the bound conformation of Cilengitide (green tube 
representation). Only selected integrin residues involved in the interactions with the ligand are 
shown. The metal ion in the MIDAS region is represented by a magenta sphere. Nonpolar 
hydrogen atoms were removed for clarity. 
 
The positively charged Arg guanidinium group of the ligand interacts with the negatively 
charged carboxylates of Asp218 and Asp150 in the α unit, one carboxylate oxygen of the ligand is 
coordinated to the metal cation in the metal-ion-dependent adhesion site (MIDAS) region of the β 
unit, whereas the second carboxylate oxygen forms hydrogen bonds with the backbone amides of 
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Asn215 and Tyr122 in the β unit. A further stabilizing interaction involves the formation of a 
hydrogen bond between the ligand backbone NH of the Gly residue and the backbone carbonyl 
group of Arg216 in the β unit. 
These docking calculations were reported here, while the docking calculations for the RGD 
compounds are better explained in the Section 2, for more clarity. 
 
2.1.7 Cell lines expressing integrins 
Integrins are membrane proteins and, in contrast to soluble proteins, there is little 
information available about ligand-receptor interactions that occur at membrane surfaces. In fact, 
the aggregation behaviour of these proteins is unpredictable, the production of the isolated, 
soluble membrane proteins is difficult and, when a truncated, soluble form of the receptor is 
accessible, the binding affinity of this form may differ from that of the native receptor embedded 
into a membrane. So, it is crucial to characterize this type of interactions working in the 
biophysical neighborhood of the membrane itself and not in an isotropic extracellular medium.  
Many studies showed the application of different NMR techniques to study the interaction 
between some RGD-based ligands and integrins embedded in planar lipid bilayers or 
liposome.39,40,41 
However, more recent studies demonstrate many differences in the interaction if 
evaluated into liposomes or directly in the native intact cells overexpressing integrins,42 supporting 
the importance to study membrane proteins in their natural environment. 
Before my thesis, numerous NMR experiments were conducted using transfected cells 
without giving results due to the fact that the number of the receptors expressed on the cell 
surface is largely variable (unpublished results). However, also the work with cells that naturally 
overexpressed integrins has numerous problems; in fact, the initiation and progression of cancer is 
accompanied by alterations in the expression profile of various adhesion receptors, including 
integrins. Endothelial cells in the angiogenic vessels within solid tumours express several proteins 
that are absent or hardly detectable in established blood vessels, including integrins and receptors 
for certain angiogenic growth factors. The V3 integrin, for instance, is expressed at low levels on 
epithelial cells and mature endothelial cells; however, it is highly expressed on activated 
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endothelial cells in the neovasculature of tumours, including osteosarcomas, neuroblastomas, 
glioblastomas, melanomas, lung carcinomas, and breast cancer.43 
Notwithstanding these problems, we found different available cell lines that naturally 
express integrins in different ratio. At the beginning, in particular, I set up live cell NMR 
methodologies by using human platelets, that express on their surface only integrin IIb3. 
Platelets are cells without a nucleus, but with an active energy metabolism. As reported in the 
paragraphs above, in the activated state, the integrin binds to fibrinogen and then mediates 
thrombus formation by platelet aggregation.42 Then, we used ECV-304 bladder and MDA-MB-231 
breast cancer cell lines. In the Figure 2.1.27. and in Table 2.1.2. is reported the expression of 
different types of integrins in different cell lines obtained by fluorescence analysis (FACS) method, 
that exploits fluorescent signals emitted from individual proteins express on the cell surface.  
 
 
 
 
 
 
 
 
Figure 2.1.27. and Table 2.1.2. Cytofluorimetric analysis of V3, V5 and 51 integrin expression 
on human epithelial cancer cell panel; MFI= Mean Fluorescence Intensity. 
 
Despite their epithelial origin, ECV-304 cells share many characteristics with the human 
endothelium, and they are widely used as endothelial-like cells. ECV-304 bladder cancer cell line, 
Cell lines  MFI  Expression 
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ECV-304  1977  3322  3867  1.16  
MDA-MB-231  795  592  4208  7.11  
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derived from solid tumours, highly expresses V3 integrin. The average number of V3 receptors 
per ECV-304 cell was estimated to be about 4*103, as well as the average number of 51 
receptors. Instead, for MDA-MB-231 the average number of 51 receptors is about 4*10
3, but 
expresses seven-fold excess of 51 with respect to V3 (ratio = 7.11). T98G cells express 
approximately a three-fold excess of 51 with respect to V3 (ratio = 2.75). This suggests that a 
comparison among these two cell lines should be a good way to investigate the selectivity of test 
compounds for integrins 51 and V3. In our next discussion, however, to evaluate the obtained 
NMR results we had to take into consideration the ratio of expression rather than the absolute 
values. In the Figure 2.1.28. the optical microscopy analysis of the two cell lines are reported. 
 
 
 
 
 
 
Figure 2.1.28. Optical microscopy analysis of ECV-304 and MDA-MB-231 human cell lines; 
Magnification 20x. 
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Section 2: Results and Discussion  2.2.1 INTERACTIONS WITH PLATELETS 
In this part of the work, we have used NMR methodologies to shed light on the interaction 
of the peptidomimetic integrin ligands Cyclo-[DKP-1-RGD] (1), Cyclo[DKP-2-RGD] (2) and 
Cyclo[DKP-3-RGD] (3) with human platelets, known to express on their membrane only integrin 
αIIbβ3. Previous work demonstrated that the binding of selected RGD ligands to the integrin αIIbβ3 
of intact human platelets can be studied by using saturation transfer double difference NMR 
(STDD)42 and tr-NOESY5 NMR techniques. In this thesis, STD and tr-NOESY NMR experiments were 
conducted in the presence of platelet suspension with the aim to identify the epitope and the 
bound conformation of three DKP-RGD ligands, and to investigate the effect of scaffold 
stereochemistry on ligand binding mode. 
In fact, the selected DKP-RGD ligands differ only for the configuration at the two stereocenters of 
the DKP scaffold. The STD-NMR results were compared to docking studies into the X-ray structure 
of αIIbβ3. For compounds 2 and 3, docking calculations showed a good disposition of the ligands 
into the binding site, conserving all the important interactions observed in the X-ray complex. 
 2.2.1.1 The docking model of αIIbβ3  
Starting from the ligand representative conformations obtained from the MC/SD 
simulations, docking calculations were performed using GLIDE v 4.5.47 Computational models for 
the interaction of RGD peptidomimetic ligands with the αIIbβ3 integrin were built using a 
previously developed docking approach,4,25 starting from the crystal structure of the integrin αIIbβ3 
headpiece bound to the cyclic heptapeptide Eptifibatide or Integrilin (Protein Data Bank entry 
2VDN, see “Experimental Section”), which is currently in clinical use to prevent thrombosis 
(Figure 2.2.1.).19 Integrilin is a cyclic heptapeptide mimic derived from a disintegrin containing the 
Lys-Gly-Asp-Trp sequence with the Lys residue converted to homoarginine. The homoArg with its 
longer aliphatic chain than Arg confers selectivity to integrilin for αIIbβ3, whereas Trp confers high 
affinity.  
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Figure 2.2.1. Left: representation of the binding site of the integrin αIIbβ3 (red and blue) complexed 
with Integrilin (gray) from PDB 2VDN. Right: structure of Eptifibatide. 
 
In the X-ray complex, Eptifibatide binds to the interface of the α and β units forming 
specific electrostatic interactions. The acid and basic pharmacophoric groups and their orientation 
are essential for the binding because they act like an electrostatic clamp, interacting with charged 
regions of the receptor binding site. 
Eptifibatide is disposed in an extended conformation in the receptor site (with Cβ(Arg) – Cβ(Asp) = 
9.14 Å) placing the carboxylic and guanidine groups on the positive Ca2+ ion (MIDAS) in the β 
subunit and on the negative Asp224 residue side chain of the α subunit, respectively. Further 
stabilizing interactions occur between the ligand and the receptor residues. The guanidine group 
of the Integrilin homoArg forms a charged hydrogen bond to αIIb residue Asp224 as well as a 
hydrogen bond to an αIIb backbone carbonyl (Phe160). The carboxylate of the Integrilin Asp side 
chain directly coordinates to the MIDAS cation and is further stabilized by three hydrogen bonds 
to the β3 backbone (Asn215, Tyr122 and Ser123). A further stabilizing interaction involves the 
formation of a hydrogen bond between the ligand backbone NH of the Asp residue and the 
backbone carbonyl group of Arg216 in the β3 unit. In addition, there is a π-stacking interaction 
between the Trp moiety and the Phe160 residues of the α chain. All these interactions were used 
as a guide for the description and for the evaluation of the binding mode of the studied 
compounds. 
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Docking results showed that the two geometries adopted by compound 1, namely Type I-
cis and Type II H-bonding pattern, due to their short Cβ(Arg) – Cβ(Asp) distances (values lower 
than 8 Å) fail in forming all the interaction pattern observed for Eptifibatide. Probably the bent 
conformations prevent the guanidine and carboxylic groups from achieving the required distance 
for binding to the αIIbβ3. In fact, docking calculations starting from the RGD extended 
conformations featuring the Type III H-bonding pattern for compounds 2 and 3 (Cβ(Arg) – Cβ(Asp) 
distance values ≥ 8.8 Å), produced top-ranked binding modes conserving all the important 
interactions of the X-ray complex. 
 2.2.1.2 Control experiments and tr-NOESY results of compounds 1 – 34 
Compounds 1 – 3 were thus analyzed in the presence of human platelets for the first time 
using STD and tr-NOESY NMR techniques.3,39,44 All the experiments with platelets were conducted 
at 298 K in a non deuterated buffer. 
Negative control experiments were performed using mannose that was added to a platelet 
suspension containing a previously developed peptidomimetic ligand (ST1646).5,22,23,24 Under 
these conditions a NOESY spectrum was recorded. The platelet membrane does not contain 
mannose receptors and the NOESY spectrum showed negative cross-peaks (trNOEs) for the tested 
compound, that are with the same negative sign as the diagonal, indicating a binding situation, 
while positive cross-peaks were present for mannose, indicating absence of binding. This suggests 
that the interaction observed for the tested compound is not aspecific, but rather depends on a 
specific receptor on the platelet membrane. In addition, no transferred NOEs were detected in the 
control experiments for the free ligands at identical conditions without the presence of platelets.5  
In addition, as many studies suggest the prominent role played by divalent cations, Ca2+, as 
a key element in receptor activation, further negative controls were conducted in the presence 
and absence of Ca2+ ions (unpublished results). In the absence of Ca2+ ions, the integrin receptors 
are not activated and we did not have any evidence of binding both from the tr-NOESY and from 
STD experiments. In fact, tr-NOESY experiments, conducted in the presence of ST1646 compound 
and without Ca2+ ions indicated the absence of binding, with positive cross-peaks, and we did not 
observe STD signals in the STD experiment. 
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Transferred intramolecular NOEs are well established as unique sources of structural 
information on bound ligand. The technique, fully described in the Chapter 1, relies on the size-
dependence of the intramolecular NOE, which shows slow NOE build-up with weak positive 
maxima for free ligands and rapid build-up with strong negative maxima for the bound state. If 
dissociation of the ligand occurs quickly enough (Kd > 10-7 M), a sufficient percentage of the 
observable free ligand will retain intense negative trNOE and thus binding of a ligand to a receptor 
protein can be easily detected by looking at the sign and size of the observed NOEs.  
Compound 1 in the free-state revealed the presence of two main conformations (see 
paragraph “NMR Characterization and Conformational Analysis”, Chapter 1): a Gly-Asp β-turn 
conformation (Type I-cis) stabilized by a hydrogen bond between DKP-NH10 and Arg-C=O (Figure 
2.2.2.a), and an Arg-Gly β-turn conformation (Type II) stabilized by a hydrogen bond between 
NHAsp and C(8)=O (Figure 2.2.2.b). 
 
Figure 2.2.2. Preferred free state conformations of cis-DKP-RGD-peptidomimetic. Arrows indicate 
significant NOE contacts and dotted lines the hydrogen bonding patterns stabilizing β-turn motifs: 
(a) Gly-Asp β-turn; (b) Arg-Gly β-turn. 
 
The weakness of the NH- NOE contacts in the tr-NOESY experiments does not allow 
considerations about the conformational equilibrium that characterized the compound in the 
bound-state. However, the tr-NOESY experiment of compound 1 in the presence of platelets at 
298 K showed negative cross-peaks (i.e., with the same negative sign as the diagonal) in contrast 
to the positive ones found in the free-state, which gave evidence of binding. Probably, the 
conformational equilibrium of compound 1 is unalterated by the binding to platelets. 
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Compound 2 is characterized by a DKP-Arg β-turn conformation (Type III) stabilized by a 
hydrogen bond between NHGly and C(5)=O (Figure 2.2.3.), as suggested by the relevant long-range 
NOE interaction between NHGly and NHArg (positive at 298 K). 
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Figure 2.2.3. Free and bound conformation of trans-DKP-RGD-peptidomimetic 2. Hydrogen bond 
(dotted line) and NOE contact (arrow) are indicated. 
 
Also in this case, the weakness of the NH- NOE cross-peaks does not allow considerations 
about the conformation adopted by compound 2 in the bound-state; however, the presence of 
negative cross-peaks in the tr-NOESY experiment gave evidence of binding. In addition, the cross-
peaks between the aromatic protons and the Arg-side chain protons, which can be observed in the 
NOESY experiments (free ligand), are lacking in the tr-NOESY spectrum. The absence of these 
cross-peaks in the bound state suggests an extended conformation of the Arg-side chain, suitable 
for the constitution of the electrostatic clamp inside the binding pocket. 
Also compound 3 adopts, in the free state, mainly one conformation characterized by the 
presence of a β-turn stabilized by a hydrogen bond between NHGly and C(5)=O (Type III, Figure 
2.2.4.), and by an extended arrangement of the RGD sequence [Cβ(Arg) – Cβ(Asp) distance of about 
9 Å]. NOESY experiments showed a long range contact (positive) between NHGly and NHArg, 
confirming this conformation. 
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Figure 2.2.4. Free and bound conformation of trans-DKP-RGD-peptidomimetic 3. Hydrogen bond 
(dotted line) and NOE contact (arrow) are indicated. 
 
The tr-NOESY experiment does not permit to evaluate the bound conformation because 
the cross-peaks intensity is close to zero and the only detectable cross-peaks were related to the 
platelet membrane. However, in the free-state the cross-peaks are positive and not close to zero, 
this variation suggests that a binding event happened, even if the cross-peaks do not have the 
same negative sign as the diagonal.  2.2.1.3 STD-NMR and molecular docking results of compounds 1 - 3 
Then, STD experiments5 were performed in the presence of the platelet suspension for all 
the three compounds at 298 K. The STD sequence helps identifying the group epitope, revealing 
which moieties of the ligand molecule are closest to the receptor in the bound state. The method, 
fully described in Chapter 1, is based on the transfer of saturation from the protein to the bound 
ligand which, by exchange, is released into solution where it is detected. The degree of saturation 
of individual ligand protons (expressed as absolute-STD percent) reflects their proximity to the 
protein surface and can be used to describe the ligand-target interactions.  
 Compound 1 
The STD-NMR experiment on compound 1 displayed signals for the guanidine NH, DKP-NH1 
and the aromatic protons (1.0, 0.6 and 0.3% STD absolute intensity, Figure 2.2.5., blue bars). These 
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results highlight that this compound interacts through its basic moiety with the αIIb subunit of 
integrin αIIbβ3. 
 
Figure 2.2.5. Relevant absolute STD percentages for the protons of cyclic DKP-RGD 1 - 3 obtained 
at T = 298 K in the presence of a platelet suspension: compound 1 (blue bars), compound 2 (red 
bars), compound 3 (green bars). 
 
Docking calculations into the αIIbβ3 integrin starting from the two conformations of 
compound 1, namely Type I-cis and Type II, showed poses failing in forming all the interaction 
pattern observed for Eptifibatide. Probably these bent conformations (Cβ(Arg) – Cβ(Asp) distances 
values lower than 8 Å) prevent the guanidine and carboxylic groups to achieve the required 
distance for binding to the αIIbβ3. In fact, for compound 1 the interaction mainly occurs through its 
basic moiety (guanidine NH) with the αIIb subunit, for which we observed the largest STD effect. 
We observed STD effects also for aromatic and DKP-NH1 protons of the scaffolds but not for other 
protons of the RGD sequence, confirming a non-optimal or weak interaction of 1 with the 
receptor. 
 Compound 2 
In the STD experiment of compound 2 in the presence of platelets, the protons involved in 
the interaction belong to the DKP scaffold (DKP-NH1 and DKP-H9, 1.0 and 0.4% STD absolute 
intensity, respectively) as well as to the RGD sequence (NHGly, NHAsp and the guanidine NH, 0.3, 0.3 
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and 1.1% STD absolute intensity, respectively), while the aromatic protons do not appear in 
contact with the protein (Figure 2.2.5., red bars). 
Docking calculations, starting from the preferred RGD extended conformation of 
compound 2 (Figure 2.2.3.) obtained from previous MC/SD simulations, produced top-ranked 
binding poses conserving all the important polar interactions of the X-ray complex with 
Eptifibatide. The guanidine group of the ligand Arg forms a charged hydrogen bond to αIIb residue 
Asp224 as well as a hydrogen bond to an αIIb backbone carbonyl (Phe160 or Tyr189). The 
carboxylate of the ligand Asp side chain directly coordinates to the MIDAS cation and is further 
stabilized by three hydrogen bonds to the β3 backbone (Asn215, Tyr122 and Ser123) and one to 
the β3 Asn215 side chain. A further stabilizing interaction involves the formation of a hydrogen 
bond between the ligand backbone NH of the Asp residue and the backbone carbonyl group of 
Arg216 in the β3 unit. Moreover, favourable van der Waals contacts can be detected between 
DKP-NH1 and the Hβ of Ser123, between DKP-H9 and the aromatic protons of β3-Tyr122, and 
between NHGly and the methyl protons of β3-Ala218. So, docking results are consistent with the 
STD data showing the RGD sequence in close contact to the receptor.  Compound 3 
In the case of compound 3, the largest STD effect is again observed for the guanidine NH 
(2.7% STD absolute intensity, see Figure 2.2.5., green bars); hence this proton closely approaches 
the αIIb subunit of the protein. Remarkably, also DKP-NH10, DKP-NH1, NHGly, NHAsp and the 
aromatic protons of this ligand show quite intense STD effects (2.3, 0.9, 0.8, 0.8 and 0.5%, 
respectively) and, as observed for 2, also compound 3 can be considered as lying close to the 
protein surface. The epitopes of the compounds 2 and 3 appear to be quite similar, except for the 
aromatic protons that are not present for compound 2. 
Also for compound 3, the STD-NMR results in the presence of platelets can be nicely 
interpreted by the docking poses of the ligand into the αIIbβ3 integrin binding site. In fact, docking 
studies starting from the extended conformation (Figure 2.2.4.) obtained from MC/SD simulations, 
produced top-ranked binding modes conserving all the key RGD interactions of the X-ray complex 
between αIIbβ3 integrin and Eptifibatide (Figure 2.2.6.). 
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Figure 2.2.6. Docking best pose of trans-DKP-RGD-peptidomimetic 3 (tube representation, C atoms 
in green, N in blue, O in red, H in white) into the crystal structure of the integrin αIIbβ3 headpiece 
(α unit red and β unit blue wire representation) overlaid on the bound conformation of 
Eptifibatide (gray tube representation). Only selected integrin residues involved in the interactions 
with the ligand are shown. The metal ion at MIDAS is shown as a magenta CPK sphere. For the 
sake of clarity, all H atoms bound to carbon are omitted. 
 
Compared to compound 2, for compound 3 favourable van der Waals contacts can be 
detected between the ligand benzyl group and the aromatic moiety of β3-Tyr122 and the Hα of 
Ser123 (Figure 2.2.7.). 
 
 
 
89 
 
  
Figure 2.2.7.  Docking best poses of trans-DKP-RGD-peptidomimetics 2 and 3 (pink and green atom 
colour tube representation, respectively) into the crystal structure of the integrin αIIbβ3 headpiece 
(α unit red and β unit blue wire representation). 
 
The superimposition of the best poses of 2 and 3 into the binding site showed a similar 
disposition of the two compounds, perfectly overlapped in the RGD sequence, but different in the 
benzyl group which points into opposite direction (Figure 2.2.7.). According to the absence of the 
STD effect for the aromatic protons of compound 2, in the docking poses no residue of the protein 
is in contact with the ligand benzyl group. 
 2.2.2 INTERACTIONS WITH ECV-304 BLADDER CANCER CELLS 
Starting from the encouraging results obtained with platelets, we applied the same NMR 
techniques to study the interaction of DKP-RGD ligands 1 - 3 with integrin αVβ3. To this end, we 
performed our experiments on the ECV-304 bladder cancer cells, known to overexpress on their 
membrane integrin αVβ3 (see paragraph “Cell lines expressing integrins”). We then expanded our 
investigation considering also the DKP-RGD ligands 4 - 7. Aware of the fact that the ECV-304 cell 
line expresses a panel of different integrins, namely αVβ3, α5β1 and αVβ5, we also performed 
experiments on MDA-MB-231 breast cancer cells, known to overexpress mainly integrin α5β1.  
For clarity, I will discuss first the results obtained with ECV-304 cells for compounds 1 - 3 
and I will compare them with those obtained with platelets. Then, I will show the results of ligands 
4 - 7 with ECV-304 cells and the comparison with the data achieved with MDA-MB-231 cells. 
 
90 
 
2.2.2.1 The docking model of αVβ3 
A computational model for the interaction with the αVβ3 integrin was built starting from 
the X-ray structure of the extracellular segment of integrin αVβ3 complexed with the cyclic 
pentapeptide ligand Cilengitide (Protein Data Bank entry 1L5G) (Figure 2.2.8.).18 In the X-ray 
complex, Cilengitide binds to the interface of the α and β units forming specific electrostatic 
interactions. The acid and basic pharmacophoric groups and their orientation are essential for the 
binding because they act like an electrostatic clamp, interacting with charged regions of the 
receptor binding site. 
 
 
 
 
 
 
 
 
Figure 2.2.8. Left: representation of the binding site of the integrin αVβ3 (red and blue) complexed 
with Cilengitide (gray) from PDB 1L5G. Right: structure of Cilengitide. 
 
Cilengitide is disposed in an extended conformation (Cβ(Arg) – Cβ(Asp) = 8.87 Å) in the 
receptor site placing the carboxylic and guanidine groups respectively on the β (Ca2+) and α chain 
(residues Asp150 and Asp218). The stabilization of the compound inside the receptor site occurs 
also with other types of interactions, such as H-bonding (with the residues Arg216, Asn215 and 
Tyr122 of the β subunit) and hydrophobic interactions (for example with Tyr122 of the β subunit). 
All these interactions were used as a guide for the description and for the evaluation of the 
binding mode of the studied compounds. In particular, the positively charged Arg guanidinium 
group of the ligand interacts with the negatively charged side chains of Asp218 and Asp150 in the 
α unit, one carboxylate oxygen of the ligand Asp side chain is coordinated to the metal cation in 
the metal-ion-dependent adhesion site (MIDAS) region of the β unit, whereas the second 
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carboxylate oxygen forms hydrogen bonds with the backbone amides of Asn215 and Tyr122 in the 
β unit. Further stabilizing interaction involves the formation of a hydrogen bond between the 
ligand backbone NH of the Asp residue and the backbone carbonyl group of Arg216 in the β unit. 
Favourable aromatic ring interactions between the ligand benzylic groups and the β3-Tyr122 side 
chain could also be observed. The X-ray structures of αVβ3 and αIIbβ3 complexed with RGD ligands 
have revealed an identical atomic basis for the interaction: RGD binds to the interface of the α and 
β subunits, the Arg residue fitting into a cleft in the α subunit, and the Asp coordinating a cation in 
the β subunit. The RGD tripeptide adopts a highly extended conformation across the αVβ3 and 
αIIbβ3 integrin intersubunit interface. The Arg and Asp side chains extend in opposite directions, 
and the backbone in between is also extended. Looking at the distinguishing features, the basic 
ligand side chain must reach further into the deeper β propeller pocket of αIIb to interact with 
Asp224, whereas the residues Asp150 and Asp218 are nearer in the shallower αV binding pocket.  2.2.2.2 In vitro biological assays of compounds 1 - 3  
We can take advantage also of the presence of biological assays both on the isolated 
receptors (αVβ3 and αVβ5) and on the cell line.  Integrin receptor competitive binding assays 
The cyclic RGD peptidomimetics 1 - 3 were examined in vitro for their ability to inhibit 
biotinylated vitronectin binding to the purified αvβ3 and αvβ5 receptors (Table 2.2.1.).  
 
Structures αvβ3  
IC50 [nM][a] 
αvβ5  
IC50 [nM][a] 
cyclo[DKP-1-RGD] 3898 ± 418 > 104 
cyclo[DKP-2-RGD] 3.2 ± 2.7 114 ± 99 
cyclo[DKP-3-RGD] 4.5 ± 1.1 149 ± 25 
ST164622,24 1.0 ± 0.5 1.4 ± 0.8 
cyclo[RGDfV]45 3.2 ± 1.3 7.5 ± 4.8 
cyclo[RGDf(N-Me)V]21 0.6 ± 0.1 11.7 ± 1.5 
Table 2.2.1. Inhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors. [a] IC50 values 
were calculated as the concentration of compound required for 50% inhibition of biotinylated 
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vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean ± 
SD of triplicate determinations. 
 
Screening assays were performed incubating the immobilized integrin receptors with 
various concentrations (10-12–10-5 M) of the RGD ligands 1, 2 and 3 in the presence of biotinylated 
vitronectin (1 µg/mL), and measuring the concentration of bound vitronectin in the presence of 
the competitive ligands (see “Experimental Section”). The ability of the new compounds to inhibit 
the binding of vitronectin to the isolated αvβ3 receptor was compared with that of the reference 
compounds c(RGDfV) and ST1646. The results are collected in Table 2.2.1.. Low nanomolar IC50 
values were obtained for all the ligands containing trans DKP scaffolds, and a micromolar IC50 
value was obtained for ligand 1 derived from the cis DKP1 scaffold. These data further 
demonstrate that the  extended RGD sequence forced by the trans diketopiperazine scaffolds of 
compounds 2 and 3 (compared to the folded RGD sequence due to the cis scaffold of compound 1) 
gives rise to a better pre-organization of the cyclic peptidomimetics for binding to the integrin 
receptors. Interestingly, unlike reference compounds, the RGD peptidomimetics were about 10 – 
500-fold more selective for the αVβ3 integrin with respect to the αVβ5 in this kind of assay.  
 Cell adhesion assays 
To assess the activity of the compounds as integrin antagonists on a cell model, cell 
adhesion experiments were performed using ECV-304 bladder cancer cells. Cells were allowed to 
adhere to the immobilized physiological ligand, vitronectin (VN, the highest affinity ligand for αVβ3 
integrin) or fibronectin (FN, the highest affinity ligand for α5β1 integrin), in the presence of 
increasing concentration of the tested compound (see “Experimental Section”). Adhesion assay is 
a cell biology test extensively used to determine the ability of compounds to compete with the 
adhesion of a cell line to physiological ligand. 
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Ligand 
ECV-304 
Vitronectin 
IC50 [µM][a] 
Fibronectin 
IC50 [µM][a] 
cyclo[DKP-1-RGD] > 200 > 200 
cyclo[DKP-2-RGD] 13.8 ± 0.2 2.2 ± 0.4 
cyclo[DKP-3-RGD] 49.5 ± 3.0 15.0 ± 3.9 
cyclo[RGDfV] 0.22 ± 0.00 0.36 ± 0.09 
Table 2.2.2. Effect of DKP-RGD compounds on ECV-304 cell adhesion to vitronectin and 
fibronectin. [a] Each data point was performed in triplicate in two independent experiments.  
 
As shown in Table 2.2.2., compound 1 was not able to impair the adhesion of the ECV-304 
cell line on either vitronectin or fibronectin, thus confirming its low affinity for the αVβ3 integrin. In 
contrast, both cyclic peptidomimetics 2 and 3 (containing trans DKP scaffolds) significantly 
inhibited cell adhesion to either fibronectin or vitronectin, exhibiting a micromolar anti-adhesive 
activity.  
The micromolar activities obtained in the adhesion assays represent an ideal range for 
testing interactions between the ligands and the integral membrane protein of intact cells by 
means of tr-NOE and STD techniques. 
 2.2.2.3 tr-NOESY results of compounds 1 - 3 
The NOE experiments for compound 1 in phosphate buffer at 298 K showed positive NOE 
contacts. The tr-NOESY experiment of compound 1 in the presence of ECV-304 cells at 298 K also 
showed positive cross-peaks, which indicate absence of binding. Lowering the temperature to 282 
K, the NOESY spectrum of the free ligand 1 showed cross-peaks with an inverted phase, i.e. with 
the same negative sign as the diagonal. The tr-NOESY spectrum performed at 282 K showed a 
negative cross-peak between NHGly (8.82 ppm) and NHAsp (8.13 ppm); this NOE contact is 
consistent with the β-turn conformation at Arg-Gly stabilized by the hydrogen bond between 
NHAsp and C(8)=O mentioned above and depicted in Figure 2.2.9.. This would indicate that, upon 
binding to cells, the conformational equilibrium present in the free state is shifted towards one 
conformation, and precisely to the less abundant in the free state. 
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Figure 2.2.9. Preferred bound state conformation of cis-DKP1-RGD-peptidomimetic. Arrows 
indicate significant NOE contacts and dotted lines the hydrogen bonding patterns stabilizing β-turn 
motifs: Arg-Gly β-turn (Type II, bound conformation). 
 
In the tr-NOESY experiments of compound 2 at 298 K the cross-peak intensity is close to 
zero, while at 282 K the contacts are negative like in the free state. However, as described above, 
the NOESY spectrum at 298 K showed positive cross-peaks in contrast to what observed in the tr-
NOESY experiment, where the cross-peak intensity is close to zero; this variation is enough to 
demonstrate the binding event, even if the cross-peaks did not adopt in the tr-NOESY an inverted 
phase. In addition, the weakness of the NHGly/NHArg cross-peak does not allow considerations 
about the bound conformation, but all the other cross-peaks are overlapping with those of the 
free state, suggesting the maintenance of the conformation characterized by a β-turn at DKP-Arg 
also in the bound state (Type III, Figure 2.2.10.). 
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Figure 2.2.10. Bound conformation of trans-DKP2-RGD-peptidomimetic 2. Hydrogen bond (dotted 
line) and NOE contact (arrow) are indicated. 
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For compound 3, the NOESY experiments at 282 K in the free-state showed a long range 
contact (positive) between NHGly and NHArg, suggesting a DKP-Arg β-turn conformation (Type III). 
The tr-NOESY experiments of compound 3 at 282 K showed negative cross-peaks (i.e., with the 
same phase as the diagonal), indicating a binding situation. However, only a very weak NOE 
contact between NHGly and NHArg is observed in the tr-NOESY spectrum at 282 K, indicating the 
maintenance of the free state conformation, Type III (Figure 2.2.11.), also in the bound state.  
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Figure 2.2.11. Bound conformation of trans-DKP3-RGD-peptidomimetic 3. Hydrogen bond (dotted 
line) and NOE contact (arrow) are indicated. 
 
Moreover, the cross-peaks between the aromatic protons and the Arg side chain protons, 
which can be observed in the NOESY experiments (free ligand), are lacking in the tr-NOESY 
spectrum (Figure 2.2.12.). These cross-peaks suggest folding of the Arg-side chain, which does not 
occur in the bound ligand. In fact, the formation of the electrostatic clamp inside the binding 
pocket requires that the side chains of Arg and Asp lie in an extended conformation. 
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Figure 2.2.12. Left: NOESY spectrum of compound 3 in non-deuterated buffer. Right: tr-NOESY 
spectrum of compound 3 in a cell suspension. Experiments performed at T = 282 K. The aromatic 
region is highlighted with a red circle. 
 
STD-NMR experiments were performed in the presence of ECV-304 cells at 298 K and at 
282 K. Temperature is an important parameter for the sensitivity of STD spectroscopy; it strongly 
influences the kinetics and the affinity constant of protein-ligand complex formation and, doing so, 
it affects the observed STD signals. 
 2.2.2.4 STD-NMR and molecular docking results of compounds 1 – 3 Compound 1 
For compound 1, STD-NMR experiments performed at 298 K did not give satisfactory 
results, whereas at 282 K the region of the spectrum corresponding to the aromatic and amide 
protons is well resolved and can be used to measure the absolute intensity of STD (Figure 2.2.13., 
blue bars). The largest STD effects (1.3% STD absolute intensity) were observed for the guanidine 
NH protons (7.26 ppm), which are expected to be in contact with the protein. Also the aromatic 
protons and the DKP-NH1 showed a STD effect (0.4 and 0.8% STD absolute intensity, respectively) 
and consequently can be considered lying close to the protein surface. A very small STD effect is 
observed for NHAsp (0.2% STD absolute intensity). 
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Figure 2.2.13. Relevant absolute STD percentages for the protons of cyclic DKP-RGD 1 – 3 obtained 
at T = 282 K in the presence of ECV-304 cells: compound 1 (blue bars), compound 2 (red bars), 
compound 3 (green bars). 
 
As previously reported for the integrin αIIbβ3, NMR data were compared with docking 
results into the αVβ3 model. Docking studies starting from the bound conformation of compound 1 
(Type II, Figure 2.2.9.) produced top-ranked poses conserving optimal interactions only between 
the positively charged Arg guanidinium group of the ligand and the negatively charged side chains 
of Asp218 and Asp150 in the α unit (Figure 2.2.14.). 
 
Figure 2.2.14. Docking best pose of cis-DKP1-RGD-peptidomimetic 1 (tube representation, C atoms 
in light blue, N in blue, O in red, H in white) into the crystal structure of the extracellular domain of 
αvβ3 integrin (α unit red and β unit blue wire representation) overlaid on the bound conformation 
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of Cilengitide (gray tube representation). Only selected integrin residues involved in the 
interactions with the ligand are shown. The metal ion at MIDAS is shown as a magenta CPK sphere. 
For the sake of clarity, all H atoms bound to carbon are omitted. 
 
Probably, the short Cβ(Arg)-Cβ(Asp) distance (< 8 Å) of this geometry does not allow the 
simultaneous superimposition of the guanidine and carboxylic groups of the ligand with the 
corresponding moieties of Cilengitide. In particular, the stabilizing hydrogen bond interactions of 
Cilengitide carboxylate oxygen with the backbone amides of Asn215 and Tyr122 in the β unit, and 
the hydrogen bonds between Cilengitide backbone N-H and protein backbone carbonyl groups in 
the β unit are missing in the poses of compound 1. The STD data indicated that the RGD sequence 
of compound 1 is not in close contact with the protein residues. Experimental and docking results 
are in agreement showing a non-optimal disposition of the RGD sequence into the binding site. 
Furthermore, also the STD effects observed for the aromatic protons and the DKP-NH1 can be 
nicely interpreted on the basis of docking poses. In fact, the ligand benzyl group is suitably 
positioned to interact with the aromatic moiety of the β3-Tyr122, and the DKP-NH1 shows 
favourable van der Waals contacts with the β3-Arg214 side chain (Figure 2.2.14.).  
 Compound 2 
STD-NMR experiments for compound 2 were performed at two temperatures, 298 and 282 
K. The experiment at 298 K showed quite large STD effects for the guanidine NH, NHAsp and NHGly 
(2.8, 2.0 and 2.1 % STD absolute intensity, respectively), also some aliphatic protons are present, 
but their contributions are not quantifiable. When the temperature was lowered to 282 K, a 
decreased intensity of STD signals was observed for the guanidine NH, NHAsp and NHGly protons 
(1.2, 0.6 and 0.6 % STD absolute intensity, respectively), but we can quantify the contributions of 
aliphatic protons. Also  DKP-NH1 is observable, but its contribution was not considered because 
the STD signal is present also in the control experiment. Additionally, at 282 K, the signals for the 
aromatic protons, HαGly and HβArg (0.3, 0.7 and 1.4 % STD absolute intensity, respectively) 
appeared in the STD spectrum (Figure 2.2.13., red bars). The absence of the aromatic protons at 
298 K as well as their low STD effect at 282 K are worth noting . 
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Docking calculations into the αvβ3 integrin binding site, starting from the RGD extended 
conformation [Cβ(Arg)-Cβ(Asp) distance of about 9 Å] of compound 2 (Type III, Figure 2.2.10.) 
produced top-ranked binding modes conserving a good correspondence with the receptor-bound 
structure of Cilengitide. The positively charged guanidinium group of the ligand interacts with the 
negatively charged carboxylates of Asp218 and Asp150 in the α unit; one carboxylate oxygen of 
the ligand is coordinated to the metal cation in the metal-ion-dependent adhesion site (MIDAS) 
region of the β unit, while the second carboxylate oxygen forms hydrogen bonds with the 
backbone amides of Asn215 and Tyr122 in the β unit. A further stabilizing interaction involves the 
formation of a hydrogen bond between the ligand backbone NH of the Asp residue and the 
backbone carbonyl group of Arg216 in the β unit (Figure 2.2.15.). Even if all the important polar 
interactions of the X-ray complex are maintained, the phenyl ring does not interact with the 
aromatic moiety of β3-Tyr122, but is placed between the guanidinium group of the β3-Arg214 and 
the aromatic moiety of αV-Tyr178.  
 
Figure 2.2.15. Docking best pose of trans-DKP2-RGD-peptidomimetic 2 (tube representation, C 
atoms in pink, N in blue, O in red, H in white) into the crystal structure of the extracellular domain 
of αvβ3 integrin (α unit red and β unit blue wire representation) overlaid on the bound 
conformation of Cilengitide (gray tube representation). Only selected integrin residues involved in 
the interactions with the ligand are shown. The metal ion at MIDAS is shown as a magenta CPK 
sphere. For the sake of clarity, all H atoms bound to carbon are omitted. 
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Compound 3 
In the STD experiment of compound 3 at 298 K the signals of DKP-NH1, NHAsp and NHGly 
overlap, and therefore it is difficult to assess their involvement in the binding process (Figure 
2.2.16.). The largest STD effect is observed for the guanidine NH protons (7.15 ppm, 2.3% STD 
absolute intensity). 
 
Figure 2.2.16. STD spectra and 1H-NMR spectra (selected regions) of ligand 3 at 282 and 298 K. At 
T = 298 K, DKP-NH1, NHAsp and NHGly overlap. 
 
At 282 K (see Figure 2.2.13., green bars) the largest STD effects are observed for DKP-NH1 
(0.8% STD absolute intensity) and for the guanidine NH protons (7.26 ppm, 0.7% STD absolute 
intensity). The aromatic protons, DKP-NH10, NHGly and NHAsp show similar STD effects (0.4, 0.4, 0.4 
and 0.3%, respectively) and can also be considered as lying close to the protein surface. The 
signals observed in the STD spectrum suggest that ligand 3 is in an extended conformation when 
binding to cells, and it interacts closely with both the αv (by the guanidine NHs) and β3 (by NHAsp, 
NHGly, DKP-NH10, DKP-NH1 and the aromatic protons) subunits.  
Docking studies starting from the bound conformation of compound 3 (Type III, Figure 
2.2.11.) produced top-ranked binding modes conserving all the key polar interactions of the X-ray 
complex, as described above. Moreover, favourable van der Waals contacts can be detected 
between the ligand benzyl group and the aromatic moiety of β3-Tyr122 and the Hα of Ser123, 
between DKP-NH1 and the terminal methyl protons of β3-Met180, between DKP-NH10 and the Hβ 
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of Ser123 and the carbonyl group of Tyr122, and between NHGly and the methyl protons of β3-
Ala218 (Figure 2.2.17.).  
 
Figure 2.2.17. Docking best pose of trans-DKP3-RGD-peptidomimetic 3 (tube representation, C 
atoms in green, N in blue, O in red, H in white) into the crystal structure of the extracellular 
domain of αvβ3 integrin (α unit red and β unit blue wire representation) overlaid on the bound 
conformation of Cilengitide (gray tube representation). Only selected integrin residues involved in 
the interactions with the ligand are shown. The metal ion at MIDAS is shown as a magenta CPK 
sphere. For the sake of clarity, all H atoms bound to carbon are omitted. 
 2.2.2.5 Platelets and ECV-304 cells: a comparative discussion 
The tr-NOE and STD experiments were run in the presence of ECV-304 bladder cancer cells, 
expressing αVβ3, αVβ5, and α5β1 integrins, and platelets, expressing integrin αIIbβ3. These 
experiments helped identifying the binding epitopes of the peptidomimetics and defining the 
ligand-integrin bound conformations and the ligand-receptor interactions at a molecular level. 
The ligands 1 - 3 are cyclic peptidomimetics containing the RGD sequence and chiral 
bifunctional diketopiperazine scaffolds, differing for the configuration at the C-3 and C-6 
stereogenic centres. The scaffold stereochemistry influences the conformation of the ligands both 
in the free and in the cell-bound states. In particular, the cis (3S, 6S)-configuration of DKP1 scaffold 
in ligand 1 imparts a kinked conformation to the RGD sequence which implies relatively short 
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Cβ(Arg)-Cβ(Asp) distance values (< 8 Å) and a low binding affinity to integrin αvβ3 as proved by the 
high IC50 values in the competitive receptor binding and cell adhesion assays (Table 2.2.1. and 
2.2.2.). On the other hand, the trans stereochemistry of the DKP scaffolds in ligands 2 and 3 
ensures an extended arrangement of the RGD sequence [Cβ(Arg)-Cβ(Asp) distance values of about 
9 Å] which is well suited for the αvβ3 and αIIbβ3 integrin receptors. This is reflected in the high 
binding affinity to the αvβ3 integrin receptor and in the efficient ECV-304 cell adhesion inhibition 
displayed by these compounds (Table 2.2.1. and 2.2.2.). 
 
In particular, for compound 1, the binding epitope is conceivably the same with few 
interactions for the two cell lines, the only difference is the presence of NHAsp (0.2% STD absolute 
intesnsity) in the interaction with ECV-304 (Figure 2.2.18.). This could be because the basic ligand 
side chain must reach further into the deeper β-propeller pocket of αIIb to interact with Asp224, 
whereas in the αV chain the residues Asp150 and Asp218 are nearer in its shallower pocket. 
 
 
 
 
 
 
 
Figure 2.3.18. Binding epitopes: map of the STD signals of ligand 1 in the presence of platelets 
(black squares) with respect to ECV-304 cells (orange circles). 
 
For compound 2, the binding epitope of the RGD sequence remains for the two cell lines, 
but in general the intensity and the number of the STD effects suggest a greater interaction with 
ECV-304. In fact, some differences are observed for the DKP scaffold. STD-NMR experiments with 
ECV-304 cells show that the aromatic protons of the ligand are in contact with the protein, while 
NH1 and H9 of the DKP scaffold interact with the receptor in the experiments with platelets 
(Figure 2.2.19.). 
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Figure 2.2.19. Binding epitopes: map of the STD signals of ligand 2 in the presence of platelets 
(black squares) with respect to ECV-304 cells (orange circles).  
 
For compound 3, the same protons belonging to both the RGD sequence and the DKP 
scaffold provide significant STD percentages (higher for platelets) and, as a consequence, the 
epitope is conceivably the same with the two cell lines (Figure 2.2.20.). 
 
 
 
 
 
 
Figure 2.2.20. Binding epitopes: map of the STD signals of ligand 3 in the presence of platelets 
(black squares) with respect to ECV-304 cells (orange circles).  
 
In conclusion, for both cell lines we observed that: (i) the primary interaction between 
ligand and receptor is performed by the guanidine residue of the Arginine side chain (see 
behaviour of peptidomimetic 1), (ii) the extended conformation of the trans ligands 2 and 3 
ensures the formation of the electrostatic clamp (STD effects on protons of the Arg and Asp 
residues), (iii) the opposite configuration at C-3 and C-6 stereogenic centres of the DKP scaffold of 
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the trans ligands 2 and 3 induces a different binding epitope for the non-RGD moiety of the ligands 
(diketopiperazine and benzyl substituent). Finally, these results are well modelled by docking 
analysis of 1 - 3 in the active sites of αvβ3 and αIIbβ3 integrin receptors. 
 2.2.2.6 In vitro biological assays of compounds 4 - 7  
We completed our analysis with the study of the peptidomimetic ligands 4 - 7 containing 
the two enantiomeric trans DKP scaffolds with different substitution at the endocyclic nitrogen 
atoms (Figure 2.2.21.).  
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Figure 2.2.21. Bifunctional DKP scaffolds.  Integrin receptor competitive binding assays 
The cyclic RGD peptidomimetics were examined in vitro for their ability to inhibit 
biotinylated vitronectin binding to the purified αvβ3 and αvβ5 receptors (Table 2.2.3., see 
“Experimental Section” for details).  
 
Structures αvβ3  
IC50 [nM][a] 
αvβ5  
IC50 [nM][a] 
cyclo[DKP-4-RGD] 7.6 ± 4.3 216 ±  5 
cyclo[DKP-5-RGD] 12.2 ± 5.0 131 ± 29 
cyclo[DKP-6-RGD] 2.1 ± 0.6 79 ±  3 
cyclo[DKP-7-RGD]-A 220.2 ± 82.3 > 104 
cyclo[DKP-7-RGD]-B 0.2 ± 0.09 109 ± 15 
cyclo[RGDfV] 3.2 ± 1.3 7.5 ± 4.8 
Table 2.2.3. Inhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors. [a] IC50 values 
were calculated as the concentration of compound required for 50% inhibition of biotinylated 
vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean ± 
SD of triplicate determinations. 
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Low nanomolar values were obtained for all the ligands except for compound 7-A. The 
behavior of this ligand is peculiar, considering that the diastereomeric compound 7-B is the most 
potent ligand of this series, effectively inhibiting the binding of vitronectin to the isolated αvβ3 
receptor in sub-nanomolar concentration. Interestingly, unlike reference compound, the RGD 
peptidomimetics were about 10 – 500-fold more selective for the αVβ3 integrin with respect to the 
αVβ5 in this kind of assay. 
 Cell adhesion assays 
To assess the activity of the compounds as integrin antagonists on a cell model, as already 
reported for compounds 1 - 3, cell adhesion experiments were performed using ECV-304 bladder 
cancer cells. Cells were allowed to adhere to immobilized fibronectin or vitronectin in the 
presence of increasing concentration of the tested compound (Table 2.2.4., see “Experimental Section” for details). 
 
Ligands 
ECV-304 
Vitronectin 
IC50 [µM][a] 
Fibronectin 
IC50 [µM][a] 
cyclo[DKP-4-RGD] >70 0.58 ± 0.21 
cyclo[DKP-5-RGD] 17.3 ± 7.6 N. R. 
cyclo[DKP-6-RGD] 6.8 ± 2.0 >90 
cyclo[DKP-7-RGD]-A N.D. N.D. 
cyclo[DKP-7-RGD]-B 6.6 ± 0.8 N.D. 
cyclo[RGDfV] 2.00 ± 0.35 0.24 ± 0.03 
Table 2.2.4. Effect of DKP-RGD compounds on ECV-304 cell adhesion to vitronectin and 
fibronectin. [a] Each data point was performed in triplicate in two independent experiments. N.D. 
= Not Detectable, N.R. = Not Reproducible. 
 
Except for compound 7-A, whose activity is too low to be detected, ligands 4 - 7 showed a 
micromolar activity in inhibiting the VN-mediated adhesion. Surprisingly, compound 4, which has a 
nanomolar affinity for the isolated αVβ3 and αVβ5 receptors comparable to the other ligands, 
resulted 10 time less active in inihibiting the VN-ECV-304 adhesion. Moreover, compound 4 is the 
only compound able of inhibiting the FN-mediated adhesion at sub-micromolar concentration. 
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The micromolar activities obtained for compounds 4 – 7-B in the ECV-304 cell adhesion 
assay represent an ideal range for testing interactions between the ligands and the integral 
membrane protein of intact cells by means of tr-NOE and STD experiments, as for the other three 
compounds.   2.2.2.7 tr-NOESY, STD-NMR and docking results of compounds 4 – 5 Compound 4 
The RGD peptidomimetic ligands 4 and 5, as well as ligand 2, contain the (3R, 6S) DKP 
scaffold. The three ligands differ for the substitution at the endocyclic nitrogen atoms of the DKP 
scaffold. In particular, compound 4 incorporates a benzyl group at N-1 and a hydrogen atom at N-
4. Investigation of the conformational preferences of ligand 4 by NMR and MC/SD simulations 
suggested a preferred solution conformation characterized by the type I-trans extended geometry 
(i.e. β-turn at Gly-Asp) (Figure 2.2.22.). This conformation, apparently unaltered upon binding to 
ECV-304 cells, is featured by the orientation of the DKP scaffold shown in Figure 2.2.22. in 
comparison to the different orientation adopted by the scaffold in the type III conformation.  
 
Figure 2.2.22. Left: Free and bound conformation of trans-DKP-RGD-peptidomimetic 4. Hydrogen 
bond (dotted line). Right: representation of the rotated DKP scaffold characterizing the 
conformation. 
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As shown by the docking results described below, the ligand conformation coupled with 
scaffold substitution and orientation strongly influenced the orientation of the benzyl group inside 
the binding pocket and, as a result, the binding mode of the entire compound. 
In the tr-NOESY experiment of compound 4 in the presence of ECV-304 cells, at 298 K the 
cross-peak intensity is close to zero as in the free state, at 282 K the contacts are negative (i. e., 
with the same phase as the diagonal), while in the free state are close to zero. 
STD-NMR experiments were performed at two temperatures, 298 and 282 K. The 
experiment at 298 K showed quite large STD effects for the protons belonging to the RGD 
sequence (guanidine NH, Hδ of Arg and Hβ of Asp, 1.1, 0.2 and 0.3% STD absolute intensity, 
respectively) as well as to the DKP scaffold (DKP-NH4 and aromatic protons, 1.0 and 0.6% STD 
absolute intensity, respectively). When the temperature was lowered to 282 K, additional STD 
signals were detected. In fact, at 282 K, the signals for the guanidine NH, Hδ of Arg, Hβ of Asp, 
DKP-NH4 and aromatic protons showed values of 0.4, 0.3, 0.5, 0.8 and 1.2% STD absolute 
intensity, respectively. Additionally, at 282 K, the signals of Arg Hβ and Hγ (0.4 and 0.4% STD 
absolute intensity, respectively), NHArg, DKP-H7 and DKP-NH10 (1.3, 0.9 and 1.1 % STD absolute 
intensity, respectively) appeared in the STD spectrum (Figure 2.2.23., orange bars). For 
comparison, the STD data of ligands 2, 4 and 5 sharing the (3R, 6S) DKP scaffold, are shown in the 
Figure 2.2.23.. 
 
 
 
 
 
 
 
 
Figure 2.2.23. Relevant absolute STD percentages for the protons of cyclic DKP-RGD obtained at 
282 K in the presence of ECV-304 cells: compound 2 (blue bars), compound 4 (orange bars), 
compound 5 (green bars). For compound 5, signal overlaps are marked with lines above each bar. 
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The binding epitope of compound 4 is characterized by Arg and Asp pharmacophoric 
moieties (guanidine NH proton and Hβ of Asp), by many protons of the DKP scaffold and of the 
Arg-side chain and by the lack of Gly and Asp backbone atoms (Figure 2.2.24.). 
 
 
 
 
 
 
Figure 2.2.24. Binding epitope: map of the STD signals (left) of ligand 4 in the presence of ECV cells 
(orange circles), STD and 1H-NMR spectra (right). Only the amidic and the aromatic regions are 
shown. 
 
Docking calculations into the αVβ3 integrin binding site, starting from the preferred RGD 
extended conformation [Cβ(Arg)-Cβ(Asp) distance of about 9 Å] of ligand 4 (Figure 2.2.22.), 
produced top-ranked binding modes conserving a good correspondence with the receptor-bound 
structure of Cilengitide (Figure 2.2.25., left). The analysis of the docking poses identified a 
different possible disposition of the molecule within the binding pocket, where the ligand still 
maintains the typical electrostatic clamp, but does not overlay to the Cilengitide cyclic backbone. 
The two types of binding mode, called A and B (their superposition is shown in Figure 2.2.25., 
right), are very similar in terms of contacts of the RGD sequence with the receptor (average 
distance values for the relevant interactions identified by STD experiment are reported in Table 
2.2.5.), but significantly different as regards the contacts of the scaffold protons. In fact, only for 
poses of type B binding mode favourable van der Waals contacts between ligand DKP-NH4, DKP-
H7, DKP-NH10 and receptor β-chain atoms are detected (Table 2.2.5.). 
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Figure 2.2.25. Left: docking best pose (binding mode A) of compound 4 (tube representation, C 
atoms in orange, N in blue, O in red, H in white) into the crystal structure of the extracellular 
domain of αvβ3 integrin (α unit red and β unit blue wire representation) overlaid on the bound 
conformation of Cilengitide (gray tube representation); the metal ion at MIDAS is shown as a 
magenta CPK sphere. Right: Superposition of A (orange) and B (cyan) binding modes identified 
among the docking poses of ligand 4 into the αvβ3 integrin binding site. 
Table 2.2.5. Average values of the distances between ligand 4 protons (selected from STD 
experiment) and αvβ3 residues calculated from docking poses for the two binding modes A and B. 
 
The ligand epitope disclosed by STD-NMR results nicely agree with the calculated docking 
poses, though type B binding mode provides the best explanation for the protons of the DKP 
scaffold. Therefore, we can assume that the epitope observed by NMR depends on the 
contribution of both the binding dispositions. 
Ligand 
protons 
Binding mode A Binding mode B 
Residues Mean distance Residues Mean distance 
NH-Arg HO-Tyr178 (α) 4.67 Å CH3-Ala215 (α) 3.54 Å 
βH-Arg CAr-Tyr178 (α) 2.68 Å CH3-Ala215 (α) 2.41 Å 
γH-Arg CH3-Ala215 (α) 2.57 Å O2=C-Asn218 (α) 2.88 Å 
δH-Arg HAr-Tyr178 (α) 2.90 Å HAr-Tyr178 (α) 2.65 Å 
NH_Guan O2=C-Asp218 (α) 2.42 Å O2=C-Asp218 (α) 2.20 Å 
βH_Asp O=C-Asn215 (α) 2.38 Å O=C-Asn215 (α) 3.00 Å 
DKP-NH4 HAr-Tyr122 (β) 6.88 Å (Min=4.69 Å) CH3-Ala218 (β) 2.38 Å 
H_Ar CH2β-Met180 (β) 5.61 Å (Min=2.21 Å) O=C-Asp251 (β) 4.60 Å (Min=2.48 Å) 
DKP-H7 HO-Tyr178 (α) 6.07 Å (Min=3.51 Å) NH3-Lys253 (β) 3.63 Å 
DKP-NH10 O=C-Tyr122 (β) 4.48 Å (Min=3.98 Å) αCH-Ala218 (β) 1.84 Å 
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Moreover, our analysis pointed out the stereochemistry and the substitution of the DKP 
scaffold, that strongly influenced the type of conformation adopted by compound 4 (see 
paragraph “NMR characterization and conformational analysis”), also affected the disposition of 
the compound in the receptor binding pocket. NMR and docking results well agree with the 
nanomolar IC50 value obtained in the isolated αvβ3 receptor binding assay (7.6 ± 4.3 nM). 
 Compound 5 
Similarly to compound 2, the free state conformation of ligand 5 (featuring a benzyl group 
at both the endocyclic nitrogens N1 and N4) is characterized by a β-turn motif at DKP-Arg 
stabilized by a hydrogen bond between NHGly and C(5)=O (Type III conformation, Figure 2.2.26.), as 
suggested by the relevant long-range NOE interaction between the NHGly and NHArg (positive at 
298 K and negative at 282 K). 
 
 
 
 
Figure 2.2.26. Free and bound type III conformation of trans-DKP-RGD-peptidomimetic 5. 
Hydrogen bond (dotted line) and NOE contact (arrow) are indicated. 
 
The tr-NOESY experiment of compound 5 in the presence of ECV-304 cells at 298 K showed 
negative cross-peaks (i.e., with the same phase as the diagonal) in contrast with the free state, 
indicating a binding situation; instead, at 282 K the contacts are negative like in the free state. In 
addition, the tr-NOESY spectrum performed at 298 K showed a negative cross-peak between NHArg 
(8.39 ppm) and NHGly (8.08 ppm); this NOE contact (Figure 2.2.27.) is consistent with the β-turn 
conformation at DKP-Arg stabilized by the hydrogen bond between NHGly and C(5)=O mentioned 
above (Figure 2.2.26.). 
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Figure 2.2.27. NOE contact between NHArg and NHGly indicating a Type III bound conformation for 
Compound 5. 
 
STD-NMR experiments were performed in the presence of ECV-304 cells at 298 K and 282 
K. In these spectra, the region corresponding to the aromatic and amide protons is better resolved 
at 282 K with respect to 298 K and can be used to measure the absolute intensity of STD (Figure 
2.2.23., green bars). The largest STD effects are observed for NH10 (1.0% STD absolute intensity) 
and for the guanidine NH protons (6.95 ppm, 0.9% STD absolute intensity). Also the protons DKP-
H7 and βHAsp show high STD effects (1.2% STD absolute intensity), but their overlapping prevents a 
right evaluation of the contribution. Additionally, spectra show protons belonging to the DKP 
scaffold, i.e. the aromatic protons and DKP-H9 (0.4 and 0.5% STD absolute intensity, respectively) 
as well as to the RGD sequence (NHArg, δHArg, NHGly and αHGly, 0.8, 0.1, 0.5 and 0.4% STD absolute 
intensity, respectively) in contact with the receptor (Figure 2.2.28.). However, as the signals of the 
protons of the two aromatic rings overlapped and it was not possible to distinguish them, the STD 
intensity reported in the graph (Figure 2.2.23., green bars) was halved for each aromatic ring. 
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
Figure 2.2.28. Binding epitope: map of the STD signals (left) of ligand 5 in the presence of ECV cells 
(green dots), STD and 1H-NMR spectra (right). Only the amidic and the aromatic regions are 
reported. 
 
Docking calculations into the αVβ3 integrin binding site, starting from the preferred RGD 
extended conformation of compound 5 produced top-ranked binding modes conserving a good 
correspondence with the receptor-bound structure of Cilengitide and all the important polar 
interactions of the X-ray complex. For this compound, we observe a single binding mode which 
provides average distances between ligand epitope protons and binding site residues in 
agreement with the NMR data (Figure 2.2.29. and Table 2.2.6.). 
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Figure 2.2.29. Docking best pose of compound 5 (tube representation, C atoms in green, N in blue, 
O in red, H in white) into the crystal structure of the extracellular domain of αvβ3 integrin (α unit 
red and β unit blue wire representation) overlaid on the bound conformation of Cilengitide (gray 
tube representation); the metal ion at MIDAS is shown as a magenta CPK sphere. 
  
 
 
 
 
 
Table 2.2.6. Average values of the distances between ligand 5 protons (selected from STD 
experiment) and αvβ3 residues calculated from docking poses. 
 
The stereochemistry of the DKP moiety and the dibenzylation at the two nitrogen atoms, 
strongly influence the conformation adopted by compound 5 (see paragraph “NMR characterization and conformational analysis”) and its disposition inside the receptor binding 
Ligand 
protons Protein residues Mean Distance 
NHArg CAr-Tyr178 3.61 Å 
δHArg HAr-Tyr178 2.71 Å 
NH_Guan O2=C-Asp218 3.05 Å 
NHGly HAr-Tyr178 3.24 Å 
βHAsp O=C-Asn215 2.53 Å 
H_Ar NHGuan_Arg214 3.40 Å 
DKP-H7 HO-Tyr178 4.32 Å (Min=3.01 Å) 
DKP_H9 HAr-Tyr122 2.71 Å 
DKP-NH10 CH2-Ser123 4.18 Å (Min=3.59 Å) 
αH_Gly CH3-Ala218 2.42 Å 
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pocket. In the docking poses, the ligand is well overlaid to the experimental binding mode of 
Cilengitide, one aromatic moiety points outwards and the other lies within the binding site (Figure 
2.2.29.). NMR and docking results are consistent with the IC50 value obtained in binding (αvβ3 IC50 
12.2 ± 5.0 nM) and adhesion assays (ECV-304 IC50 (VN) = 17.3 ± 7.6 µM). 
A comparative analysis of the results obtained for the series of active ligands containing 
the (3R, 6S) DKP scaffold, i.e. ligands 2, 4 and 5, highlights that: i) the conformational preferences 
depend on both the scaffold stereochemistry and substitution; ii) all the compounds adopt 
extended conformations in solution that produce top-ranked docking poses fitting the 
experimental binding mode of Cilengitide; iii) both ligand conformation and scaffold substitution 
strongly affect the binding epitope detected by STD-NMR; (iv) a good agreement between docking 
models and STD data has been obtained. 
In particular, compound 2 (Figure 2.2.23., blue bars) mainly involves in the interaction the 
RGD sequence (NHGly, αHGly, NH_Guan and NHAsp), compound 4 (Figure 2.2.23., orange bars) 
mostly involves Arg and Asp pharmacophoric moieties and scaffold protons (DKP-NH4, DKP-H7 and 
DKP-NH10), and compound 5 (Figure 2.2.23., green bars) involves in the interaction both the RGD 
sequence and the DKP scaffold, strengthening the idea that the double benzylation helps to 
stabilize the interaction with the receptor binding pocket. 
 2.2.2.8 tr-NOESY, STD-NMR and docking results of compounds 6 -7 Compound 6 
The RGD peptidomimetic ligands 6 and 7, as well as ligand 3, contain the (3S, 6R) DKP 
scaffold. The three ligands differ for the substitution at the endocyclic nitrogen atoms of the DKP 
scaffold. In particular, compound 6, which incorporates a benzyl group at N-1 and a hydrogen 
atom at N-4, is characterized by a rather strong NOE contact between NHAsp and NH10 and a 
moderate NOE involving NH4 and NH10. These two contacts, as discussed in the paragraph “NMR characterization and conformational analysis”, are mutually exclusive and indicative of an 
equilibrium between two different conformations, type I-trans (β-turn at Gly-Asp, Figure 2.2.30.a) 
and type IV (β-turn at Asp-DKP, Figure 2.2.30.b). 
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Figure 2.2.30. Free state conformations of trans-DKP-RGD-peptidomimetic 6. a) Type I-trans H-
bonding pattern (β-turn at Gly-Asp); b) Type IV H-bonding pattern (β-turn at Asp-DKP). Hydrogen 
bond (dotted line) and NOE contact (arrow) are indicated. 
 
The two conformations are characterized by different orientations of the DKP scaffold, as 
shown for the Type I-trans geometry of compound 4 in comparison to the Type III conformation 
(Figure 2.2.22.).  
In the tr-NOESY experiments at 298 K the cross-peak intensity is close to zero, while at 282 
K the contacts are negative like in the free state. However, at 298 K, even if we did not observe a 
complete inversion of phase (from positive of the free state to negative in the bound state), the 
fact that the cross-peaks are not positive (like in the free state), but close to zero, suggests a 
binding event.  
In addition, the tr-NOESY performed at 282 K showed a very weak negative cross-peak 
(Figure 2.2.31.) between NHAsp (8.92 ppm) and NH10 (7.99 ppm); this NOE contact is consistent 
with the Type I-trans conformation (β-turn at Gly-Asp) (Figure 2.2.30.). This could indicate that, 
upon binding to cells, the conformational equilibrium present in the free state is shifted towards 
one conformation and, precisely, to the most populated in the free state. 
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Figure 2.2.31. NOE contact between NHAsp and NH10 indicating a Type I-trans bound conformation 
for compound 6. 
 
STD-NMR experiments in the presence of the cell suspension were performed both at 298 
K and 282 K. At 298 K some overlaps make difficult to evaluate the contribution of several protons 
in the binding event; the experiment showed quite large STD effects for the guanidine NH, NH4 
and the aromatic protons (1.3, 1.1 and 0.6% STD absolute intensity, respectively) and STD absolute 
intensity below 0.2% for other aliphatic protons. At 282 K (see Figure 2.2.32., orange bars), the 
signals for the guanidine NH, NH4 and the aromatic protons showed values of 1.1, 1.0 and 0.7% 
STD absolute intensity, respectively. Additionally, at 282 K, the signals for the DKP-H9 and HαGly 
(1.4 and 0.8% STD absolute intensity, respectively) appeared with an increased intensity. However, 
also at 282 K the signals of NHArg and NHGly (0.3% STD absolute intensity) overlap as well as the 
signals of HβAsp and DKP-H7 (0.4% STD absolute intensity), making difficult to assess their 
contribution in the binding process. 
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Figure 2.2.32. Relevant absolute STD percentages for the protons of cyclic DKP-RGD obtained at T 
= 282 K in the presence of ECV-304 cells: compound 3 (blue bars), compound 6 (orange bars), 
compound 7-A (green bars), compound 7-B (black bars). The overlaps are marked with lines above 
each bar. 
 
In the Figure 2.2.33. the amidic and the aromatic regions of the STD spectrum at 282 K are 
reported with the structure, on the left, of compound 6 where the protons involved in the epitope 
are highlighted with orange dots. 
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Figure 2.2.33. Binding epitope: map of the STD signals (left) of ligand 6 in the presence of ECV cells 
(orange circles), STD and 1H-NMR spectra (right). The amidic and the aromatic regions are 
reported. 
 
Docking calculations into the αVβ3 integrin binding site, starting from the bound RGD 
extended conformation of compound 6 (Type I-trans) produced top-ranked binding modes 
conserving a good correspondence with the receptor-bound structure of Cilengitide and all the 
important polar interactions of the X-ray complex already described (Figure 2.2.34.). The analysis 
of the docking poses in terms of ligand epitope protons that could be in contact with the receptor 
binding site highlights some important considerations (Table 2.2.7.).  
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Figure 2.2.34. Docking best pose of compound 6 (tube representation, C atoms in orange, N in 
blue, O in red, H in white) into the crystal structure of the extracellular domain of αvβ3 integrin (α 
unit red and β unit blue wire representation) overlaid on the bound conformation of Cilengitide 
(gray tube representation); the metal ion at MIDAS is shown as a magenta CPK sphere.  
 
 
 
 
 
 
 
 
 
Table 2.2.7. Average values of the distances between ligand 6 protons (selected from STD 
experiment) and αvβ3 residues calculated from docking poses. Asterisks and dots indicate 
overlapping proton pairs. 
 
For each overlapping proton pair of the NMR spectrum (NHArg/NHGly and HβAsp/DKP-H7) 
there is only one proton that shows a distance compatible with the interaction i.e. NHGly and HβAsp. 
Ligand protons Protein residues Mean Distances 
•NHArg CH3-Ala215 (α) 4.87 Å 
NH_Guan O2=C-Asp218 (α) 2.02 Å 
•NHGly HAr-Tyr178 (α) 2.83 Å 
αH_Gly HAr-Tyr178 (α) 3.04 Å 
*βH_Asp O=C-Asn215 (β) 2.35 Å 
DKP-NH4 βCH2-Ser123 (β) 5.00 Å (Min=4.83 Å) 
H_Ar CH3-Ala215 (α) 4.59 Å (Min=2.79 Å) 
*DKP-H7 CH3-Ala215 (α) 
5.18 Å 
(Min=4.55 Å) 
DKP-H9 βCH2-Ser123 (β) 2.34 Å 
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In the docking poses, the aromatic protons show a mean distance of 4.59 Å from the protein 
residues, but such distance can decrease up to a minimum value of 2.79 Å. 
The compound shows a low nanomolar IC50 value in the binding assays (αvβ3 IC50 2.1 ± 0.6 
nM) and a low micromolar IC50 value in the adhesion assays (ECV-304 IC50(VN) = 6.8 ± 2.0 µM).  Compound 7-A 
As described in the paragraph “NMR Characterization and Conformational Analysis”, 
compound 7 was obtained as a mixture of two separable diastereomers, DKP-7 A and DKP-7 B. 
The low affinity isomer 7-A (αvβ3 IC50 220.2 ± 82.3 nM) displayed an equilibrium between 
two different conformations: one featuring a type III H-bonding pattern and an extended RGD 
arrangement (β-turn at DKP-Arg, Figure 2.2.35.a) and one showing a type II H-bonding pattern and 
a bent RGD arrangement (β-turn at Arg-Gly, Figure 2.2.35.b). 
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Figure 2.2.35. Free state and bound conformations of trans-DKP-RGD-peptidomimetic 7-A. a) Type 
III H-bonding pattern (β-turn at DKP-Arg); b) Type II H-bonding pattern (β-turn at Arg-Gly). 
Hydrogen bond (dotted line) and NOE contact (arrow) are indicated. 
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In the tr-NOESY experiment at 298 K the cross-peak intensity was close to zero, while in the 
free state the cross-peaks are positive indicating a binding event, as well as in the tr-NOESY at 282 
K where the cross-peaks had the same phase as the diagonal in contrast with the NOESY in the 
free state where the cross-peak intensity is close to zero. The conformational equilibrium of the 
compound in the free state is apparently unaltered upon binding to ECV-304; at 282 K a very weak 
NOE contact between NHArg (8.65 ppm) and NHGly (8.05 ppm) appears in the tr-NOESY spectrum, 
the presence of the other NOE contact between NHAsp (8.04 ppm) and NHGly (8.05 ppm) is not 
evaluable due to the overlap between the two amidic protons. 
STD-NMR experiments in the presence of the cell suspension were performed both at 298 
and 282 K. However, at 298 K several overlaps made difficult to assess the involvement of the 
protons in the binding process. At 282 K, the largest STD effects (Figure 2.2.32., green bars) are 
observed for NH10 (1.0% STD absolute intensity) and for the guanidine NH (1.5% STD absolute 
intensity). The aromatic protons and HαGly show similar STD effects (0.5 and 0.7% STD absolute 
intensity, respectively). Additionally, at 282 K, the signals of NHGly and NHAsp overlap (0.5% STD 
absolute intensity) and therefore it is difficult to assess their involvement in the binding process 
(Figure 2.2.36.). 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.36. Binding epitope: map of the STD signals (left) of ligand 7-A in the presence of ECV 
cells (green circles), STD and 1H-NMR spectra (right). Only the amidic and the aromatic regions are 
reported. 
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In docking calculations, the exended Type III conformation produced top-ranked binding 
modes conserving a quite good correspondence with the receptor-bound structure of Cilengitide, 
while the non-extended Type II geometry was not able to properly fit into the αVβ3 binding pocket. 
For this isomer, the presence of an equilibrium between an extended (β-turn DKP-Arg) and a 
closed geometry (β-turn Arg-Gly) could explain the high nanomolar IC50 value in the αvβ3 binding 
assay (αvβ3 IC50 220.2 ± 82.3 nM) and the poor inhibition displayed in the adhesion assays (ECV-
304 IC50(VN) not detectable at 100 µM). 
 Compound 7-B 
The diastereomer 7-B showed in the free state a single NOE contact between NHAsp and 
NH10, indicative of a type I-trans H-bonding pattern (β-turn at Gly-Asp, Figure 2.2.37.). 
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Figure 2.2.37. Free state and bound conformation of trans-DKP-RGD-peptidomimetic 7-B. Type I-
trans H-bonding pattern (β-turn at Gly-Asp). Hydrogen bond (dotted line) and NOE contact (arrow) 
are indicated. 
 
As discussed for ligands 4 and 6, the Type I-trans geometry adopted by compound 7-B is 
characterized by a specific orientation of the DKP scaffold that differs from the orientation 
displayed by the Type III conformation.  
The tr-NOESY experiment of compound 7-B in the presence of ECV-304 cells at 298 K 
showed negative cross-peaks (i.e., with the same phase as the diagonal) indicating a binding event. 
In addition, the tr-NOESY spectrum performed at 282 K showed a negative cross-peak 
between NHAsp (8.56 ppm) and NH10 (7.72 ppm); this NOE contact (Figure 2.2.38.) is consistent 
with the β-turn conformation at Gly-Asp (type I-trans H-bonding pattern). 
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Figure 2.3.38. NOE contact between NHAsp and NH10 indicating a Type I-trans bound conformation 
for compound 7-B. 
 
STD-NMR experiments were performed in the presence of the cell suspension both at 298 
and 282 K. At 298 K STD effect is observed for the aromatic protons, the guanidine NH, the DKP-H7 
and NH10 (0.3, 0.3, 0.7 and 0.3% STD absolute intensity). Also the signals of some aliphatic protons 
(HδArg, HβAsp and HγArg, 0.2, 0.5 and 0.3% STD absolute intensity, respectively) appeared in the 
spectrum. However, when the temperature was lowered to 282 K, the ligand remains in the 
receptor site for a longer time and an increased intensity of these STD signals was observed 
making easier the analysis. In fact, at 282 K (Figure 2.2.32., black bars), the signals for the 
guanidine NH and the aromatic protons showed values higher than those obtained at 298 K (0.6% 
STD absolute intensity), and we observed signals for NHArg, HγArg and HδArg (0.5, 0.3 and 0.3% STD 
absolute intensity, respectively), for HαGly, HβAsp, DKP-H7, DKP-H9 and NH10 (1.1, 0.5, 0.9, 1.1 and 
0.9% STD absolute intensity, respectively). Additionally, the signals of NHGly and NHAsp overlap 
(0.2% STD absolute intensity) and it is difficult to assess their involvement in the binding process 
(Figure 2.2.39.). 
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Figure 2.2.39. Binding epitope: map of the STD signals (left) of ligand 7-B in the presence of ECV 
cells (black circles), STD and 1H-NMR spectra (right) performed at 282 K, a) Amidic protons region 
(the aromatic zone was not reported due to the high intensity of STD signals), b) Aliphatic region. 
 
Docking studies starting from the Type I-trans bound conformation of compound 7-B 
(Figure 2.2.37.) produced two top-ranked binding modes (A and B), both conserving all the key 
polar interactions of the X-ray complex. The two binding modes (Figure 2.2.40.) are characterized 
by a different disposition of the ligand in the binding pocket. The binding mode A showed a good 
superposition of the whole molecule to the Cilengitide reference structure (Table 2.2.8.). In 
particular, the protons belonging to the RGD portion are in close contact with the receptor and the 
two benzyl moieties point toward the aromatic side chain of Tyr122, similarly to the (D)-Phe 
residue of Cilengitide. In the binding mode B, the ligand does not overlay to the RGD backbone of 
Cilengitide and only the electrostatic clamp is preserved. The comparison between the docking 
poses and the NMR data does not allow to choose one of the two binding modes, that probably 
both contribute to an optimal interaction. 
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a)                                                                                b) 
 
 
 
 
 
 
 
 
Figure 2.2.40. Left: Docking best pose (binding mode A) of compound 7-B (tube representation, C 
atoms in black, N in blue, O in red, H in white) into the crystal structure of the extracellular domain 
of αvβ3 integrin (α unit red and β unit blue wire representation) overlaid on the bound 
conformation of Cilengitide (gray tube representation); the metal ion at MIDAS is shown as 
amagenta CPK sphere. Right: Superposition of A (black) and B (cyan) binding modes identified 
among the docking poses of ligand 7-B into the αvβ3 integrin binding site. 
Table 2.2.8. Average values of the distances between ligand protons (selected from STD 
experiment) and αvβ3 residues calculated from docking poses  for the two binding modes A and B. 
Asterisks indicate overlapping protons. 
 
Ligand 
protons 
Binding mode A Binding mode B 
Residues Mean distances Residues Mean distances 
NH-Arg CH3-Ala215 (α) 3.84 Å CH3-Ala215 (α) 2.48 Å 
γH-Arg O2=C-Asp218 (α) 3.07 Å O2=C-Asp218 (α) 3.66 Å 
δH-Arg HAr-Tyr178 (α) 2.79 Å HAr-Tyr178 (α) 3.84 Å 
NH_Guan O2=C-Asp218 (α) 2.56 Å O2=C-Asp150 (α) 3.87 Å 
*NH-Gly HAr-Tyr178 (α) 3.31 Å HAr-Tyr178 (α) 3.27 Å 
αH-Gly HAr-Tyr178 (α) 2.74 Å HAr-Tyr178 (α) 2.30 Å 
*NH-Asp αCH-Arg216 (β) 3.37 Å αCH-Arg216 (β) 4.66 Å (Min=2.70 Å) 
βH-Asp O=C-Asn215 (β) 3.59 Å O=C-Asn215 (β) 3.70 Å 
H_Ar HAr-Tyr122 (β) 6.97 Å (Min=3.24 Å) NH_Guan-Arg248 (α) 3.24 Å 
DKP-H7 CH3-Ala215 (α) 4.34 Å (Min=2.92 Á)  CH3-Ala215 (α) 2.50 Å 
DKP-H9 βCH2-Ser123 (β) 3.53 Å CH3-Ala252 (β) 3.28 Å 
DKP-NH10 βCH2-Ser123 (β) 4.27 Å (Min=2.84 Å) CH3-Ala218 (β) 3.94 Å (Min=2.53 Å) 
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These data well support the sub-nanomolar IC50 value in the αvβ3 binding assay of this 
compound (IC50 0.2 ± 0.09 nM) and its low micromolar IC50  value in the adhesion assays (ECV-304 
IC50(VN) = 6.6 ± 0.8 µM). 
 
As discussed above for compounds 2, 4 and 5 derived from the (3R, 6S) DKP scaffold, also 
for the set of compounds 3, 6 and 7 derived from the (3S, 6R) DKP scaffold both the bound 
conformation and the scaffold substitution strongly influenced the disposition of the ligand in the 
binding pocket. For this set of ligands, the identification of the experimental binding epitope of 
compounds 6 and 7 was complicated by the presence of several overlapping signals into STD 
spectra. The most active compound of the DKP series, the diastereomer 7-B (Figure 2.2.32., black 
bars), is characterized by high STD absolute percentages and lots of interactions with the receptor. 
On the other hand, the diastereomer 7-A (Figure 2.2.32., green bars), showing the lowest affinity 
for the αVβ3 integrin, displayed a STD pattern of signals intermediate between those of the 
compounds 3 (Figure 2.2.32., blu bars) and 7-B. Entropic reasons, i.e. the presence of both 
extended and non-extended geometries in the free state conformational equilibrium, can account 
for the lower affinity for the αVβ3 integrin of the isomer 7-A compared to the other trans DKP-RGD 
ligands. 
 2.2.3 INTERACTIONS WITH MDA-MB-231 BREAST CANCER CELLS 
The ECV-304 cell line expresses different integrins on the membrane (see “Cell lines expressing integrins”). In particular, integrins αVβ3 and α5β1 show the same high level of 
expression (α5β1/αVβ3 expression of 1.16). Since also integrin α5β1 recognizes the RGD sequence, 
we wondered if the NMR results obtained on ECV-304 cells might be affected by the presence of 
both the integrins. For this reason, we performed tr-NOESY and STD NMR experiments using the 
MDA-MB-231 breast cancer cell line, known to overexpress only integrin α5β1. MDA-MB-231 was 
then considered the reference cell line to investigate the interaction of the compounds with the 
α5β1 integrin. In parallel, molecular docking calculations starting from the crystal structure of the 
extracellular segment of α5β1 in complex with a linear RGD peptide17 were implemented with the 
aim to obtain computational models for the interaction of the DKP-RGD ligands with the α5β1 
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integrin. In addition, competitive binding assays on the isolated α5β1 integrin and adhesion assays 
using MDA-MB-231 cells were carried out. 
As previously discussed, the preferred free state conformations strongly influence the 
ligand binding to integrin receptors. Ligands 2 – 6 and 7-B mainly adopt two types of extended 
conformations, regardless of the stereochemistry of the DKP scaffold: the type I-trans 
conformation (compounds 4, 6 and 7-B) and the type III conformation (compounds 2, 3 and 5). 
Accordingly, NMR results on MDA-MB-231 cells and docking calculations in the α5β1 model will be 
discussed on the basis of the ligand bound conformation. First, the results obtained for the 
compounds adopting the type I-trans geometry and showing the highest affinities for the receptor 
α5β1 (compounds 7-B, 6 and 4) will be discussed, than those obtained for the compounds adopting 
the type III geometry (compounds 2, 3 and 5). Ligands featuring non-extended RGD conformations 
(1 and 7-A) were not included in the study focused on the α5β1 integrin, as this receptor is known 
to recognize an extended RGD arrangement almost identical to that recognized by the αVβ3 
integrin.18  2.2.3.1 The docking model of α5β1 
β1 integrins constitute the largest integrin subfamily and recognize a wide range of ligands 
depending on the partner α subunit. α5β1 was one of the first integrin heterodimers to be 
identified, and its function as fibronectin receptor has been extensively studied.46 However, the X-
ray structure of this integrin closed headpiece in complex with SG/19 Fab (an allosteric inhibitory 
antibody) was only recently solved both in the absence and presence of a linear peptide ligand 
containing the Arg-Gly-Asp (RGD) sequence (PDB entry 3VI4).17 This structure revealed high 
similarity to the ligand unbound form of αVβ3 and αIIbβ3 integrins. The most important differences 
between the receptor binding pockets of αVβ3 and α5β1 are shown in the Figures 2.2.41. and 
2.2.42.. The mutation of Asp150 (αV) into Ala159 (α5) produces a less acidic region, while the 
mutation of Arg214 and Arg216 (β3) into the hydrophobic residues Gly223 and Leu225 (β1) both 
expands the site and reduces the polar character of the region. 
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Figure 2.2.41. Schematic representation of the differences between the binding sites of αVβ3 and 
α5β1 receptors; Cilengitide X-ray structure in αVβ3 (gray), αV chain (gray) and β3 chain (orange), 
linear RGD sequence in α5β1 (green), α5 chain (light blue) and β1 chain (red). 
 
 
Figure 2.2.42. Cilengitide docking best poses into the α5β1 and αVβ3 binding sites: molecular 
surfaces coloured by residue property (red = acidic, blue = basic, green = hydrophobic, cyan = 
neutral). 
 
Notwithstanding slight differences, the X-ray structures of αVβ3 and α5β1 complexed with 
RGD ligands reveal an identical atomic basis for the interaction: RGD binds to the interface of the 
α and β subunits, the Arg residue fitting into a cleft in the α subunit, and the Asp coordinating a 
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cation in the β subunit. The RGD sequence is disposed in an extended conformation in the 
receptor site with the carboxylic and guanidine groups acting as an electrostatic clamp, 
respectively, on the Ca2+ ions (MIDAS) of the β subunit and on the Asp residues of the α chain. 
The distance between the negatively charged carboxylate group (Asp Cγ labeled C-) and the 
positively charged guanidinium moiety (Arg Cζ labeled C+) of the ligand is similar in the two crystal 
structures (Cilengitide C+/C- distance in αVβ3 = 14.15 Å, linear RGD C+/C- distance in α5β1 = 14.22 
Å) and also the distance between the corresponding receptor anchor points is almost the same 
(distance Ca2+ - CγAsp218 in αVβ3 = 12.95 Å, distance Ca2+-CγAsp227 in α5β1 = 13.26 Å). In 
particular, the Arg side chain of the RGD peptide ligand in α5β1 makes hydrogen bonds with α5 
residues Gln221 and Asp227, the Asp carboxylate directly coordinates the β1 MIDAS Ca2+, making 
also hydrogen bonds with the backbone NH of Tyr133 (β1) and Asn224 (β1). The docking protocol 
was developed from the recently solved crystal structure of the α5β1 integrin (PDB entry 3VI4)17 
and validated by evaluating its ability to reproduce the X-ray binding geometry of the linear 
hexapeptide and to properly dock Cilengitide, known to be a nanomolar ligand of this receptor.21  2.2.3.2 In vitro biological assays of compounds 2 - 7 Integrin receptor competitive binding assays 
The cyclic RGD peptidomimetics were examined in vitro for their ability to inhibit 
biotinylated fibronectin binding to the purified α5β1 receptor (Table 2.2.9.). 
 
Structures αVβ3  
IC50 [nM][a] 
α5β1  
IC50 [nM][a] 
α5β1/αVβ3 
IC50 [nM] 
cyclo[DKP-2-RGD] 3.2 ± 2.7 1647 ± 871 514.7 
cyclo[DKP-3-RGD] 4.5 ± 1.1 532 ± 35 118.2 
cyclo[DKP-4-RGD] 7.6 ± 4.3 314 ± 1.4 41.3 
cyclo[DKP-5-RGD] 12.2 ± 5.0 1217 ± 157 99.8 
cyclo[DKP-6-RGD] 2.1 ± 0.6 73.3 ± 3.7 34.9 
cyclo[DKP-7-RGD]-A 220.2 ± 82.3 > 10-5 /// 
cyclo[DKP-7-RGD]-B 0.2 ± 0.09 25.7 ± 6.2 128.5 
cyclo[RGDfV] 3.2 ± 1.3 166 ± 28 51.9 
cyclo[RGDf(N-Me)V]21 
(Cilengitide) 
0.6 ± 0.1 14.4 ± 3.1 24 
Table 2.2.9. Inhibition of biotinylated vitronectin binding to αVβ3 receptor and of biotinylated 
fibronectin binding to α5β1 receptor. [a] IC50 values were calculated as the concentration of 
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compound required for 50% inhibition of biotinylated vitronectin and fibronectin binding as 
estimated by GraphPad Prism software; all values are the arithmetic mean ± SD of triplicate 
determinations. 
 
Screening assays were performed incubating the immobilized integrin receptors with 
various concentrations (10-12–10-5 M) of the RGD ligands in the presence of biotinylated 
fibronectin (1 µg/mL), and measuring the concentration of bound fibronectin in the presence of 
the competitive ligands (see “Experimental Section”). The ability of the new compounds to inhibit 
the binding of fibronectin to the isolated α5β1 receptor was compared with that of the reference 
compounds cyclo[RGDfV] and Cilengitide. 
The compounds were able to inhibit biotinylated fibronectin binding to integrin α5β1 at 
concentrations ranging from nanomolar (7-B and 6) to sub-micromolar (4 and 3) and micromolar 
(2 and 5) IC50 values. Compound 7-A appeared to be the worst ligand, confirming the low 
conformational preorganization also for binding to α5β1 integrin. Compared with the binding 
results for αVβ3 receptor, all the DKP ligands and the reference peptides lost at least one order of 
magnitude in affinity (α5β1 IC50 values 30 - 500 times higher than αVβ3 IC50 values). Since the X-ray 
structures reveal similar RGD geometrical requirements for the binding to α5β1 and αVβ3 integrins, 
the observed selectivity may depend on the physicochemical features of the binding sites. In fact, 
the receptor region that binds to the ligand guanidinium group is less acidic in α5β1 than in αVβ3, 
thus leading to a weaker interaction of the ligand Arg side chain with the α5 subunit. Moreover, 
due to both the less efficient electrostatic clamp and the larger binding pocket compared to αVβ3, 
the ligands interact less strongly with α5β1 and may reveal a greater mobility within the receptor 
site. Interestingly, compounds characterized by a type I-trans geometry (7-B, 6 and 4) showed the 
highest affinities for the α5β1 integrin.   Cell adhesion assays 
Adhesion assay tests were performed in two different laboratories using the same MDA-
MB-231 breast cancer cell line and experimental protocol (see “Experimental section” for details). 
The results obtained for compounds 2 and 3 and the reference peptide cyclo[RGDfV] at the cell 
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biology laboratory of CISI (an Interdepartmental Centre of Milan University), that first developed 
the adhesion assay protocol for both ECV-304 and MDA-MB-231 cells, are shown in Table 2.2.10.. 
As for ECV-304 cells, both ligands showed a micromolar activity in the inhibition of MDA-MB-231 
cell adhesion to both VN and FN. 
 
Ligands 
ECV-304 MDA-MB-231 
Vitronectin 
IC50 [µM][a] 
Fibronectin 
IC50 [µM][a] 
Vitronectin 
IC50 [µM][a] 
Fibronectin 
IC50 [µM][a] 
cyclo[DKP-2-RGD] 13.8 ± 0.2 2.2 ± 0.4 6.8 ± 2.9 3.0 ± 0.9 
cyclo[DKP-3-RGD] 49.5 ± 3.0 15.0 ± 3.9 1.6 ± 0.0 0.7 ± 0.1 
cyclo[RGDfV] 0.22 ± 0.00 0.36 ± 0.09 11.3 ± 0.1 3.4 ± 0.4 
Table 2.2.10. Effect of DKP-RGD compounds on ECV-304 and MDA-MB-231 cell adhesion to 
vitronectin and fibronectin. [a] Each data point was performed in triplicate in two independent 
experiments. N.D. = Not Detectable, N.R. = Not Reproducible. 
 
 
Ligands 
ECV-304 MDA-MB-231 
Vitronectin 
IC50 [µM][a] 
Fibronectin 
IC50 [µM][a] 
Vitronectin 
IC50 [µM][a] 
Fibronectin 
IC50 [µM][a] 
cyclo[DKP-4-RGD] > 70 0.58 ± 0.21 9.7 ± 4.4 0.27 ± 0.02 
cyclo[DKP-5-RGD] 17.3 ± 7.6 N.R. 9.4 ± 2.2 N.R. 
cyclo[DKP-6-RGD] 6.8 ± 2.0 > 90 4.6 ± 2.2 N.D. 
cyclo[DKP-7-RGD]-A N.D. N.D. > 200 N.D. 
cyclo[DKP-7-RGD]-B 6.6 ± 0.8 N.D. 3.8 ± 1.1 > 100 
cyclo[RGDfV] 2.00 ± 0.35 0.24 ± 0.03 0.90 ± 0.21 0.19 ± 0.08 
Table 2.2.11. Effect of DKP-RGD compounds on ECV-304 and MDA-MB-231 cell adhesion to 
vitronectin and fibronectin. [a] Each data point was performed in triplicate in two independent 
experiments. N.D. = Not Detectable, N.R. = Not Reproducible. 
 
The results obtained for compounds 4 - 7 and the reference peptide cyclo[RGDfV] at the 
Department of Medical Biotechnology and Translational Medicine (University of Milan) are shown 
in Table 2.2.11.. Except for 7-A, all the compounds show a micromolar activity in the inhibition of 
MDA-MB-231 cell adhesion to VN. Similarly to what is observed for ECV-304 cells, only ligand 4 is 
able to inhibit MDA-MB-231 cell adhesion to FN at micromolar concentrations. The results of FN-
mediated adhesion assays do not correlate with the data obtained in the isolated receptor binding 
assays, especially for compound 7-B, the highest affinity ligand of the library in the cell-free test. 
An explanation of such behaviour may be difficult considering only the molecular basis of the 
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ligand - protein recognition process. Several aspects (e.g. biological variability given by the cell 
culture microenvironment) could affect and contribute to the complexity and dynamics of a cell-
ligand system.  2.2.3.3 Type I-trans bound conformation: NMR and docking results 
As already discussed, the preferred conformation adopted by ligands strongly influenced 
their disposition in the receptor binding pocket and, as consequence, their NMR epitope. The STD 
results obtained with MDA-MB-231 cells at 282 K are described on the basis of ligand bound 
conformation in comparison with those obtained with ECV-304 cells at the same temperature.  Compound 7-B 
The tr-NOESY experiment of compound 7-B in the presence of MDA-MB-231 cells at 282 K 
showed negative cross-peaks as the NOESY spectrum. As a result, binding evidence cannot be 
obtained from this experiment. However, it showed a negative cross-peak between NHAsp (8.57 
ppm) and NH10 (7.73 ppm) (Figure 2.2.43.), consistent with the β-turn conformation at Gly-Asp 
found in the free state (type I-trans). 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.43. NOE contact between NHAsp and NH10 indicating a Type I-trans bound conformation 
for compound 7-B (β-turn at Gly-Asp, right). Hydrogen bond (dotted line) and NOE contact (arrow) 
are indicated. 
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The largest STD effects in the presence of MDA-MB-231 cells are observed for DKP-H9, 
DKP-H3 and HαGly (1.8, 1.4 and 1.1% absolute STD percentages, respectively) (Figure 2.2.44., black 
dots and bars). Many other protons appeared in the spectrum, the guanidine NH proton and the 
aromatic protons (both 0.6% absolute STD percentages), the NH10 (0.9% absolute STD 
percentages), NHArg (0.6% absolute STD percentages), HδArg and DKP-H7 (0.2 and 1.0% absolute 
STD percentages, respectively). Additionally, the signals of NHGly and NHAsp overlap (0.2% STD 
absolute intensity) and it is difficult to assess their involvement in the binding process. So, the 
interaction of 7-B with the receptor site involves many protons of both the RGD sequence and the 
DKP moiety. Compared with the STD data obtained with ECV-304 cells (Figure 2.2.44., orange dots 
and bars), a similar pattern is observed, although higher intensities and more signals (DKP-H3) of 
DKP protons are detected with MDA-MB-231 cells. For the RGD signals, Arg and Asp side chains 
seem to interact more tightly with the receptors in the presence of ECV-304 cells. 
 
 
 
 
 
 
 
 
Figure 2.2.44. Binding epitope: a) map of the STD signals of ligand 7-B in the presence of ECV-304 
cells (orange dots) with respect to MDA-MB-231 cells (black squares), b) relevant absolute STD 
percentages for the protons of compound 7-B obtained at T = 282 K in the presence of ECV-304 
(orange bars) and MDA-MB-231 (black bars) cells. Stars indicate overlapped protons. 
 
In general, the map of the STD signals obtained for ligand 7-B in the presence of ECV-304 
and MDA-MB-231 cells (Figure 2.2.44.) shows that the ligand epitope is conceivably the same.  
Docking calculations of ligand 7-B into the α5β1 integrin binding site produced top-ranked 
poses conserving optimal interactions with the receptor, as shown in Table 2.2.12.. This result is in 
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agreement with the nanomolar affinity reported for the isolated α5β1 receptor. Moreover, the 
ligand binding modes described by docking calculations in α5β1 and αVβ3 models are similar 
(Figure 2.2.45.) and well interpret the NMR data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.45. Schematic representation of the differences between the two docking best poses of 
compound 7-B in αVβ3 and α5β1 receptors; superimposition of the docking best pose in αVβ3 
(gray), αV chain (gray) and β3 chain (orange) with the docking best pose in α5β1 (green), α5 chain 
(light blue) and β1 chain (red).  
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Table 2.2.12. Average values of the distances between ligand protons (selected from STD 
experiment) and α5β1 residues calculated from docking poses. Asterisks indicate overlapping 
protons. 
 
For both the receptors the compound 7-B is the most potent ligand of the series and it 
effectively inhibits the binding of biotinylated vitronectin and fibronectin to the isolated αVβ3 and 
α5β1 integrins at sub-nanomolar and nanomolar concentrations, respectively.  
 Compound 6 
The tr-NOESY experiment of compound 6 showed negative NOE contacts like in the free 
state and does not permit to evaluate the binding event. It showed a cross-peak between NHAsp 
and NH10, consistent with the type I-trans H-bonding pattern found in the free state and in the 
bound state in the presence of ECV membrane proteins (Figure 2.2.46.). This could indicate that, 
upon binding to cells, the conformational equilibrium present in the free state is shifted towards 
one conformation, and precisely to the most abundant in the free state. 
 
 
 
 
Ligand 
protons 
Pose in α5β1  
Residues Mean distance 
NH_Arg βCH2-Ser224 (α) 4.52 Å 
δH_Arg HAr-Phe187 (α) 3.21 Å 
NH_Guan O2=C-Asp227 (α) 1.90 Å 
*NH_Gly βCH2-Ser227 (β) 2.62 Å 
αH_Gly HAr-Phe187 (α) 2.84 Å 
*NH_Asp O=C-Leu225 (β) 2.72 Å 
H_Ar HAr-Tyr133 (β) 2.77 Å 
DKP_H7 O=C-Glu320 (β) 4.72 Å 
DKP_H3 βCH2-Ser134 (β) 4.68 Å 
DKP_H9 βCH2-Ser134 (β) 2.70 Å 
DKP_NH10 HO-Ser227 (β) 4.02 Å 
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Figure 2.2.46. NOE contact between NHAsp and NH10 indicating a Type I-trans bound conformation 
for compound 6 (β-turn at Gly-Asp, right). Hydrogen bond (dotted line) and NOE contact (arrow) 
are indicated. 
 
The largest STD effects with MDA-MB-231 cells are observed for the aromatic protons and 
for the HαGly (1.3 and 0.8% absolute STD intensity, respectively) (Figure 2.2.47.). The guanidine NH 
proton, NH4 and DKP-H9 showed a similar STD effect (0.7, 0.7 and 0.6% absolute STD intensity, 
respectively). Additionally, the signals of HβAsp and DKP-H7 overlap (0.2% STD absolute intensity) 
and it is difficult to assess their involvement in the binding process. 
 
 
 
 
 
 
 
Figure 2.2.47. Binding epitope: a) map of the STD signals of ligand 6 in the presence of ECV-304 
cells (orange dots) with respect to MDA-MB-231 cells (black squares), b) relevant absolute STD 
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percentages for the protons of cyclic DKP-RGD 6 obtained at T = 282 K in the presence of ECV-304 
(orange bars) and MDA-MB-231 (black bars) cells. Stars indicate overlapped protons. 
 
The comparison of the STD signals obtained for ligand 6 in the presence of ECV-304 and 
MDA-MB-231 cells (Figure 2.2.47.) shows that the ligand epitope is similar. Some differences in 
signal intensities are observed both for the DKP and RGD moieties and NHGly and NHArg signals 
(overlapping with ECV-304 cells) are missing in presence of MDA-MB-231 cells. As observed for 
compound 7-B, it seems that the interaction of the RGD sequence with the receptors is stronger 
with ECV-304 than with MDA-MB-231 cells. In agreement with the nanomolar binding affinity, 
docking calculations of ligand 6 into the α5β1 integrin binding site produced top-ranked poses 
conserving optimal interactions with the receptor (Figure 2.2.48.). However, the analysis of the 
docking poses into αVβ3 and α5β1 models reveals different preferred binding modes of compound 
6 with the two receptors. In αVβ3 ligand 6 well overlaps to the Cilengitide crystal structure (Figure 
2.2.34) and directs the aromatic moiety toward the Tyr122 side chain of the β chain; in α5β1 the 
compound orientates the scaffold and the aromatic ring toward a different region of the receptor 
site (Figure 2.2.48.). This binding mode affects the interaction of the whole ligand with the 
receptor and, as a consequence, could explain the lack of STD signals for NH-Arg and NH-Gly 
protons and the lower STD intensity observed for most signals in the presence of MDA-MB-231 
with respect to ECV-304 cells.  
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Figure 2.2.48. Schematic representation of the differences between the two docking best poses of 
compound 6 in αVβ3 and α5β1 receptors; superimposition of the docking best pose in αVβ3 (gray), 
αV chain (gray) and β3 chain (orange) with the docking best pose in α5β1 (green), α5 chain (light 
blue) and β1 chain (red). 
 
 
 
 
 
 
 
 
Table 2.2.14. Average values of the distances between ligand protons (selected from STD 
experiment) and α5β1 residues calculated from docking poses. Asterisks indicate overlapping 
protons. 
 
 
Ligand 
protons 
Pose in α5β1 
Residues Mean distances 
NH_Guan O2=C-Asp227 (α) 2.06 Å 
αH_Gly HAr-Phe187 (α) 2.27 Å 
∗βH_Asp O=C-Asn224 (β) 3.15 Å 
DKP-NH4 CH2-Ser134 (β) 4.72 Å 
H_Ar HO-Ser227 (β) 4.71 Å Min=2.54 Å  
*DKP-H7 CH2-Ser224 (α) 4.32 Å 
DKP-H9 CH2-Ser134 (β) 2.74 Å 
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Compound 4 
Even if the tr-NOESY and NOESY contacts are negative, the superimposition of the cross-
peaks of both spectra confirms that in the bound state the ligand adopts the same conformation 
of the free state (β-turn at Gly-Asp, Type I-trans H-bonding pattern) (Figure 2.2.49.). 
 
Figure 2.2.49. Bound conformation of trans-DKP-RGD-peptidomimetic 4. Hydrogen bond (dotted 
line). 
The largest STD effects with MDA-MB-231 cells are observed for the aromatic protons and 
for DKP-H7 (1.2 and 1.1% absolute STD percentages) (Figure 2.2.50.). Additionally, we note the 
presence of NHArg, the guanidine NH proton, NH4, DKP-H3 and DKP-H9 (0.9, 0.6, 0.8, 0.6 and 0.5% 
absolute STD intensity, respectively). 
 
 
 
 
 
 
 
 
Figure 2.2.50. Binding epitopes: a) map of the STD signals of ligand 4 in the presence of ECV-304 
cells (orange dots) with respect to MDA-MB-231 cells (black squares), b) relevant absolute STD 
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percentages for the protons of cyclic DKP-RGD 4 obtained at T = 282 K in the presence of ECV-304 
(orange bars) and MDA-MB-231 (black bars) cells. 
 
The comparison of the STD signals obtained for ligand 4 in the presence of ECV-304 and 
MDA-MB-231 cells (Figure 2.2.50.) shows that the ligand epitope is significantly different: i) the 
protons of the Arg-side chain appear with relevant STD percentages only in the interaction with 
ECV-304 (orange bars), ii) the protons DKP-H3 and DKP-H9 appear only in the interaction with 
MDA-MB-231 (black bars), iii) the protons βHAsp and DKP-NH10 appear only in the interaction with 
ECV-304 (orange bars). This different behaviour allows us to make some considerations. As 
observed for compounds 7-B and 6, the interaction of the RGD sequence is stronger with ECV-304 
cells. In particular, in the presence of MDA-MB-231 cells, compound 4 loses the interaction of the 
Asp side chain and prefers to interact with the DKP scaffold protons. On the basis of the different 
ligand epitope highlighted by STD-NMR with the two cell lines, a preferred interaction of ligand 4 
with αVβ3 integrin can be hypothesized in the presence of ECV-304 cells (which express αVβ3 and 
α5β1 in 1:1 ratio), whereas the interaction with α5β1 integrin is characterized by NMR in the 
experiments with MDA-MB-231 cells. The higher affinity of compound 4 for αVβ3 compared to 
α5β1 emerging from binding assays (see Table 2.2.9.) supports this hypothesis. As discussed for 
ligand 6, top-ranked docking poses of compound 4 with the two receptors show different 
preferred binding modes (Figure 2.2.51.). 
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Figure 2.2.51. Schematic representation of the differences between the docking best poses of 
compound 4 in αVβ3 and α5β1 receptors; superimposition of the docking best pose in αVβ3 (gray), 
αV chain (gray) and β3 chain (orange)with the docking best pose in α5β1 (green), α5 chain (light 
blue) and β1 chain (red). 
 
 
 
 
 
 
 
 
Table 2.2.16. Average values of the distances between ligand protons (selected from STD 
experiment) and α5β1 residues calculated from docking poses. 
 
Moreover, due to the larger binding pocket of the integrin α5β1, docking calculations show 
that compound 4 can fit into the pocket with different energetically favorable orientations, mainly 
differing in the position of DKP scaffold and cyclic peptide backbone. The mobility of the ligand 
Ligand 
protons 
Pose in α5β1 
Residues Mean distance 
NH_Arg βCH2-Ser224 (α) 3.16 Å 
NH_Guan O2=C-Asp227 (α) 2.05 Å 
DKP-NH4 HO-Ser227 (β) 2.38 Å 
H-Ar O2=C-Glu320 (β) 2.59 Å 
DKP-H7 βCH2-Ser224 (α) 3.42 Å 
DKP-H3 HO-Ser227 (β) 2.05 Å 
DKP-H9 HO-Ser227 (β) 2.53 Å 
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within the α5β1 binding site revealed by docking poses is likely responsible of the non optimal 
interaction pattern observed for the RGD sequence with the MDA-MB-231 cells and of the sub-
micromolar affinity for the α5β1 receptor (IC50 314 nM). 
In conclusion, for the type I-trans geometry ligands we showed that small differences 
between epitopes were detected by STD-NMR experiments on ECV-3014 and MDA-MB-231 cells 
for the highest affinity α5β1 ligands 7-B and 6, while relevant differences between epitopes were 
detected for ligand 4. Therefore, only for this compound, the recognition of different receptors 
(αVβ3 or α5β1) can be hypothesized in the interaction with ECV-304 and MDA-MB-231 cells. 
 2.2.3.4 Type III bound conformations: NMR and docking results  
The results obtained for compounds 2, 3 and 5 featuring a type III H-bonding pattern will 
be reported. These ligands are characterized by sub-micromolar or micromolar IC50 values in the 
binding assays on the isolated α5β1 receptor.  Compound 2 
The free state conformation of ligand 2 is characterized by a β-turn motif at DKP-Arg (Type 
III, Figure 2.2.52.), suggested by the relevant long-range NOE interaction between NHGly and NHArg 
(negative at 282 K).  
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Figure 2.2.52. Free and bound conformation of trans-DKP-RGD-peptidomimetic 2. Hydrogen bond 
(dotted line) and NOE contact (arrow) are indicated. 
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In the tr-NOESY we do not observe the NOE contact between NHArg and NHGly that 
characterizes ligand 2 in the free state, however the lack of differences between the other NOE 
contacts in the free and bound state suggests no change in the bound conformation with respect 
to the free state. 
 
 
 
 
 
 
a)                                                                            b) 
Figure 2.2.53. Binding epitopes: a) map of the STD signals of ligand 2 in the presence of ECV-304 
(orange dots) and MDA-MB-231 cells (black squares), b) relevant absolute STD percentages for the 
protons of cyclic DKP-RGD 2 obtained at T = 282 K in the presence of ECV-304 (orange bars) and 
MDA-MB-231 (black bars) cells. 
 
The comparison of the STD signals obtained for ligand 2 in the presence of ECV-304 and 
MDA-MB-231 cells (Figure 2.2.53.) shows that the epitope is different. In fact, in the interaction 
with MDA-MB-231 cells we can observe the involvement of some DKP scaffold protons (DKP-H7 
and DKP-H9, 0.4 and 0.4% STD absolute intensity, respectively) that did not appear in the 
interaction with ECV-304 cells, as well as NHArg and γHArg (0.8 and 0.2% STD absolute intensity, 
respectively). The signals for the protons of the RGD sequence (NHGly, αHGly and NHAsp, 0.5, 0.4 and 
0.5% STD absolute intensity for MDA-MB-231) are similar in both the cell lines as well as the 
guanidine NH protons (1.4% STD absolute intensity for MDA-MB-231).  
In the presence of MDA-MB-231 cells, the protons of both the DKP moiety and the RGD 
sequence are involved in the interaction. Docking calculations into the α5β1 model identified two 
possible binding modes (A and B): in the best pose, representing the most populated binding 
mode A, the ligand forms all the key crystallographic interactions (Figure 2.2.54.a). In the second 
binding mode B, at less favourable docking scores, the ligand loses the interaction between the 
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guanidinium group and the side chain of α-Asp227 (the guanidinium group interacts with the 
aromatic ring of β-Phe321) and forms a stacking interaction between the ligand benzyl group and 
the β-Phe187 aromatic ring (Figure 2.2.54.b). A selection of the distances obtained by docking 
poses is shown in Table 2.2.16..  
a)                                                                      b) 
                                      b) 
 
 
 
 
Figure 2.2.54. a) Docking best pose (binding mode A) and b) binding mode B of compound 2 (gray) 
in α5β1 receptor (α5 chain red and β1 chain blue). 
 
Table 2.2.16. Average values of the distances between ligand protons (selected from STD 
experiment) and α5β1 residues calculated from docking poses for binding modes A and B. 
 
The two binding modes can be used to interpret NMR results with MDA-MB-231 cells, 
suggesting that both the ligand arrangements in the α5β1 binding pocket could contribute to the 
experimental binding epitope. The possibility of adopting different binding modes within the α5β1 
receptor site, due to the specific features of the pocket and to the weaker coordination of the 
Ligand 
protons 
Binding mode A Binding mode B 
Residues Distances Residues Distances 
NHArg CAr-Phe187 (α) 4.90 Å (Min=3.70 Å) βCH2-Ser224 (α) 5.39 Å 
δH_Arg HAr-Phe187 (α) 2.74 Å O=C-Ser224 (α) 3.19 Å 
NH_Guan O2=C-Asp227 (α) 1.93 Å HAr-Phe321 (β) 3.62 Å 
NHGly HAr-Phe187 (α) 4.09 Å (Min=3.54 Å) HO-Ser227 (β) 3.21 Å 
αH_Gly βCH2-Ser227 (β) 2.71 Å HO-Ser227 (β) 2.09 Å 
NHAsp O=C-Leu225 (β) 2.99 Å αCH-Ser227 (β) 2.56 Å 
H_Ar HAr-Tyr133 (β) 7.42 Å (Min=5.58 Å) HAr-Phe187 (α) 4.02 Å 
DKP-H7 O2=C-Glu320 (β)  9.28 Å (Min=6.38 Å) βCH2-Ser224 (α) 6.46 Å 
DKP-H9 αCH-Ser134 (β) 4.69 Å (Min=2.60 Å) HAr-Tyr133 (β) 4.37 Å 
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ligand to integrin charged regions compared to αVβ3, could explain the low affinity of ligand 2 for 
the isolated receptor and the great variability observed in the competitive binding assay (α5β1 IC50 
1647 ± 871 nM).  
 Compound 3 
Compound 3 adopts, in the free and in the bound state, mainly one conformation 
characterized by a β-turn at DKP-Arg (Type III, Figure 2.2.55.) and confirmed by the cross-peak 
between NHArg (8.79 ppm) and NHGly (8.12 ppm) (Figure 2.2.56.) in the NOE experiment. 
Compound 3 is the only, among those tested, that shows at 282 K positive NOE contacts in the 
free state and negative in the tr-NOESY, showing binding evidence. 
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Figure 2.2.55. Free and bound conformation of trans-DKP-RGD-peptidomimetic 3. Hydrogen bond 
(dotted line) and NOE contact (arrow) are indicated. 
 
Moreover, the cross-peaks between the aromatic protons and the Arg-side chain protons, 
which can be observed in the NOESY experiments (free ligand), are lacking in tr-NOESY spectrum, 
indicating an extended arrangement of the Arg-side chain. 
 
146 
 
 
Figure 2.2.56. NOE contact between NHArg and NHGly indicating a Type III bound conformation for 
compound 3. 
 
 
 
 
 
 
 
Figure 2.2.57. Binding epitope: a) map of the STD signals of ligand 3 in the presence of ECV-304 
cells (orange circles) and MDA-MB-231 cells (black squares), b) relevant absolute STD percentages 
for the protons of cyclic DKP-RGD 3 obtained at T = 282 K in the presence of ECV-304 (orange bars) 
and MDA-MB-231 (black bars) cells. 
 
The comparison  of the STD signals obtained for ligand 3 in the presence of ECV-304 and 
MDA-MB-231 cells (Figure 2.2.57.) shows that  the epitope is similar. The main differences 
concern: i) the presence of NHAsp in the epitope with ECV-304 cells (low STD percentage) and ii) 
the higher STD percentages of the MDA-MB-231 signals  compared to the ECV-304 signals, mainly 
for the aromatic protons. In fact, at 282 K the largest STD effects in the presence of MDA-MB-231 
cells are observed for DKP-NH1 (1.0% STD absolute intensity) and for the aromatic protons (7.26 
ppm, 1.3% STD absolute intensity). The guanidine NH proton, DKP-NH10, and NHGly show quite 
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similar STD effects (0.8, 0.6 and 0.9%, respectively) and can also be considered as lying close to the 
protein surface.  
The analysis of the docking results highlighted two binding modes of the ligand in the 
receptor site of α5β1 (Figure 2.2.58), both in agreement with the NMR epitope found with MDA-
MB-231 cells. The comparison between NMR epitope and distance values calculated for the two 
families of poses is reported in Table 2.2.18.. 
a)                                                                               b) 
 
 
Figure 2.2.58. a) Docking best pose (binding mode A) and b) binding mode B of compound 3 (gray) 
in α5β1 receptor(α5 chain red and β1 chain blue).  
 
Table 2.2.18. Average values of the distances between ligand protons (selected from STD 
experiment) and α5β1 residues calculated from docking poses for binding modes A and B. 
 
As observed for compound 2, in the best pose (binding mode A) compound 3 forms all the 
key interactions with the α5β1 integrin, but in binding mode B, characterized by a less favourable 
docking score, the guanidinium moiety loses the interaction with Asp227 of α chain and interact 
with the aromatic ring of the α-Trp157 (Figure 2.2.58.).  
 
Ligand 
protons 
Binding mode A Binding mode B 
Residues Distances  Residues Distances  
NH_Guan O2=C_Asp227 (α) 2.02 Å CAr-Trp157 (α) 3.46 Å 
NHGly HAr-Phe187 (α) 5.15 Å HAr-Phe187 (α) 3.31 Å 
DKP-NH1 HAr_Tyr133 (β) 6.30 Å HAr_Tyr133 (β) 3.89 Å 
H_Ar βCH2_Ser134 (β) 3.76 Å HAr_Phe187 (α) 4.73 Å (Min=3.26 Å) 
DKP-NH10 βCH2_Ser134 (β) 2.98 Å βCH2_Ser134 (β) 3.80 Å 
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Compound 5 
The tr-NOESY experiment of compound 5 in the presence of MDA-MB-231 cells at 282 K 
showed a negative cross-peak between NHArg (8.39 ppm) and NHGly (8.08 ppm); this NOE contact 
(Figure 2.2.59.) is consistent with the β-turn conformation at DKP-Arg found in the free state (type 
III). 
 
 
Figure 2.2.59. NOE contact between NHArg and NHGly indicating a Type III bound conformation for 
compound 5. 
 
In the presence of MDA-MB-231 cells the largest STD effect is observed for the DKP-H7 
(1.1% absolute STD intensity). This signal was overlapped in the experiment with ECV-304 cells, 
while for MDA-MB-231 cells a slight difference in the chemical shift between the DKP-H7 and HβAsp 
permits to determine which of the two protons contributes to the STD effect. Additionally, we 
observed the presence of HδArg, the guanidine NH proton , HαGly, the aromatic protons, and DKP-H9 
(0.2, 0.8, 0.3, 0.5 and 0.5% absolute STD intensity, respectively) (Figure 2.2.60.). The benzyl groups 
are overlapped, so their contribution is halved in the graph, but it is not possible to evaluate the 
contribution of each ring separately.  
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Figure 2.2.60. Binding epitopes: a) map of the STD signals of ligand 5 in the presence of ECV-304 
cells (orange dots) andMDA-MB-231 cells (black squares), b) relevant absolute STD percentages 
for the protons of cyclic DKP-RGD 5 obtained at T = 282 K in the presence of ECV-304 (orange bars) 
and MDA-MB-231 (black bars) cells. 
 
The comparison of the STD signals obtained for ligand 5 in the presence of ECV-304 and 
MDA-MB-231 cells (Figure 2.2.60.) shows that the same protons of the DKP scaffold provide 
significant STD percentages (except for DKP-NH10). On the contrary, some differences appear in 
the RGD sequence, although overlapping protons prevent to exactly define the ligand epitope with 
ECV-304 cells. However, it is worth noting the absence of NHArg, NHGly and βHAsp in the interaction 
with MDA-MB-231 cells. 
Docking calculations into α5β1 receptor produced poses forming all the relevant 
interactions observed in the X-ray complex. Moreover, the binding modes of compound 5 in the 
two receptor sites of integrins αVβ3 and α5β1, are very similar as clearly shown in the 
superimposition of the docking best poses  (Figure 2.2.61.). 
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Figure 2.2.61. Superimposition of the docking best poses of compound 5 in αVβ3 and α5β1 
receptors;docking best pose in αVβ3 (gray), αV chain (gray) and β3 chain (orange), docking best 
pose in α5β1 (green), α5 chain (light blue) and β1 chain (red). 
 
 
 
 
 
 
 
 
Table 2.2.20. Distances relative to the protons of the epitope, calculated as mean on all the poses.  
 
However, the micromolar binding affinity of compound 5 for the α5β1 isolated integrin (IC50 
= 1217 ± 157 nM) suggests some difficulties of the docking model in properly describing ligand - 
receptor interactions (e.g. overestimation of the electrostatic contributions). 
 
Ligand 
protons 
Pose in α5β1 
Residues Mean distances 
δH_Arg HAr-Phe187 (α) 3.28 Å 
NH_Guan O2=C-Asp227 (α) 2.01 Å 
αH_Gly βCH2-Ser227 (β) 2.87 Å 
H_Ar HAr-Tyr133 (β) 4.93 Å (Min = 2.95 Å) 
DKP_H7 HAr-Phe187 (α) 5.89 Å (Min = 4.74 Å) 
DKP_H9 HAr-Tyr133 (β) 2.12 Å 
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Section 3: Conclusions 
In this thesis, NMR methodologies, based on saturation transfer and detection of 
transferred NOEs, were revealed useful methods for the investigation of ligand - protein 
interactions. In particular, we used these techniques to shed light on the binding epitope of 
peptidomimetic integrin ligands in the interaction with human platelets, known to express on their 
membrane integrin IIb3, and with living cancer cells known to express integrins V3 and 51 
(ECV-304 bladder and MDA-MB-231 breast cancer cell lines). The NMR results were supported by 
docking and molecular dynamics studies and were compared to the results of competitive 
receptor binding and cell adhesion assays.  
The ligands are cyclic peptidomimetics containing the RGD sequence and chiral 
diketopiperazine (DKP) scaffolds, differing for the configuration at the C-3 and C-6 stereogenic 
centres and for the substitution at the diketopiperazinic nitrogen atoms (Figure 2.3.1.).4 
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Figure 2.3.1. Cyclic RGD-peptidomimetics containing bifunctional DKP scaffolds. Compound 7 
exists as two separable diastereomers, 7-A and 7-B. 
 
Conformational studies of the cyclic RGD peptidomimetics by 1H VT-NMR and NOESY 
experiments and Monte Carlo/Stochastic Dynamics (MC/SD) simulations revealed that the ligands 
display well-defined preferred conformations featuring intramolecular hydrogen-bonded turn 
motifs. For clarity, these -turn were classified in five types of conformations: Type I-cis (-turn at 
Gly-Asp), Type I-trans (-turn at Gly-Asp), Type II (-turn at Arg-Gly), Type III (-turn at DKP-Arg) 
and Type IV (-turn at Asp-DKP) (Figure 2.3.2.). In particular, Type I-cis and Type II geometries 
characterize compound 1, Type III conformation characterizes compounds 2, 3, 5 and, in 
152 
 
equilibrium with Type II, compound 7-A, Type I-trans conformation characterizes compounds 4, 7-
B and, in equilibrium with Type IV, compound 6. The scaffold stereochemistry and the 
regiochemistry of the benzyl ring strongly influenced the conformation of the ligands both in the 
free and in the bound states. 
 
Figure 2.3.2. Representation of the five types of conformations. 
 
Docking calculations were performed starting from the representative conformations 
obtained from the restrained MC/SD simulations and were analyzed using as reference models the 
crystal structures of the extracellular segment of the integrins V3, IIb3 and 51 in complex 
with Cilengitide,18 Eptifibatide19 and a linear RGD peptide,17 respectively. 
Ligands displaying an extended arrangement of the RGD sequence [C(Arg) – C(Asp) 
average distance values ≥ 8.8 Å] produced top-ranked binding modes, conserving all the important 
interactions of the X-ray complex. Instead, non-extended RGD arrangements [C(Arg) – C(Asp) 
average distance values lower than 8 Å), imparted by Type I-cis and Type II geometries, seem to 
prevent the guanidine and carboxylic groups from achieving the required separation for binding to 
integrins. This feature is a necessary requirement, even if not sufficient, for a good interaction 
with the receptors; in fact, the acid and basic pharmacophoric groups and their orientation are 
Type II Type III Type IV 
Type I-cis Type I-trans 
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essential for the binding, because they act like an electrostatic clamp, interacting with charged 
regions of the receptor binding site.  
The ligands, characterized by extended RGD arrangements, show the highest affinities for 
integrins, as demonstrated by the results of the biological assays. On the contrary, compounds 1 
and 7-A, characterized by closed geometries show the lowest receptor affinities.  
First, I set up NMR methodologies by using human platelets and investigating the 
interaction of RGD peptidomimetic ligands 1 – 3 with the platelet-specific integrin IIb3. The STD-
NMR results were compared with docking studies. The bent conformations (C(Arg) – C(Asp) 
distances values lower than 8 Å), adopted by compound 1, in presence of human platelets prevent 
the guanidine and carboxylic groups to achieve the required distance for binding to the IIb3. In 
fact, for compound 1 the interaction mainly occurs through its basic moiety (guanidine NH) with 
the IIb subunit, for which we observed the largest STD effect. Compounds 2 and 3 are  
characterized by the same regiochemistry of the benzyl group and by the Type III geometry, but 
they differ for the stereochemistry at the two stereocenters of the DKP scaffold. Analyzing the 
NMR results of the experiments with platelets, the influence of a different stereochemistry on the 
binding epitope is evident. The compounds show the same interactions in the RGD moiety. In 
addition, for 3 the epitope comprises the aromatic protons and NH10 that are absent in the STD 
spectrum of 2. The superimposition of the best poses of 2 and 3 into the IIb3 binding site showed 
a similar disposition of the two compounds, perfectly overlapped in the RGD sequence, but 
different in the benzyl group which points into opposite direction (Figure 2.3.3.). According to the 
absence of the STD effect for the aromatic protons of compound 2, in the docking poses no 
residue of the protein is in contact with the ligand benzyl group. 
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Figure 2.3.3.  Docking best poses of trans-DKP-RGD-peptidomimetics 2 and 3 (pink and green atom 
colour tube representation, respectively) into the crystal structure of the integrin IIb3 headpiece 
( unit red and  unit blue wire representation). 
 
Then, I expanded the NMR study by using ECV-304 cancer cell line and gaining insight into 
the interaction of the small library of ligands with the tumour-associated integrin V3.  
For both cell lines, human platelets and ECV-304 cells, we observed that: i) the primary 
interaction between the ligand and the receptor is performed by the guanidine residue of the Arg 
side-chain (see behaviour of compound 1), ii) the extended conformation of the trans ligands 2 
and 3 ensures the formation of the electrostatic clamp (STD effects on protons of the Arg and Asp 
residues), iii) the opposite configuration at C-3 and C-6 stereogenic centres of the DKP scaffold of 
the trans ligands 2 and 3 induces a different binding epitope for the non-RGD moiety of the ligands 
(diketopiperazine and benzyl substituents). 
 
We completed our analysis on ECV-304 cell line with the study of peptidomimetic ligands 4 
– 7 containing the two enantiomeric trans DKP scaffolds with different substitution at the 
endocyclic nitrogen atoms. Compounds 4 and 6, monobenzylated at N-1, and the dibenzylated 
compound 7-B adopt the Type I-trans conformation with respect to the Type III geometry adopted 
by compounds 2 and 3, monobenzylated at N-4, and by the dibenzylated ligand 5 (Figure 2.3.4.).  
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A                                                            B 
 
 
 
 
Figure 2.3.4. Representation of the two most populated extended conformations; A) Example of a 
Type III H-bonding pattern, B) Example of a Type I-trans H-bonding pattern. Red arrows indicate 
NOE contacts, while dashed black line the H-bonds. 
 
The type I-trans conformation produced deep differences in the binding epitope with 
respect to Type III, involving in the interaction not only the RGD sequence, but also the protons of 
the DKP scaffold. This behaviour is evident in the comparison between the epitopes of compounds 
2 and 4 (Figure 2.3.5.). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.5. Comparison between the epitopes of compounds 2 and 4. a) - b) Map of the STD 
signals of ligand 2 (blue dots) and 4 (orange dots). Relevant absolute STD percentages for the 
protons of 2 (blue bars) and 4 (orange bars) obtained at 282 K in the presence of ECV-304 cells 
(bottom). 
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While compound 2 mainly involves in the interaction the protons of the RGD sequence, 
compound 4 involves the protons of the Arg and Asp side chains and some protons of the DKP 
scaffold. 
 
 
Figure 2.3.6. Docking best pose of compound 2 (purple) superimposed with the docking pose of 
compound 4 (green) into the crystal structure of the extracellular domain of v3 integrin ( unit 
red and  unit blue wire representation); the metal ion at MIDAS is shown as a magenta CPK 
sphere.  
 
The different epitope of the two compounds is well represented by superimposing their 
docking best poses into the V3 receptor site, where they mainly differ in the position of DKP 
scaffold (Figure 2.3.6.).  
The dibenzylated compounds, 7-A and 7-B, show the influence of the preferred 
conformation adopted by ligands on their disposition in the receptor binding pocket and, as 
consequence, on their NMR epitope. In fact, the most active compound of the DKP series, the 
diastereomer 7-B (type I-trans), is characterized by high STD absolute percentages and lots of 
interactions with the receptor. On the other hand, the diastereomer 7-A, showing the lowest 
affinity for the V3 integrin among the trans ligands, displayed a STD signal pattern  intermediate 
between those of the compounds 3 and 7-B. Entropic reasons, i.e. the presence of both extended 
(type III) and non-extended geometries in the free state conformational equilibrium, can account 
for the lower affinity for the V3 integrin of the isomer 7-A compared to the other trans DKP-RGD 
ligands. 
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The ECV-304 cell line expresses different integrins on the membrane. In particular, 
integrins V3 and 51 show the same high level of expression (ratio of 51/V3 expression =  
1.16). Since also integrin 51 recognizes the RGD sequence, we wondered if the NMR results 
obtained on ECV-304 cells might be affected by the presence of both the integrins. For this reason, 
we performed tr-NOESY and STD NMR experiments using the MDA-MB-231 breast cancer cell line, 
known to overexpress only integrin 51. MDA-MB-231 was then considered the reference cell 
line to investigate the interaction of the compounds with the 51 integrin. 
Compared with the binding results for V3 receptor, all the DKP ligands and the reference 
peptides lost at least one order of magnitude in affinity (51 IC50 values 30 - 500 times higher 
than V3 IC50 values). Since the X-ray structures reveal similar RGD geometrical requirements for 
the binding to 51 and V3 integrins, the observed selectivity may depend on the 
physicochemical features of the binding sites. In fact, the receptor region that binds to the ligand 
guanidinium group is less acidic in 51 than in V3, thus leading to a weaker interaction of the 
ligand Arg side chain with the 5 subunit. Moreover, due to both the less efficient electrostatic 
clamp and the larger binding pocket compared to V3, the ligands interact less strongly with 51 
and may reveal a greater mobility within the receptor site. 
The behaviour of compound 4 is the most useful to differentiate and appreciate the 
interaction of the ligands of the library with the two receptors, making clear the differences that 
characterized the two binding pockets. The comparison of the STD signals obtained for ligand 4 in 
the presence of ECV-304 and MDA-MB-231 cells (Figure 2.3.7.) shows that the ligand epitope is 
significantly different: i) the protons of the Arg-side chain appear with relevant STD percentages 
only in the interaction with ECV-304 (orange bars), ii) the protons DKP-H3 and DKP-H9 appear only 
in the interaction with MDA-MB-231 (black bars), iii) the protons HAsp and DKP-NH10 appear only 
in the interaction with ECV-304 (orange bars). 
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Figure 2.3.7. Binding epitopes: a) map of the STD signals of ligand 4 in the presence of ECV-304 
cells (orange dots) with respect to MDA-MB-231 cells (black squares), b) relevant absolute STD 
percentages for the protons of cyclic DKP-RGD 4 obtained at T = 282 K in the presence of ECV-304 
(orange bars) and MDA-MB-231 (black bars) cells. 
 
On the basis of the different ligand epitopes highlighted by STD-NMR with the two cell 
lines, a preferred interaction of ligand 4 with V3 integrin can be hypothesized in the presence of 
ECV-304 cells (which express V3 and 51 in 1:1 ratio), whereas the interaction with 51 
integrin is characterized by NMR in the experiments with MDA-MB-231 cells. The higher affinity of 
compound 4 for V3 compared to 51 emerging from binding assays supports this hypothesis.  
Also compound 2 is characterized by a relevant different NMR binding epitope with the 
two cell lines. STD-NMR experiments, in fact, show for compound 2 differences in its binding 
epitope with the two cell lines, ECV-304 and MDA-MB-231 cells (Figure 2.3.8.).  
 
 
 
 
 
 
Figure 2.3.8. Binding epitopes: map of the STD signals of ligand 2 in the presence of ECV-304 cells 
(orange dots) and MDA-MB-231 cells (black squares). 
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Compound 2 with ECV-304 cell line involves in the interaction the protons of the RGD 
sequence, while with MDA-MB-231 it interacts also with the proton of the DKP scaffold (Figure 
2.3.8.).  
In conclusion, compounds 2 and 4 (same stereochemistry at the two stereocenters of the 
DKP scaffold, but different substitution pattern) are characterized by differences between 
epitopes in the two cell lines. Therefore, only for these compounds, the recognition of different 
receptors (V3 or 51) can be hypothesized in the interaction with ECV-304 and MDA-MB-231 
cells. In the presence of ECV-304 cells, where the integrins V3 and 51 are expressed in the 
same ratio, they interact preferentially with integrin V3. The other ligands, including compounds 
of opposite stereochemistry (e.g. 3 and 6), appear to interact with the two integrins in a similar 
way.  
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Section 4: Experimental section 
 
NMR EXPERIMENTS 
Conformational analysis: NMR spectroscopy experiments were performed at 298 K and 
282 K on Bruker Avance 400 and 600 MHz spectrometers. All proton and carbon chemical shifts 
were assigned unambiguously. The NMR experiments were carried out in a H2O/D2O 9:1 mixture 
in order to observe amide protons. Two-dimensional experiments (TOCSY, NOESY and HSQC) were 
carried out on samples at a concentration range of 3-6 mM. NOESY experiments were performed 
at 0.7 or 0.8 s. The water resonance was saturated with the excitation sculpting sequence from the 
Bruker library. The conformations of the cyclic peptidomimetics were analyzed with respect to 
hydrogen bonding of amide protons (VT-NMR spectroscopy) and NOE contacts.4 
 
NMR spectroscopy studies with cells: The spectra were acquired with a Bruker Avance 
600 MHz instrument at 298 and 282 K. Each sample was prepared in a 3 mm NMR tube with ligand 
(0.5-0.6 mg) and cells (106) in phosphate buffer (200 l, pH 7.4, 20 mM additionally containing 
NaCl 157 mM, KCl 6 mM and CaCl2 4 mM with D2O 10%). The interaction between our ligands and 
membrane proteins expressed on human platelets, ECV304 (bladder cancer cells) and MDA-
MB231 (breast cancer cells) cell lines was detected using tr-NOESY and STD experiments.3,44 In 
addition, tr-ROESY experiments, performed to exclude spin-diffusion artefacts, showed the same 
set of cross-peaks as the NOESY. In the tr-NOESY experiment water suppression was achieved by 
use of an excitation sculpting pulse sequence. In the STD experiments water suppression was 
achieved by use of the WATERGATE 3-9-19 pulse sequence. The on-resonance irradiation of the 
protein was performed at a chemical shift of -0.05 ppm and the saturation time is 3 sec. Off-
resonance irradiation of the protein was applied at 200 ppm, where no protein signals were 
visible. STD: 60 Gaussian pulses, each requiring 50 ms. STD spectra of the ligands in the absence of 
cells did not show any signals. Instead, in the STD spectra of the ligands with cells, intensities of 
STD effects (absolute STD) were calculated by integrating the corresponding signals in 1H NMR 
reference spectra. The signal intensities of the individual protons are best analyzed from the 
integral values in the reference and STD spectra. (I0 – Isat)/I0 is the fractional STD effect, expressing 
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the signal intensity in the STD spectrum as a fraction of the intensity of an unsaturated reference 
spectrum. In this equation, I0 is the intensity of one signal in the off-resonance or reference NMR 
spectrum and Isat is the intensity of a signal in the on-resonance NMR spectrum. 
 
CELL CULTURES 
Platelets were extracted from human blood received from Multimedica Centre of Milan. A 
portion of 15 mL of CPD plasma (plasma suspended in citrate-phosphate-dextrose solution) was 
centrifuged and the remaining pellet cautiously suspended in 2 mL of deuterated TRIS-buffered 
saline containing EDTA (1 mM). This procedure was repeated twice. Four additional washing-
centrifuging cycles were performed using deuterated TRIS-buffered saline containing 1 mM CaCl2. 
After the last centrifugation, the pellets were suspended in 1 mL of the last buffer and the 
suspension was split into two NMR tubes. To each tube, 1 mg of ligand was added.  
 
Both the ECV-304 and MDA-MB-231 cell lines were expanded after freezing and were 
grown in RPMI culture medium (mother medium supplemented with 1% glutamine, 1% 
PENSTREPT (penicillin-streptomycin), 10% FBS (fetal bovine serum)). Cells were adherent to the 
flask wall and cover with RPMI medium. To prepare cells for NMR tube, cells were removed by 
trypsin and then resuspended in 10 mL of a RPMI – serum solution. After two washing-centrifuging 
cycles with PBS, the pellets were suspended in 200 L of phosphate buffer.  
 
COMPUTATIONAL STUDIES 
All calculations were run with the Schrödinger suite of programs 
(http://www.schrodinger.com) through the Maestro graphical interface. 
Conformational analysis: Conformational preferences of the RGD peptidomimetics were 
investigated by Monte Carlo/Stochastic Dynamics (MC/SD)31,32,33 hybrid simulations by using NMR 
spectroscopy restraints derived from the experimental NOE contacts (for distance restraints used 
for each calculation, see the ∗Supporting Information∗). All the NOE restraints were set to a 
distance value of 2(±0.5) Å with a force constant of 100 Kj*mol-1*Å-2. MC/SD simulations were 
performed at 300 K within the framework of MacroModel version 9.5 by employing the 
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OPLS_2001 force field33 and the implicit water GB/SA solvation model.32 The OPLS_2001 force 
field, among several commonly used force fields, provided the highest correlation between 
calculated and experimental conformational preferences within the series of cyclic RGD 
peptidomimetics containing diketopiperazine scaffolds with different stereochemistry and 
substitution at the piperazinic nitrogen atoms. RGD side-chain dihedral angles were defined as 
internal coordinate degrees of freedom in the Monte Carlo part of the algorithm. A time step of 1 
fs was used for the stochastic dynamics (SD) part of the algorithm for 10 ns of simulation time. 
Samples were taken at 2 ps intervals during each simulation, yielding 5000 conformations for 
analysis. The percentages of H bonds discussed here were calculated as percentages of 
conformations sampled during the simulation in which donor H-acceptor O distance <2.5 Å (-
turn) or <4 Å (b-turn). 
 
Protein setup:  
IIb3: the solved crystal structure of the integrin IIb3 headpiece bound to the cyclic 
heptapeptide Eptifibatide (PDB entry code 2VDN)19 was used for docking studies. Docking was 
performed only on the globular head of the integrin because the headgroup of integrin has been 
identified in the X-ray structure as the ligand-binding region. The protein structure was setup for 
docking as follows. The protein was truncated to residue sequences 18-452 for chain  and 108-
352 for chain . The coordination shell of metal cation belonging to MIDAS (metal-ion-dependent 
adhesion site) and ADMIDAS (adjacent to MIDAS) in the chain was completed on the basis of the 
integrin IIb3 X-ray structures by adding two and one water molecules, respectively. The Mg
2+ ion 
at MIDAS and ADMIDAS in the experimental protein structure was modeled by replacing it with a 
Ca2+ ion. The resulting structure was prepared using the Protein Preparation Wizard of the 
graphical user interface Maestro and the OPLSAA force field. 
 
V3: the solved crystal structure of the extracellular domain of the integrin V3 receptor 
in complex with the cyclic pentapeptide cilengitide and in the presence of the proadhesive Mn2+ 
ion (PDB ID: 1L5G)18 was used for docking studies. Docking was performed only on the globular 
head of the integrin because the head group of integrin has been identified as the ligand-binding 
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region in the X-ray structure. The protein structure was set up for as follows: the protein was 
truncated to residue sequences 41-342 for  chain  and 114-347 for  chain. Because of a lack of 
parameters, the Mn2+ ions in the experimental protein structure were modelled by replacing them 
with Ca2+ ions. The resulting structure was prepared by use of the Protein Preparation Wizard in 
the graphical user interface Maestro and the OPLSAA force field. 
 
51: the recently solved crystal structure of the extracellular domain of the integrin 51 
receptor in complex with the linear esapeptide GRGDNP (PDB ID: 3VI4)17 was used for docking 
studies. Docking was performed only on the globular head of the integrin because, also in this 
case, the closed head group of integrin has been identified as the ligand-binding region in the X-
ray structure. The protein structure was set up as follows: the protein was truncated to residue 
sequences 40 – 351 for  chain and 121 – 358 for chain. Because of the absence of ADMIDAS ion 
in the X-ray structure, a Ca2+ ion was added in this region based on the ADMIDAS position in V3 
X-ray structure. The resulting structure was prepared by use of the Protein Preparation Wizard in 
the graphical user interface Maestro and the OPLSA_2005 force field. 
All models were validated through docking studies conducted with the respective 
crystallographic ligands. The results well agree with the experimental data, both for a good 
"docking score" and for the number of poses that reflect the arrangement of the crystal structure 
of the ligand in the receptor pocket. 
Molecular Docking: the automated docking calculations were performed using Glide (Grid-
based Ligand Docking with Energetics)47 within the framework of Impact version 4.5 (for IIb3 and 
V3) or 5.7 (for 51) in a standard precision mode (SP). Glide uses a hierarchical series of filters 
to search for possible locations of the ligand in the active site region of the receptor. The shape 
and properties of the receptor are represented on a grid by several different sets of fields that 
provide progressively more accurate scoring of the ligand poses. The grid generation step started 
from the extracellular fragment of X-ray structure of the complex protein : ligand, as described in 
the protein setup section. The center of the grid enclosing box was defined by the center of the 
bound ligand, as described in the original PDB entry. The enclosing box dimensions, which are 
automatically deduced from the ligand size, fit the entire active site. For the docking step, the size 
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of the bounding box for placing the ligand center was set to 12 Å. No further modifications were 
applied to the default settings. The GlideScore function was used to select 20 poses for each 
ligand. The Glide program was initially tested for its ability to reproduce the binding geometry of 
the crystallized ligands. The program was successful in reproducing the experimentally determined 
mode of these compounds, as they correspond to the best-scored pose. 
The automated docking calculations were performed by starting from the representative 
geometries previously obtained from computational studies (free-state molecular mechanics 
conformational searches and MC/SD simulations) for the RGD cyclopeptides. 
 
Molecular Dynamics simulations: MD simulations were performed on some 
peptidomimetic integrin ligands within the X-ray crystal structure of the IIb3, V3 and 51 
integrin binding sites prepared as described in the protein setup. Starting from docking best poses, 
MD simulations were performed at 300 K within the framework of MacroModel version 9.5 by 
employing the OPLS_2001 force field33 and the implicit water GB/SA solvation model.32 The 
substructure utility was used to model the receptor atoms. Residue atoms within 5 Å of the ligand 
were constrained to crystallographic coordinates by a harmonic potential (with a force constant k 
= 100 Kj mol-1 Å2 for atoms up to 3 Å and with k = 200 Kj mol-1 Å2 for atoms between 3 and 5 Å) 
allowing the polar and aromatic hydrogen atoms free movement. Residue atoms between 5 Å and 
10 Å were frozen to their X-ray position. The remaining receptor atoms were ignored during the 
calculations. Molecular dynamic simulations gave similar results (disposition of the ligand and 
interactions) to those obtained with docking calculations. 
 
IN VITRO BIOLOGICAL ASSAYS 
Integrin receptor binding assays: the cyclic RGD peptidomimetics were examined in vitro 
for their ability to inhibit biotinylated vitronectin binding to the purified V3 integrin and to 
inhibit biotinylated fibronectin binding to the purified 51 receptor.  
 
V3: Purified V3 receptor (Chemicon International, Inc., Temecula, CA, USA) were 
diluted to 0.5 g mL-1 in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM 
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MnCl2, 2 mM CaCl2, and 1 mM MgCl2. An aliquot of diluted receptors (100 Lwell
-1) was added to 
96-well microtiter plates (NUNC MW 96F Medisorp Straight) and incubated overnight at 4 °C. The 
plates were then incubated with blocking solution (coating buffer plus 1 % bovine serum albumin) 
for additional 2 h at room temperature to block nonspecific binding, followed by 3 h incubation at 
room temperature with various concentrations (10-12 – 10-5 M) of test compounds in the presence 
of biotinylated vitronectin (1 g mL-1) using an EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, 
Rockford, IL, USA). After washing, the plates were incubated for 1 h at room temperature with 
biotinylated streptavidin-peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed 
by 30 min incubation with 100 L Substrate Reagent Solution (R&D Systems, Minneapolis, MN) 
before stopping the reaction with the addition of 50 L 1 N H2SO4. Absorbance at 415 nm was read 
in a Synergy HT Multi-Detection Microplate Reader (BioTek Instruments, Inc.). 
 
51: Purified 51 receptor was diluted to 0.5 μg/mL in coating buffer containing 20 
mmol/L Tris- HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L MnCl2, 2 mmol/L CaCl2 and 1 mmol/L 
MgCl2. An aliquot of diluted receptors (100 μL/well) was added to 96-well microtiter plates (NUNC 
MW 96F MAXISORP STRAIGHT) and incubated overnight at 4°C. The plates were then incubated 
with blocking solution (coating buffer plus 1% bovine serum albumin (Sigma) for additional 2 hours 
at room temperature to block non specific binding followed by 3 hours incubation at room 
temperature with various concentrations of test compounds in the presence of 1 μg/mL 
fibronectin biotinylated using EZ-Link Sulfo-NHS-Biotynilation kit (Pierce, Rockford, IL). After 
washing, the plates were incubated for 1 hour at room temperature with streptavidin-biotinylated 
peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 minutes incubation 
with 100 μL Substrate Reagent Solution (R&D Systems, Minneapolis, MN) before stopping the 
reaction by addition of 50 μL of 1 N H2SO4. Absorbance at 415 nm was read. 
The ability of the new compounds to inhibit the binding of vitronectin and fibronectin to 
the isolated V3 and 51 receptors was compared with that of the reference compounds 
c(RGDfV) and ST1646. IC50 values were calculated as the concentration of compound required for 
50 % inhibition of biotynilated vitronectin/fibronectin binding as estimated by GraphPad Prism 
166 
 
software by nonlinear regression analysis; all values are the arithmetic mean ± SD of triplicate 
determinations. 
 
Cell adhesion assays: to assess the activity of RGD compounds as integrin antagonists on a 
cell model, cell adhesion experiments were performed using ECV-304 bladder cancer cells which 
highly express integrin V3 and MDA-MB-231 breast cancer cells which overexpress integrin 51. 
Cells were allowed to adhere to immobilized fibronectin or vitronectin in the presence of 
increasing concentrations of the tested compounds. Adhesion assay tests were performed in two 
different laboratories using the same ECV-304 and MDA-MB-231 cancer cell lines and 
experimental protocol. The results were obtained for compounds 1, 2 and 3 and the reference 
peptide cyclo[RGDfV] at the cell biology laboratory of CISI (an Interdepartmental Centre of Milan 
University, Dr. E. Araldi), that first developed the adhesion assay protocol for both ECV-304 and 
MDA-MB-231 cells. The results for compounds 4 - 7 and the reference peptide cyclo[RGDfV] were 
obtained at the Department of Medical Biotechnology and Translational Medicine by Dr. C. Tringali 
and Dr. I. Silvestri (University of Milan). 
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ANALYSIS OF LIGAND – CADHERIN INTERACTIONS 
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Section 1: Introduction 
 
This part of my PhD thesis is focused on recent findings obtained in the field of rational 
design of peptidomimetic targeting the protein - protein interactions (PPIs) of cadherins, in the 
framework of the FIRB project coordinated by Dr. M. Civera (Computer-aided design, synthesis 
and biological evaluation of peptidomimetics targeting N-cadherin as anticancer agents, MIUR-
FIRB “Futuro in Ricerca” RBFR088ITV).  
The role played by PPIs is central in many physiological processes, from cell-cell messaging 
to cellular apoptosis. Targeting the interfaces between proteins has huge therapeutic potential, 
but developing drug-like small molecules that modulate PPIs is a great challenge.1 Modern 
molecular and cellular biology have enabled enormous progress in unveiling many aspects of this 
complex network. As part of an ongoing investigation into the cellular adhesion process mediated 
by protein – protein interactions, our group set out to rationally design and synthesize small 
peptidomimetic molecules aimed at providing partial or total inhibition of the cadherin – cadherin 
interaction.2 Cadherins, in fact, promote cell adhesion by an homophilic interaction of their N-
terminal extracellular domains. Classical cadherins, including type I and II subfamilies, consist of an 
extracellular portion, constituted by five domains (EC1-EC5) rigidified at the interface by calcium 
ions, a single pass transmembrane region and a conserved C-terminal cytoplasmic tail that 
interacts with the actin cytoskeleton through the binding to intracellular molecules of the catenins 
superfamily.3 Dysregulation of the type I epithelial E-cadherin, neuronal N-cadherin and placental 
P-cadherin has been shown to contribute to different aspects of tumour progression.3a Despite a 
growing interest in the field, the rational design of small ligands targeting cadherins protein – 
protein interactions is still in a very early stage. Our group designed the first small library of 
peptidomimetics targeting the adhesive interface identified by recently resolved X-ray structure of 
N- and E-cadherin homophilic dimers.4 Virtual screening results highlights three most promising 
peptitomimetic ligands for synthesis and biological evaluation as cadherin PPI inhibitors.2 
Surprisingly, structural and in silico studies of small molecule - cadherin interactions have 
not been reported yet. In this context, I applied different NMR techniques to improve the 
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structural understanding of the binding of the peptidomimetic ligands to the extracellular domains 
of the cadherins. In particular, during the last part of my PhD, I focused the attention on the 
interaction between peptidomimetic ligands and E- and P-cadherin EC1-EC2 fragment by using 
different NMR techniques. NMR can give a fundamental contribution to the characterization of 
ligand - cadherin complexes, during my PhD I performed: 
 a detailed conformational study of peptidomimetic ligands by VT-NMR and NOESY 
techniques. 
 a study of the interactions between these ligands and the EC1-EC2 constructs of the 
E- and P-cadherin by tr-NOESY and STD-NMR experiments.5,6 This study was performed on the 
isolated protein in solution. A recent paper demonstrated, in fact, that these proteins have a role 
in tumour progression, either if embedded into the membrane or free in solution.7 
 
3.1.1 CADHERINS: function and structure  
Animal tissues are bound together thanks to adhesive forces in their component cells. Two 
principal types of adhesive junctions exist: desmosomes and adherens junctions, and their role is 
the maintenance of cell shape and tissue integrity. Adherens junctions are cell-cell adhesion 
complexes found in a variety of cells,8 characterized by opposed plasma membranes with an in-
between space of 15 to 30 nm. Desmosomes reinforce adhesion and are mostly present in organs 
like heart and skin.9  
Among the adherens junction components, cadherins are the core elements.10 Cadherins 
are a superfamily of cell surface glycoproteins whose ectodomains contain multiple repeats of -
sandwich extracellular cadherin (EC) domains, in particular they are the prototypical example of 
calcium-dependent homophilic cell-cell adhesion.3b 
The level of cadherin expression influences the strength of adhesion, whereas the type of 
cadherin expressed determines the specificity and the properties of cell interactions.  
Cadherins found in adherens junctions were the first members of a broader superfamily of 
cadherins to be discovered, and thus are now being called classical cadherins. They are grouped in 
subfamilies based on selected sequence features and on the number and the arrangement of their 
173 
 
extracellular domain (EC) repeats (Figure 3.1.1.), which are common structural motifs of ca. 110 
residues showing an immunoglobulin-like fold and numbered according to their distance from the 
membrane, being EC1 the N-terminal membrane-distal domain. 
 
 
Figure 3.1.1. Schematic representation of members of the cadherin family. 
 
Phylogenetic analyses of cadherin protein sequences reveal a number of subfamilies: type I 
and type II cadherins, desmosomal cadherins, protocadherins and a variety of other cadherin-
related proteins. Vertebrate classical cadherins, comprising six type I and thirteen type II 
cadherins, are single-pass transmembrane proteins. Desmosomal cadherins, expressed in all 
vertebrate animals, have a domain organization similar to that of classical cadherins. However, 
they are attached via distinct cytoplasmic proteins to intermediate filaments forming specialized 
cell-cell junctions, referred to as desmosomes, in tissues exposed to high mechanical stress. All 
these families share a similar primary sequence and share a capacity for homophilic binding, but 
the molecular mechanisms used by different subfamilies to accomplish this appears to vary 
significantly.3b 
Classical cadherins are structurally characterized by five extracellular domains (EC1-EC5) 
rigidified at the interface by calcium ions, a single pass transmembrane region and a cytoplasmic 
tail (Figure 3.1.2.). The five EC domains are preceded by a signal sequence and a prodomain that 
must be removed by proteolysis for the adhesive functions. 
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Figure 3.1.2. Overall architecture of classical cadherins. 
 
In the adherens junctions, classical cadherins form trans complexes by bridging the 
intercellular space via their ectodomains. They project from opposing cell surfaces and form 
adhesive homodimers by interacting via their EC1 domains. The binding between cadherins and 
the actin cytoskeleton allows the structural stabilization of adherens junctions and promotes the 
regulation of cell morphology and motility.11 
In addition to trans dimerization, the adhesion is strengthened by the lateral or cis 
association of cadherin ectodomains extending from the same cell surface. With respect to the 
trans dimer, the cis dimer structures appear to involve a different portion of EC1 that interacts 
with EC2 of a neighbouring molecule emerging from the surface of the same cell (Figure 3.1.3.).4 
 
Figure 3.1.3. Proposed structural architecture of adherens junctions by X-ray dimer structures a) 
cis interaction, b) cis and trans interaction and c) the final net of cis and trans organized 
interactions.4 
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On the basis of the recently published crystallographic structures only of the whole type I 
E-(epithelial) and N (Neuronal)-cadherin ectodomain dimers,4 a model of adherent junction 
architecture has been proposed (Figure 3.1.3.). According to the X-ray model, each cadherin 
monomer could simultaneously engage two molecules for lateral association and one for trans 
dimerization, resulting in an ordered two-dimensional layer that could represent the structural 
basis of the intercellular junction adhesion. Several experimental data3b,4 showed that lateral 
binding is weaker compared to trans homodimerization and it appears to exert a supporting role 
in cadherin-mediated adhesion with respect to the primary function of the trans interface. The 
recently published structure of type I placental P-cadherin EC1-EC2 homodimers, showed a similar 
trans dimer strucuture.12 
In all the X-ray structures of E-, N- and P-cadherin trans dimerization occurs through the 
opening of the highly conserved N-terminal six-residue portion of the EC1 (the “adhesion arm”) 
that contains a Trp residue in position 2 (Trp2), and its swapping into an acceptor pocket of the 
EC1 of the interacting protein, thus resulting in the so-called “strand dimer” formation (Figure 
3.1.4.). 
 
 
Figure 3.1.4. 3D domain swapping of EC1 domain of classical type I cadherin.4 
 
Members of the same subfamily can form homo- and hetero-dimers, but different 
cadherins subfamilies do not adhere to each other, suggesting a high degree of specificity in the 
adhesion process.13 Many doubts still remain on the path leading to the cadherin dimerized 
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structures.14,15 The key feature of strand exchange dimerization is the docking of Trp2 side chain 
into the hydrophobic acceptor pocket of the intaracting cadherin (Figure 3.1.5.).16  
 
 
Figure 3.1.5. A model for the binding mechanism of type I cadherins.  
 
As reported in Figure 3.1.6., E-, N- and P-cadherin shared a high level of homology 
sequence in their EC1-EC2 domain.4,12 
Human E-cadh DWVIPPISSPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERET 57 
Human N-cadh DWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRISVTGPGADQPPTGIFILNPIS 57  
Human P-cadh DWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKET 57 
 
Human E-cadh GWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFK 114 
Human N-cadh GQLSVTKPLDRQQNARFHLRAHAVDINGNQVETPIDIVINVIDMNDNRPEFLHQVWN 114 
Human P-cadh GWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFR 114 
 
Human E-cadh GSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGV 171 
Human N-cadh GSVPEGSKPGTYVMTVTAIDADDPNALNGMLRYRILSQAPSTPSPNMFTINNETGDI 171 
Human P-cadh GSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGT 171 
 
Human E-cadh ISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTD 213 
Human N-cadh ITVAAGLDREKVQQYTLIIQATDMEGNPTYGLSNTATAVITV 213 
Human P-cadh ISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD213 
Figure 3.1.6. Sequence of E-, N- and P-cadherin EC1-EC2 fragment. 
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3.1.2 X-ray structures of E- and P-cadherin homodimers 
The swap dimer crystal structures of the whole EC1-EC5 ectodomain of mouse E-cadherin 
and EC1-EC2 fragment of mouse P-cadherin were available on Protein Data Bank (3q2w.pdb and 
4nqq.pdb, respectively).4,12 For the E-cadherin also the human EC1-EC2 X-ray dimer structure was 
resolved (2o72.pdb)16 and showed no significant differences compared to the mouse 
crystallographic homodimer. 
The key crystallographic contacts of the DWVI adhesive sequence with E-cadherin binding 
site (3q2w.pdb, Figure 3.1.7.) can be summarized as follows: 1. the formation of an intermolecular 
salt bridge between the charged N-terminal amino group of Asp1 and the side chain carboxylate of 
Glu89; 2. the anchoring of the Trp2 side chain into a hydrophobic pocket and 3. the formation of a 
hydrogen bond between the indole moiety and the carbonyl group of Asp90; 4. the involvement of 
Val3-NH in a hydrogen bond with the carbonyl group of Lys25; 5. the formation of an hydrogen 
bond between the backbone carbonyl group of Asp1 and the Asn27-NH group. 
 
Figure 3.1.7. 2D representation of the DWVI interactions into the E-cadherin binding site (residue 
within 4 Å from DWVI are shown). 
 
Mouse P-cadherin, like E-cadherin, forms strand swap dimers by exchanging the Trp2 
indole moiety into the corresponding pocket. Compared to E-cadherin, the P-cadherin N-terminal 
tetrapeptide sequence mutates the Asp1 and Ile4 into Glu1 and Met4 amino acids, respectively. As 
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observed for the interactions formed by the adhesive EWVM motif into P-cadherin X-ray structure 
(Figure 3.1.8.), the mutation does not affect the binding mode of the sequence within the binding 
site with respect to the one described for the DWVI motif in E-cadherin pocket. In fact, the salt 
bridge between Glu-NH3
+ terminal group and a conserved Glu89 side chain is formed; the Trp2 
side chain docks into a hydrophobic pocket and forms an hydrogen bond with the carbonyl group 
of Glu90; Val3-NH is hydrogen bonded to the carbonyl group of Lys25 and also the backbone 
carbonyl group of Glu1 forms an hydrogen bond with the Asn27-NH group. In addition, for P-
cadherin, we observed an interaction of Glu1 carboxylic group and Asn27 side chain. 
 
Figure 3.1.8. 2D representation of the EWVM interactions into the P-cadherin binding site (residue 
within 4 Å from EWVM are shown). 
 
It is reasonable to assume that also the human P-cadherin (94% of homology sequence to 
mouse EC1-EC2 domains) undergoes to a domain swapping of the DWVVAP adhesive sequence 
and forms a swap dimers. Compared to E-cadherin DWVIPP sequence, human P-cadherin replaced 
the Ile4 and Pro5 with Val4 and Ala5 residues, respectively. The Pro5-Pro6 motif is supposed to 
mediate conformational changes necessary for strand swapping17 by introducing a strain in the 
monomer adhesive arm intramolecularly docked into its own pocket in the monomer state that is 
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released in the swap dimer. In the case of P-cadherin, the replacing of one proline with an alanine 
residue should produce a more flexible adhesive arm.  
 
3.1.3 E-cadherin in cancer  
E-cadherin, expressed by epithelial cells, is regarded as the prototypical example of type I 
cadherin. E-cadherin expression on cells varies during the epithelial-mesenchymal transition 
(EMT), characterized as a phenotypic transition able to transform a quiescent epithelial cell in a 
highly motile and invasive cell. During cancer progression, in particular, epithelial cells undergoing 
EMT acquire the ability to migrate in a directional way, dissociating one from each other. In 
particular, during EMT E-cadherin is down-regulated and N-cadherin is de novo expressed at the 
same time, in a process called cadherin switching.11,18,19 
Although E-cadh is considered a repressor for the majority of carcinomas, it appeared to 
play a role in the proliferation of epithelial ovarian cancer (EOC). E- and N-cadherins can be co-
expressed in some advanced-stage EOC, leading to the conclusion that E-cadherin expression and 
its homophilic interaction contributes to the proliferation of EOC cells.20 
 
3.1.4 P-cadherin in cancer 
The mature P-cadherin glycoprotein has a molecular weight of 118 KDa, and its structure is 
similar to that of classical cadherins, but different from those of E-cadherin and N-cadherin in 
terms of immunological specificity and molecular mass.21 
E- and P-cadherin are the first adhesion molecules that are expressed in the mouse 
embryo. P-cadherin expression was observed in the placenta, both in the embryonic and maternal 
regions. In contrast to E-cadherin, P-cadherin seemed to be frequently up-regulated in tumours, 
being reduced when tumour cells were more differentiated. Special attention is given to the role 
of P-cadherin in breast cancer, where a high volume of knowledge exists.22 However, E-cadherin 
induced signaling pathways have been far studied in cancer; still, the signaling pathways activated 
by P-cadherin in cancer is not clear. The first limitation is due to P-cadherin dual role, as an 
invasion promoter or invasion suppressor depending on the cell model under study.23 
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3.1.5 The role of calcium 
Cadherins are named for the dependence of their adhesive function on the presence of 
extracellular calcium. Before their structures were unknown, it was speculated that Ca2+ ions 
might bridge the adhesive interface. However, the role of calcium in cadherin function is far more 
complex. Calcium binds to cadherins at stereotyped binding sites situated between successive EC 
domains. Each of these sites binds three Ca2+ ions in a highly cooperative manner such that each 
five-domain classical cadherin coordinates twelve Ca2+ ions in total. The binding affinities of the 
Ca2+ sites vary, but all bind with a dissociation constant (Kd) lower than the Ca
2+ concentration 
characteristic of the extracellular milieu, approximately 1 mM.3b Thus, it is expected that cadherin 
ectodomains will be fully Ca2+ - occupied under physiological conditions. Some roles are now 
understood for Ca2+ binding in classical cadherins. The first is rigidifying the ectodomain so that it 
adopts a characteristic crescent shape, although this structure retains considerable 
conformational flexibility. Thus, Ca2+-mediated rigidification is critical to adhesive trans binding. 
Another role of the calcium is to induce oligomerization of the N-terminal two domains of 
epithelial cadherin and this process was followed also by NMR spectroscopy in solution over a 
large range of protein (10 M – 5 mM) and calcium (0 – 5 mM) concentrations.24,25,26 Several 
spectrally distinct states could be distinguished that correspond to a calcium-free monomeric 
form, a calcium-bound monomeric form, and to calcium-bound higher oligomeric forms (Figure 
3.1.9.). 
 
Figure 3.1.9. Schematic representation of the aggregation states. 
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The calcium-free monomer adopts a flexible, kinked conformation that occludes the dimer 
interface. In contrast, the calcium-bound monomer is already in a straight, non-flexible 
conformation where this interface is accessible.  
 
3.1.6 TYPE I CLASSICAL CADHERIN: known ANTAGONISTS 
Based on the first X-ray dimer of N-cadherin,27 a first library of cyclic peptide containing the 
recognition sequences His79-Ala80-Val81 (HAV) and the Ile53-Asn54-Pro55 (INP) was developed.28 
Some of these peptides were shown to be able to modulate the outgrowth of neurite expressing 
N-cadherin either in “antagonistic” or “agonistic” modality. Among them, the antagonist peptide 
N-Ac-CHAVC-NH2 (ADH-1 or Exherin
TM, Figure .) containing the HAV motif, was shown to disrupt 
endothelial cell adhesion, induce apoptosis and inhibit angiogenesis in millimolar (mM) 
concentrations with favourable results in animal models of prostate and pancreas cancer, and of 
melanoma.29,30,31  
 
Figure 3.1.10. 2D structure of the cyclic peptide ADH-1. 
 
Thus, it was promoted to phase I clinical investigation in patients with advanced solid 
tumours which express N-cadherin, showing good tolerability in high doses, and some encouraging 
results suggestive of a potential therapeutic value.3e,32,33  
Libraries of small peptide or non-peptide compounds were explored by a virtual screening 
protocol as possible mimics of HAV and related sequences, and some compounds were shown to 
inhibit the N-cadherin-mediated neurite outgrowth and cell adhesion.34,35 Phage display 
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technology was employed to screen libraries of 12mer peptides against chimeric proteins 
composed of the human N-cadh or E-cadh ectodomains fused to the Fc fragment of human 
immunoglobulin G1.36 All the isolated clones contained a Trp residue in position 2, with high 
variability throughout the sequence, including positions 1, 3, and 4. A linear peptide (H-
SWELYYPLRANL-NH2) was reproduced by synthesis and shown to inhibit the adhesion of human 
breast cancer cells expressing E- and N-cadh in the mM range. 
 
3.1.7 Rationally designed peptidomimetic ligands 
This part of the investigation was performed by the research units involved in the FIRB 
project on N-cadherin antagonists aiming at the identification of possible inhibitors of N-cadherin-
mediated adhesion in cancer cell lines.  
In this project, following our interest in conformationally constrained peptidomimetic 
ligands taming protein - protein interactions, a small library of peptidomimetics were developed 
based on the tetrapeptide sequence Asp1-Trp2-Val3-Ile4 (DWVI) of the N-terminal “adhesive arm” 
of E- and N-cadherin (as identified by the analysis of all the relevant, available crystallographic 
structures).2  
A virtual library of about 30 peptidomimetics of general formula NH3
+-Asp-scaffold-Ile-
NHCH3 was designed by replacing the central dipeptide Trp2-Val3 unit of the DWVI adhesive motif 
with several scaffolds developed in our laboratories.37 The peptidomimetics feature a 
conformationally constrained scaffold bearing a benzyl or phenyl ring to mimic the indole moiety 
of Trp2 of the native sequence. Depending on the configurational features of the scaffold, the 
aromatic ring was expected to be properly oriented into the corresponding binding pocket. 
To evaluate the ability of the virtual library compounds to reproduce the DWVI key 
interactions observed in the dimer structures, our group built a model of EC1 fragment of E- and 
N-cadherin starting from the corresponding X-ray structures and set up a docking protocol using 
the Glide V5.7 software38 (see “Experimental Section”). Docking results were sorted on the basis 
of Glide score and filtered to match the most important binding interactions observed for the 
DWVI motif during molecular dynamic simulations run on the X-ray EC1-EC2 dimers of E- and N-
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cadherin. The interactions pattern already described for the E-cadherin X-ray dimers (Figure 
3.1.7.), well represents also the interactions observed into N-cadherin X-ray binding site. 
Moreover, during the simulations, the two systems maintained the key crystallographic contacts. 
In fact, the same three ligands were selected by docking calculations into the E- and N-cadherin 
models as most promising inhibitors (Figure 3.1.11.). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.11. The three peptidomimetic ligands synthesized. 
 
In the top-ranked poses, all the three ligands insert the scaffold benzyl ring into the 
corresponding hydrophobic pocket of Trp2 and form the salt bridge between the Asp1-NH3
+ group 
and the Glu89 side chain. The main difference in the binding mode of the three ligands is related 
to their 3D alignment with respect to the DWVI sequence of the crystallographic structures: while 
2c and 3c are able to mimic the extended conformation of the reference tetrapeptide backbone in 
both cadherin receptors (Figure 3.1.12.), 1c orients the Ile residue back to the Asp1 amino acid 
and does not reproduce the experimental backbone arrangement (Figure 3.1.13.). 
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Figure 3.1.12. Best pose of 2c (tube representation, C in grey, N in blue and O in red) into the E-
cadh binding site (red cartoon representation), overlaid to the DWVI sequence (green tube 
representation) of the X-ray dimer. Key residues of E-cadh involved in the interaction are labelled 
and highlighted in tube representation. 
 
Figure 3.1.13. Best pose of 1c (tube representation, C in grey, N in blue and O in red) into the E- 
cadherin (red ribbon representation) model, overlaid to the DWVI sequence (green tube 
representation). Key receptor residues are labeled and highlighted in tube representation. 
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The compounds were synthesized in the group of Prof. U. Piarulli (University of Insubria) 
and Dr. L. Manzoni (CNR, Consiglio Nazionale delle Ricerche). The ligands were tested by ELISA for 
their ability to inhibit calcium-dependent cadherin binding using the N-cadherin-expressing EOC 
cell line SKOV3 and N-cadherin-Fc chimeric protein. ADH-1 was also synthesized and used as 
reference. The biological tests were performed by the group of Dr. A. Tomassetti in the 
Department of Experimental Oncology and Molecular Medicine (Istituto Nazionale Tumori). Both 
2c and 3c ligands at 2 mM concentration inhibited N-cadherin homophilic binding by 84% and 
78%, respectively, and 65% and 50% at 1 mM concentration (Figure 3.1.14.). ADH-1 and 1c 
showed about 50% inhibition of N-cadherin-Fc/cells interactions at the higher concentration, and 
appeared nearly ineffective at the lower concentration (Figure 3.1.14.). The compounds were then 
analyzed for their ability to inhibit the adhesion of the EOC (epithelial ovarian cancer) cell lines by 
observing the formation of cell monolayers in presence of each ligand at two different 
concentrations (2 and 1 mM). All compounds inhibited the formation of cell monolayers of N-
cadherin-expressing cells at 2 mM concentration, comparably to ADH-1 (Figure 3.1.15.). Notably, 
2c and 3c were also active at 1 mM concentration, and 2c was able to inhibit cell–cell aggregation 
of N-cadherin-expressing cells in suspension (Figure 3.1.14.). When tested on the E-cadherin-
expressing EOC cell line OAW42, all compounds showed lesser efficiency in inhibiting the E-
cadherin homophilic interactions as well as the formation of cell monolayer with relevant effects 
only at the higher concentration (Figure 3.1.14. and 3.1.15.). In particular, by ELISA, at the 
concentration of 2 mM 1c and 2c inhibited E-cadh-Fc binding to the cells by about 50% while ADH-
1 showed 30% inhibition (Figure 3.1.14.), indicating a slightly better efficacy compared to ADH-1 in 
inhibiting also E-cadherin homophilic interactions. Compound 3c was also able to inhibit the 
formation of cell monolayers at 1 mM concentration (Figure 3.1.15.). 
Overall, compounds 2c and 3c resulted to be effective in inhibiting N-cadherin homophilic 
and, to some extent, also E-cadherin homophilic adhesion.  
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Figure 3.1.14. ELISA Inhibition assays: of N-cadherin-Fc (Left) and E-cadherin-Fc (right) binding to 
SKOV3 and OAW42 cells, respectively.  
 
 
Figure 3.1.15. Adhesion assay to evaluate the inhibition of the formation of the cell monolayer by 
the small peptidomimetic ligands. EDTA-detached N-cadherin- (SKOV3) or E-cadherin-(OAW42) 
expressing cells were seeded in absence (Control) or in presence of the ligands at 2 and 1 mM. For 
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each cell line the controls without the ligand but with same amount of the solvent (water on the 
left, DMSO on the right) are reported.  
 
Encouraged by the very promising results with N-cadherin-expressing cells, we set out to 
evaluate by Surface Plasmon Resonance (SPR) analysis the ability of the compounds 2c and 3c to 
specifically inhibit the N-cadherin homo-dimerization in a cell-free experiment using the N-
cadherin-Fc recombinant protein. As shown in the sensogram of Figure 3.1.16., at 10 M 
concentrations compounds 2c and 3c provided 55% and 98% inhibition of N-cadh homophilic 
binding, respectively (Figure 3.1.16.), while ADH-1 showed only 28% inhibition (Figure 3.1.16.C). 
These data demonstrate the ability of both compounds 2c and 3c to specifically bind to N-cadherin 
even in the μM range. 
 
Figure 3.1.16. Biacore profiles of the homophilic binding of N-cadh in the presence or absence of 
inhibitor. A. Inhibition with compound 3c. B. Inhibition with compound 2c. C. Inhibition with ADH-
1. Dark green and blue line represent the non-inhibited and inhibited N-cadh, respectively, of the 
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different compounds on N-cadh-Fc-bound to the sensor chip; pale green and pale blue lines 
represent the binding to the uncorrelated protein-bound to the sensor chip. The percentage of 
inhibition has been calculated considering as 100 % the resonance unit max obtained with the N-
Cadh-Fc alone run immediately before the loading of each inhibitor/N-cadh-Fc complex. 
 
However, although N- and E-cadherin share similar adhesive binding features for the DWVI 
sequence4 and marked differences in the interaction mode of our peptidomimetic ligands were 
not observed in the two cadherin docking models, the tests on the E-cadherin-expressing EOC cell 
line OAW42 showed lower inhibition capability of E-cadherin homophilic binding compared with 
those of N-cadherin. Since the molecular basis of differences in adhesion among the cadherins are 
still unclear39 and a variety of factors can contribute to the formation and dissociation of cadherin 
dimers on cell membranes, our results could be interpreted in light of different considerations. 
NMR techniques could give a great contribution to the understanding of the molecular 
basis of the ligand - cadherin recognition process. In fact, by exploiting the collaboration with Dr. 
Parisini at Istituto Italiano di Tecnologia (IIT, expert in protein expression, purification and X-ray 
crystallography), in the last part of my PhD, I worked on the interaction between the 
peptidomimetic ligands 1c – 3c and the EC1-EC2 fragments of E-cadherin and P-cadherin (provided 
by Dr. Parisini). It was also possible the investigation of ligand binding to P-cadherin EC1-EC2 
domains. This target share a common binding motif to E-cadherin, but a different a slightly 
different binding site. In the next future, thanks to the recently X-ray resolved P-cadherin 
structure, we are planning to study the peptidomimetic ligands 1c – 3c into a model of P-cadherin 
receptor. 
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Section 2: Results and Discussion 
 
The complex and highly dynamical cadherin dimerization pathway has been partially 
elucidated by the wealth of biochemical and biophysical studies done to date.3b,40 Ultimately, what 
appears to be understood is that a variety of transient yet critical key intermolecular interactions 
involving different residues at different stages of the full cadherin dimerization trajectory play all a 
critical role in guiding the system through a number of intermediate intermolecular protein - 
protein arrangements during the recognition process that leads from monomeric cadherin to 
strand-dimer formation and back. For instance, structural studies have suggested that strand-
dimer formation may only represent one of several adhesive mechanisms that can all contribute 
to the overall cell-cell adhesion strength, the so-called X-dimer being one viable, alternative 
intermolecular interaction that provides adhesive properties to the system.41 In this context, it is 
clear that the dynamic features of the cadherin dimerization process are likely to play against a 
traditional drug design approach whereby a key-key lock interaction would attempt to force the 
system into a stable molecular arrangement completely devoid of adhesive properties. Rather, it is 
conceivable that potential dimerization inhibitors may be designed by partially mimicking key 
cadherin structural elements known to be transiently involved in those intermediates that have 
been structurally characterized along the highly dynamic and reversible cadherin adhesion 
trajectory, thus dynamically interfering with the adhesion process by perturbing the delicate 
balance of interactions between different cadherin structural elements. We therefore anticipate 
that, given the dynamic and cooperative nature of the system, the design of a stable molecular 
interactor against the adhesion pocket would not just prove difficult, but it would fail to achieve 
complete inhibition. However, we hypothesize that peptidomimetic molecules that can transiently 
interfere with structurally validated intermediates in the cadherin dimerization pathway may 
successfully modulate cadherin-mediated adhesion, even in the absence of an unequivocal 
identification of the actual binding site and mode. 
Due to the high flexibility of the system, NMR has proved to be a useful method to 
evaluate these kind of interactions. NMR studies were performed on compounds 1c – 3c in the 
190 
 
presence of E-cadherin EC1-EC2 and P-cadherin EC1-EC2 constructs. The experiments, STD and tr-
NOESY, were conducted at three different temperatures (283 – 290 – 298 K).  
 
3.2.1 COMPOUND 1c  
3.2.1.1 NMR Characterization and conformational analysis 
 
 
 
 
 
 
 
Figure 3.2.1. Structure of compound 1c. 
 
The complete characterization of the molecule (1H and 13C chemical shifts) both at 298 K 
and 283 K is reported in the ∗Supplementary information∗. 
The NOESY spectra did not show any significant NOE contacts typical of a preferred 
conformation at both the temperatures, except for some NOE contacts between the aromatic 
protons and the CH2_ 4 and 6 of the scaffold, suggesting a movement of the benzyl ring over the 
scaffold. In fact, the trans stereochemistry of the scaffold, inserted in the compound 1c, prevents 
the folding of the side chains and the formation of conformational motifs stabilized by hydrogen 
bonds. The phase of the NOE cross peaks at 283 K is negative, while at 298 K is positive. 
 
3.2.1.2 Interaction with E-cadherin EC1-EC2 construct 
NMR experiment 
We performed tr-NOESY6 experiments of compound 1c in the presence of EC1-EC2 
fragment of E-cadherin. At 283 K the cross peaks are negative and the experiment does not 
provide information about the binding. tr-NOESY and NOESY did not show differences in the NOE 
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contacts demonstrating that the conformation of compound 1c remains unaltered in the presence 
of the protein. The first STD6 experiments at 290, 298 and 283 K showed a change in the NMR 
ligand epitope with temperatures (Figure 3.2.2.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. Low field region of the STD conducted at three different temperatures (298 K, 290 K 
and 283 K) with the graph of the STD absolute percentages at these three temperatures. The 
asterisk indicates an overlapping. 
 
The STD signals relative to the aromatic protons (~0.3% STD absolute intensity) are present 
at the three temperatures with about the same intensity (Figure 3.2.2.), while the intensity of the 
STD signals of the C-terminal NH2 protons increase with the temperature (from 0.2% at 283 K to 
0.7% STD absolute intensity at 298 K), and this suggests their proximity to the protein. In contrast 
to what happens with the C terminal NH2 protons, CH2_4/CH2_6, the protons of the scaffold, are 
present in low percentages (0.2% STD absolute intensity) only at 283 K. The NH10 proton shows a 
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decreasing STD absolute percentage raising the temperature, from a value of 2% STD absolute 
intensity at 283 K to its absence at 298 K. However, in the graph we have not reported the STD 
absolute intensity that characterized this proton at 290 K, in fact, even if it was present in the STD 
spectrum, its intensity was not quantifiable.  
The STD epitope change with temperature suggesting three possible explanations: i) the 
conformation of the protein varies with temperature and thus the interaction with ligand change, 
ii) the ligand binding change with the temperature or iii) a mix of both effects. In fact, , the ligand 
conformation change upon binding can be excluded by the NOESY spectra. It is important to note 
that these preliminary experiments do not allow an exhaustive description of the ligand - cadherin 
interaction and other experiments have to be carried out. 
 
Docking studies2 
The poses of compound 1c into E-cadherin model were analyzed in the light of the NMR 
epitope at different temperatures. It is worth noting that docking results do not include the effect 
of protein movement since during the calculation the protein is kept fixed to its X-ray structure. 
However, the rough estimation of ligand - protein contacts of docking poses could be useful for 
some preliminary considerations.  
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Figure 3.2.3. Left figure: best pose of compound 1c (tube representation, C in grey, N in blue and 
O in red) into E-cadherin (red ribbon representation) models, overlaid to the DWVI sequence 
(green tube representation). Key receptor residues are labeled and highlighted in tube 
representation. Below is reported a 2D representation of compound 1c with the protons involved 
in the NMR epitope highlighted by circles. 
 
In all the docking poses into E-cadherin, compound 1c places the benzyl ring into the 
corresponding pocket favouring also the interaction of protons CH2_4 and CH2_6 of the scaffold 
with the protein residues. These contacts are in agreement with the epitope found by NMR at 283 
K for aromatic and CH4/CH6 protons. In the docking poses, for NH10 proton an average distance 
to H protons of Asp1 side chain of 3.507 +/- 0.519 Å was calculated, while for C-terminal NH2 
protons an hydrogen bond with carboxylic group of Asp1 side chain is observed only in the best 
pose. In general, it seems that the best pose well represent the STD signal at 283 K. Moreover, 
docking results suggest a possible interaction of ligand protons NH10 and C-terminal NH2 with the 
Asp1 residue, that belongs to the adhesive arm of the receptor and lies close to the binding site. In 
fact, in the hypothesis that the opening of the adhesive arm leaves the pocket free for the binding 
of our ligand, the receptor DWVI sequence should be free to move in solution and could interact 
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with the compounds itself. Moreover, based on the analysis of several X-ray structures, it seems 
that the adhesive arm does not adopt a specific secondary structure motif, i.e. -sheet, helix etc., 
either in the dimer complex or in the monomer state. In this case, our rigid-receptor docking 
model introduce an important bias factor into analysis. To overcome this limit, in the next future 
we are planning to perform MD simulations where both ligand and protein will be free to move 
and their dynamical interaction should be more close to the experimental NMR conditions.  
 
In order to investigate the effect of protein on ligand binding, we performed NMR 
experiments using the human P-cadherin EC1-EC2 domains, a type I cadherin strongly related to E-
cahderin. In this case, the ligand binding epitope could be affected by two main factors: the 
binding site (slightly different form E-cadherin) and, as previously discussed, the increased 
flexibility of the adhesive arm (lying close to the binding site) due to the mutation of Pro5 (E-
cadherin) into Ala5 (P-cadherin). 
 
3.2.1.3 Interaction with P-cadherin EC1-EC2 construct (NMR experiments) 
tr-NOESY experiments, performed in presence of P-cadherin EC1-EC2 construct at the three 
temperatures, did not show any variation with respect to what observed with the E-cadherin EC1-
EC2. In addition, in the tr-NOESY experiments at 298 K, the cross-peak intensity is close to zero. 
This indicates a binding event. At 283 K the contacts are negative like in the free state. 
STD-NMR experiments, performed at 283, 290 and 298 K, showed three different sets of 
signals (Figure 3.2.4.). A similar behaviour was observed in the interaction with the E-cadherin 
EC1-EC2 construct at the same three temperatures. 
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Figure 3.2.4. Low field region of the STD conducted at three different temperatures (298 K, 290 K 
and 283 K) with the graph of the STD absolute percentages at these three temperatures. The 
asterisk indicates an overlapping. CH2_6* and CH2_6 indicate the two protons insisting at C-6 of 
the scaffold, characterized by two different chemical shifts in the spectrum. 
 
The aromatic protons (~0.6% STD absolute intensity) are present at the three 
temperatures. The protons CH2_4 and CH2_6*/CH2_6 of the scaffold appeared only at 283 K (0.2 
and 0.4% STD absolute intensities). The proton NH10 is only present at 283 K (1.8% STD absolute 
intensity) as observed with the E-cadherin. The C-terminal NH2 protons (NH2_A and NH2_B) 
signals appear at 290 K and 298 K, while in E-cadherin spectra were present with low STD intensity 
percentage also at 283 K. Since the X-ray structure of mouse P-cadherin was published only in the 
last month of my PhD, docking studies with this target were not performed yet. However, it seems 
that the differences observed in NMR epitope at different temperatures are independent of the 
cadherin type. In fact, the X-ray structure of mouse P-cadherin describes a binding mode of the 
EWVM recognition sequence very similar to the interaction pattern of DWVI sequence in E-
cadherin receptor and, as consequence, also our ligand could similarly interact with the two 
cadherin receptor. Further NMR experiments and in silico investigations are needed to understand 
the molecular basis of this highly dynamical protein - ligand interaction.  
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3.2.2 COMPOUND 2c  
3.2.2.1 NMR Characterization and conformational analysis 
 
 
 
 
 
Figure 3.2.5. Structure of compound 2c. 
 
The complete characterization of the molecule (1H and 13C chemical shifts) both at 298 K 
and 283 K is reported in the ∗Supplementary information∗. 
In order to investigate the conformational preference of compound 2c in the free state we 
conducted variable temperature experiments. Monodimensional 1H-NMR experiments were 
conducted to detect intramolecular hydrogen bonds, by measuring the chemical shift of the N–H 
protons and their temperature coefficients (/T); in the Table 3.2.1., the variation of the 
chemical shift on temperature (/T) for amide protons is reported.  
 
 
 
 
 
Table 3.2.1. /T and  of the amide protons. 
 
These data suggest that the compound is characterized by a dynamical conformational 
equilibrium (high absolute values of T). Only amide proton NH10 might be involved in a 
intramolecular hydrogen bond. These results and the NOE contacts at 298 K suggest an 
equilibrium between disordered conformations without specific intramolecular hydrogen bonded 
and a conformation with NH10 involved into an hydrogen bond (Figure 3.2.6.a) characterized by a 
Residues /T  
(*10-3 ppb/K) 
(ppm)
NH10 -4.56 8.50 
NH1 -8.16 8.41 
NH_isoLeu -7.52 8.10 
NH_tBu -7.68 7.44 
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folded geometry with a 10-membered -turn centered at the DKP scaffold. In fact, the long range 
NOE contacts observed at 298 K (Figure 3.2.6.) indicate the presence of a folded conformation 
(cross peaks between H_Asp and the NH_tBu and CH3_tBu). The NOESY performed at 283 K 
shows a very similar pattern of cross peaks with in addition the NOE between the aromatic 
protons and H_Asp. The magnetic properties (C) of ligand 2c lead to a positive NOE at 298 K, 
while there is evidence of a negative Overhauser effect at 283 K. 
However, NMR data (especially NOE contacts) suggest the formation of another folded 
geometry characterized by a 12-membered -turn stabilized by an H-bond between N-H of the 
isoleucine and C=O of the aspartic residue (Figure 3.2.6.b).  
 
 
Figure 3.2.6. Folded geometries (a and b) contributing at the conformational equilibrium of 
compound 2c at 298 K. NOE contacts are represented as black arrows.  
 
A cis scaffold, however, is known in literature to induce a closure of the two side-
chains.37b,42 For this compound, we ran 10 ns of restrained Metropolis Monte Carlo/Stochastic 
Dynamics (MC/SD) simulations,43 using the implicit water GB/SA solvation model44 and the 
OPLS_2005 force field.45 According to the NOE contact, we use a restraint on the distance 
between the amide protons of Leu (NH_isoLeu) and Asp H (2.5± 0.5 Å). Approximately 10% of the 
conformations sampled during the simulation is characterized by the 10-membered -turn 
centered at DKP and stabilized by the hydrogen bond between the NH10 and C(8)=O and another 
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10% is characterized by a 12-membered -turn stabilized by the hydrogen bond between 
NH_isoLeu and C=O_Asp. The unrestrained MC/SD simulation produced disordered structures 
without specific intramolecular hydrogen bonds. 
 
3.2.2.2 Interaction with E-cadherin EC1-EC2 construct 
NMR experiment 
The interaction of compound 2c with the E-cadherin EC1-EC2 construct was studied by tr-
NOESY and STD5 at 283 K, 290 K and 298 K. The tr-NOESY experiment of 2c at 298 K showed 
positive cross-peaks as in the free state, which indicates the absence of binding. In addition, at 283 
K the tr-NOESY data do not give information about the binding event. 
As observed for compound 1c, the binding epitope of compound 2c with E-cadherin change with 
temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.7. Low field region of the STD conducted at three different temperatures (298 K, 290 K 
and 283 K) with the graph of the STD absolute percentages at these three temperatures.  
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The signals of the aromatic protons are present in the STD spectra at the three 
temperatures (~0.3% STD absolute intensity) (Figure 3.2.7.). The NH1 and NH10 disappeared 
increasing the temperature. However, in the graph we have not reported the STD absolute 
intensity that characterized the NH1 proton at 290 K; in fact, even if it was present in the STD 
spectrum, its intensity was not quantifiable. The proton NH_isoLeu, on the contrary, appears in 
the experiment at 290 and 298 K (0.4 and 0.4% STD absolute intensities, respectively).  
 
Docking studies2 
As already discussed, docking calculation is not the suitable tool for a comparison with 
experimental ligand epitope, but could provide some interesting considerations.  
 
 
 
 
Figure 3.2.8. Left figure: best pose of compound 2c (tube representation, C in grey, N in blue and 
O in red) into E-cadh (red ribbon representation) models, overlaid to the DWVI sequence (green 
tube representation). Key receptor residues are labeled and highlighted in tube representation. 
Below is reported a 2D representation of compound 2c with the protons involved in the NMR 
epitope highlighted by circles. 
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In docking calculation the ligand is free to move and preferentially adopts an extended 
conformation that well overlays to the reference tetrapeptide sequence DWVI. In all the docking 
poses we observed a contact between NH10 and the H of Glu89 side chain, while NH1 is involved 
in an hydrogen bond with the carbonyl backbone of Trp2 and NH_isoLeu is in contact with the 
Lys25 side chain aliphatic protons or moves toward the H protons of Trp2 showing a greater 
motility.  
Docking calculation starting from the two folded geometries, using specific torsional 
constraints to keep the intramolecular hydrogen bonds fixed, showed a different disposition of the 
ligand inside the binding pocket. The conformation with the 10-membered -turn was not able to 
place the aromatic ring into the corresponding pocket. Interestingly, in some poses the benzyl 
group form stacking interaction with the indole ring of Trp2, while keeping the salt bridge with 
Glu89 residue, thus preserving the two key interactions for the binding to E-cadherin (Figure 
3.2.9., left). Moreover, in this second type of biding mode, NH_isoLeu and NH1 form an hydrogen 
bond with carbonyl backbone of Lys25 and Asn27 side chain, respectively, while NH1, involved in 
the intramolecular hydrogen bonds, is not available for further interactions with the receptors. A 
third type of binding mode was observed for the 12-membered -turn geometries in the analysis 
of docking results. The benzyl group fit into the corresponding pocket and, in some poses, the salt 
bridge with Glu89 was also formed (Figure 3.2.9., right). Compared to experimental epitope, in 
this third binding mode, the ligand NH_isoLeu intramolecularly involved in the hydrogen bond 
does not form interactions with the receptor, while NH1 is close to Trp2 backbone and NH10 
forms an hydrogen bond with Glu89 side chain. All this three possible binding mode are 
compatible with STD spectra and further computational studies will be carried out to investigate 
the effect of binding conformation on binding. 
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Figure 3.2.9. Docking poses of compound 2c (tube representation, C in grey, N in blue and O in 
red) featuring the 10-membered -turn geometry (left) and the 12-membered -turn geometry 
(right) into E-cadh (red ribbon representation) models, overlaid to the DWVI sequence (green tube 
representation). 
 
3.2.2.3 Interaction with P-cadherin EC1-EC2 construct (NMR experiments) 
The comparison of the NOE contacts in the free and in the bound state do not show any 
significant differences, suggesting that, in presence of the protein, the conformational equilibrium 
remains the same. The tr-NOESY experiment at 298 K of compound 2c in the presence of the P-
cadherin EC1-EC2 construct suggests a binding situation, while at 282 K the NMR data do not give 
information about the binding event. 
 
 
 
 
 
 
 
Figure 3.2.10. Low field region of the STD conducted at three different temperatures (298 K, 290 K 
and 283 K) with the graph of the STD absolute percentages at these three temperatures.  
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At 283 K the STD spectrum showed the signals of the amidic protons NH_tBu and NH10 in 
addition to the signals related to the aromatic protons (0.4, 3.5 and 0.3% STD absolute intensities, 
respectively) (Figure 3.2.10.). The contribution of NH_tBu proton disappeared increasing the 
temperature at 290 K. An opposite behaviour characterized the amidic proton NH_isoLeu, showing 
a 1.5% STD absolute intensity at 298 K, a decreased intensity at 290 K (0.7% STD absolute 
intensity) and disappeared at 283 K. The STD signals of aromatic protons are visible at all the 
temperatures with about the same STD intensity. 
The ligand epitope varies with the temperature also for the interaction with P-cahderin, 
but with a slightly different pattern of interactions. Compared to E-cadherin, compound 2c loses 
the signal of NH1 and adds the interaction of NH_tBu proton. This change could be due to the 
different binding site and further investigation using the X-ray structure of P-cadherin will be 
performed. 
 
3.2.3 COMPOUND 3c  
3.2.3.1 NMR Characterization and conformational analysis 
 
 
 
 
 
Figure 3.2.11. Structure of compound 3c. 
 
The complete characterization of the molecule (1H and 13C chemical shifts) both at 298 K 
and 283 K is reported in the ∗Supplementary information∗. 
In order to investigate the conformation adopted by compound 3c, we conducted variable 
temperature experiments. In the Table 3.2.2. the data relative to the amide protons of the 
compound were reported. Obviously, the trans configuration of the diketopiperazine and the 
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limited length of the side chains, prevents the folding of the side chains and the formation of the 
conformational motifs stabilized by hydrogen bonds. 
 
 
 
 
 
Table 3.2.2. /T and d of the amidic protons. 
 
These data suggest that the compound is characterized by conformational mobility (high 
value of T), except for the proton NH1 that is characterized by a low value of T and of the 
chemical shift (high field region). However, the absence of significant NOE contacts at the two 
temperatures (298 and 283 K) does not allow to evaluate its involvement in a intramolecular 
hydrogen bond that stabilized the molecule in a preferred conformation. The only NOE contacts 
observable are those between the aromatic protons and the methyl groups of the ter-buthyl 
group, and those between the aromatic protons and the methyl group of the isoLeu side-chain. 
The absence of relevant NOE contacts and the T data suggest the presence of an extended 
conformation. 
 
3.2.3.2 Interaction with E-cadherin EC1-EC2 construct 
NMR experiments 
The signal phase of the tr-NOESY experiments does not allow to evaluate a binding 
situation. In fact, in the tr-NOESY experiments at 298 K, the cross-peak intensity is close to zero 
(like in the free state) and at 283 K the contacts are negative like in the free state. 
STD experiments at 298 K shows signals relative to aromatic protons and NH_isoLeu. These 
protons do not appear in the experiments performed at 283 K, but there are the signals related to 
NH1 and NH10 protons (Figure 3.2.12.). Unfortunately, also in the control experiment the NH1 
appears, so NH1 cannot be integrated. 
Residues /T  
(*10-3 ppb/K) 
ppm
NH10 -6.00 8.53 
NH1 -4.50 7.49 
NH_isoLeu -8.50 7.94 
NH_tBu -8.50 8.31 
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Figure 3.2.12. Low field region of the STD conducted at two different temperatures (298 and 283 
K).  
This precludes the quantitative analysis of the interaction of the compound with the 
protein, even if the STD experiments conducted at the two temperatures 298 and 283 K suggest a 
variation of the epitope also for this compound (Figure 3.2.12., where at 298 K the STD signals of 
the NH_isoLeu appeared in contrast to NH10 that appeared at 283 K). It is worth noting that also 
the aromatic protons do not show any contribution at 283 K. 
 
Docking studies2 
The binding mode of compound 3c in the E-cadherin binding site is very similar to the 
extended arrangement observed for compound 2c. Both ligands adopt a similar disposition within 
the binding site and well reproduce the X-ray pose of the DWVI sequence. 
Experiment with P-chaderin will be carried out in the next future to elucidate the behaviour of this 
compound with respect to the E-cadherin. 
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Section 3: Conclusions 
Cadherins are known to play a key role in important physiological processes such as tissue 
morphogenesis and stability, as well as in the immune system regulation. The dysregulation of 
some type I cadherin have been shown to contribute to pathological processes, and specifically to 
tumour progression.7,3d In this project, we have evaluated two of the classical type I-cadherin: E- 
(epithelial) and P- (placental) cadherin. 
Despite a growing interest in the field, the rational design of small ligands targeting 
cadherins protein - protein interactions is still in a very early stage. Task of the group, so, was to 
rationally design and synthesize small peptidomimetic molecules aimed at providing partial or 
total inhibition of the cadherin - cadherin interaction. 
According to the results obtained from docking studies on E-cadherin and evaluated on the 
base of the typical interactions of the natural sequence DWVI, three ligands of general formula 
NH3
+-Asp-scaffold-Ile-NHR were selected for the synthesis and subsequent biological assays 
(Figure 3.3.1).2 
 
 
 
 
 
 
Figure 3.3.1. Peptidomimetic ligands synthesized. 
 
A detailed investigation of the ligand conformation were conducted. The trans 
stereochemistry of the scaffold, inserted in the compounds 1c and 3c, prevents the folding of the 
side chains and the formation of conformational motifs stabilized by hydrogen bonds. In fact, 
these compounds adopt an extended arrangement as demonstrated by NOESY and VT-NMR 
experiments.  
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For compound 2c (cis-stereochemistry), we suggest the presence of an equilibrium 
between open and closed conformations, being a closed geometry supported by the presence of 
typical NOE contacts. 
In addition, I applied NMR techniques in order to detect and study the binding of 
compounds 1c – 3c with the EC1–EC2 constructs of the epithelial subtype E – and placental 
subtype P-cadherins (expressed and purified by Dr. Parisini at IIT). Due to the difficulties to 
crystallize small molecule - cadherin complexes (just the dimeric forms were crystallized),4,16 NMR 
has proved to be a useful method of ligand binding detection. Having evidence from biological 
assays that the interaction between our compounds and cadherins happened, we conducted, 
firstly, STD experiments at 283 K with the aim of slowing the rate of the ligand exchanging 
between solvent and protein environment. Then, for both these proteins, we performed STD 
experiments at 290 and 298 K. Surprisingly, all the three compounds change the epitope as a 
function of the temperature with both cadherin constructs. Moreover, the ligand binding epitope 
is similar between the two receptors. Several aspects could contribute to the STD binding epitope 
variation with temperature: i) the ligand binding mode change with temperature, ii) a 
conformational change of the protein binding site due to temperature or iii) both aspects.  
To address this question further NMR and in silico investigations should be done. NMR 
studies using labeled protein constructs and molecular dynamics simulations allowing both ligand 
and protein free to move are in progress. It is expected that the combined use of NMR and 
computational approaches will significantly improve the structural understanding of the binding of 
peptidomimetic ligands to the extracellular domains of these cadherins.  
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Section 4: Experimental section 
 
NMR EXPERIMENTS 
Conformational analysis: NMR spectroscopy experiments were performed at 298 K and 
283 K on Bruker Avance 400 and 600 MHz spectrometers. All proton and carbon chemical shifts 
were assigned unambiguously. The NMR experiments were carried out in phosphate buffer. The 
buffer prepared has a pH of 7.4 with 20 mM phosphate salts, 150 mM NaCl and 1 mM CaCl2, with 
an addition of 10 % D2O for NMR experiments. 
Two-dimensional experiments (TOCSY, NOESY and HSQC) were carried out on samples at a 
concentration range of 3-6 mM. NOESY experiments were performed at 0.7 s. The water 
resonance was saturated with the excitation sculpting sequence from the Bruker library. The 
conformations of the linear pentapeptides were analyzed with respect to hydrogen bonding of 
amide protons (VT-NMR spectroscopy) and NOE contacts. 
 
NMR spectroscopy studies with the isolated proteins: The spectra were acquired with a 
Bruker Avance 600 MHz instrument at 298, 290 K and 283 K. Each sample was prepared in a 3 mm 
NMR tube with ligand (0.5-0.6 mg) and the isolated proteins (~36 µL, ~5 mg/mL) in phosphate 
buffer (~200 µl). 
Amount of protein used: All the experiments were conducted with the first two domain of 
E- and P-cadherin (Molecular Weight (EC1-EC2 construct E-cadherin)=23118.79 Da, Molecular 
Weight (EC1-EC2 construct P-cadherin)= 23600.00 Da) and with a ligand : protein ratio of 80 : 1. To 
calculate protein moles (x): 
80 : 1= 6*10-7 : x 
x = 7.5*10-9 mol 
To calculate grams of protein: 
g = 7.5*10-9 * 23118.79 = 0.000173 g => 0.173mg 
To calculate mL of protein solution to add: 
0.173 mg : 5 mg = x : 1 mL 
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x = (0.1733 mg*1 mL)/5 mg = 34 µL 
Amount of Ca2+ ion: It is known that a protein solution 0.22 mM needs 1 mM of Ca2+ (~5-
fold more), in our tube we need: 
mol protein = 0.22 mM * 0.036 mL (amount of protein in the tube) = 0.00000792 mmol 
M = 0.00000792 mmol / 0.2 mL (amount of buffer solution) = 0.0396 mM (concentration of 
protein) that corresponds to 0.198 mM Ca2+ (~ 5-fold more). 
The interaction between our ligands and isolated membrane proteins was detected using 
tr-NOESY and STD experiments as described in the “Experimental Section” of the Chapter 2. 
 
COMPUTATIONAL STUDIES 
Docking studies. 
Models set up and validation. 
The automated docking calculations were performed using Glide (Grid-based Ligand 
Docking with Energetics) version 5.7109.38 The grid have been generated for E-cadh structure 
prepared as described in the Protein preparation section and selecting as receptor the EC1 
domain (1-103 residues) of one monomer and as ligand the DWVIPP esapeptide sequence of the 
partner monomer. The center of the grid enclosing box was defined by the center of the DWVIPP 
sequence. The enclosing box dimensions, which are automatically deduced from the ligand size, fit 
the entire active site. Docking calculations were performed using the standard precision mode 
(SP). The receptor was considered as a rigid body while the ligand sampling was set to ‘Flexible’ 
with the option ‘Penalize non planar conformation’ for amides. No Epik state penalities were used 
in the docking score calculations. The size of the bounding box for placing the ligand center was 
set to 14 Å. No further modifications were applied to the default settings. The GlideScore function 
was used to select 10 poses for each ligand. The Glide program was initially tested for its ability to 
reproduce the crystallized binding mode of fragments of the N-terminal native sequence (i.e. from 
the tripeptide DWV up to the decapeptide). The program was successful in reproducing the 
experimentally determined binding mode of these peptides, as it corresponds to the best-scored 
pose. 
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BIOLOGICAL ASSAYS 
The N-cadh-expressing SKOV3 cells46 were obtained from ATCC (Rockville, MD) and 
maintained in RPMI 1640 medium (Sigma, Sant Louis, Missouri) supplemented with 10% fetal calf 
serum (FCS) (Hyclone, Logan, UT), 1% L-glutamine at 37°C in a humidified atmosphere of 5% CO2 in 
air. The E-cadh-expressing OAW42 cells47 were provided by Dr. A. Ullrich, (Max Planck Institute of 
Biochemistry, Martinsried, Germany) and maintained in DMEM supplemented with 10% FCS and 
1% L-glutamine in a humidified atmosphere of 5% CO2. 
Prior adhesion assay or ELISA, confluent cells were detached using EDTA to protect 
cadherin from proteolysis and washed twice with PBS without calcium to prevent cell-cell 
adhesion. For adhesion assay cells were suspended in cell culture medium supplemented with 2% 
FCS containing varying concentrations of each of the peptidomimetic ligand or the solvent and left 
to form the monolayer in a humidified atmosphere of 5 % CO2. For ELISA cells were suspended in 
PBS containing 1.2 mM CaCl2 and varying concentrations (2 and 1 mM) of each of the 
peptidomimetic ligand or the solvent as above. After 1 h incubation at 37⁰C cells were added to 
cadherin-coated plates and incubated for further 2h at 37⁰C. Ninty-six well plates were coated 
overnight with 30 ng/well of E-cadh-Fc chimeric protein or human IgG1 Fc fragment (R&D Systems, 
Minneapolis, MN). After incubation, the wells were washed three times to remove unbound cells. 
The adherent cells were detected by crystal violet substrate. The intensity of the color was 
measured at 450 nM. Binding to human Fc fragment of IGg1 was evaluated to exclude unspecific 
cell binding and subtracted from those obtained with cadherin-Fc proteins. ADH-1 and compound 
1 were dissolved in water, compounds 2 and 3 in 10% DMSO. 
 
SPR analysis 
SPR experiments were performed using Biacore 2000 (GE Healthcare). Standard EDC\NHS 
coupling was used to covalently immobilized recombinant N-cadh-Fc on CM5 (GE Healthcare) 
sensor chip. Briefly, CM5 chip was activated with ECD\NHS for 7 min with excess activated 
carboxyl groups blocked with ethanolamine for 7 min following immobilization of N-cadh-Fc, 
resuspended as suggested by the manufacturer, was diluted to 10 µg\ml in 10 mM sodium 
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acetate, pH 4.8. For all experiments with covalently immobilized N-cadh-Fc, one flow cell served as 
a reference surface following activation and blocking on each chip in the absence of N-cadh-Fc. 
One flow cell was immobilized with an uncorrelated recombinant protein (Axl-Fc, R&D) with a 
similar molecular weight (120 KDa). The sensor chip was equilibrated with PBS in absence of 
calcium ions, and N-cadh-Fc was dissociated from the chip using the same buffer and the response 
was recorded for at least 240 s. N-cadh-Fc (10 nM), freshly diluted in PBS plus 1 mM CaCl2, was 
applied to the surface of the N-cadh immobilized CM5 sensor chip for 1800 s. Since the 
compounds to be analyzed (2 and 3) are only 600 Dalton and their direct binding to N-cadh is not 
detectable by the Biacore 2000 instrumentation, an inhibition experiment was performed. For 
compound 2 and 3, 10 nM of N-cadh-Fc were pre-incubated for 30 min at 25⁰C in the presence of 
each inhibitor at a concentration of 10 µM in PBS plus 1 mM CaCl2 and then applied on the chip. N-
cadh-Fc alone was injected after each injection of N-cadh/inhibitor to verify the functionality of 
the chip and the resulted RU (Resonance Units) max was considered as 100%. After each injection, 
the sensor chip was regenerated using 30-60 μl of 20 mM EGTA pH 7 to eliminate calcium ions 
from the system. A flow rate of 5µl\min was kept for all the experiments. 
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∗Supplementary information for Chapter 2∗ 
S2.1 CHARACTERIZATION OF DKP-RGD COMPOUNDS IN THE FREE STATE AT 298 K  
Figure 2.1S Cyclic RGD-peptidomimetics containing bifunctional DKP scaffolds. 
Table 2.1S 1H and 13C chemical shifts (δ in ppm) of compound 1 in H2O/D2O solution at T=298 K. 
 
 
Compound 1 1H(δ,ppm) 298 K 13C n.O.e. contacts 
Arg-NH 8.40, d, 3.24Hz /// DKP_H7 
Arg-Hα 4.02, sb 55.1  
Arg-Hβ 1.80, m 27.1  
Arg-Hγ 1.63, m 24.3  
Arg-Hδ 3.15, m 40.6  
Guan-NH 7.12, t, 6.01Hz ///  
Gly-NH 8.75, t, 5.95Hz /// NH_Asp, γH_Arg 
Gly-Hα 4.01, dd – 3.70, dd, 17.12 – 3.47Hz 43.4 NH_Asp 
Asp-NH 8.10, d, 8.73Hz /// DKP_NH10, NH_Gly, αH_Gly 
Asp-Hα 4.45, sb 51.2 NH_Asp, βH_Asp 
Asp-Hβ 2.77, dd – 2.57, dd, 17.35 – 8.30Hz 36.5  
DKP_NH10 7.50, d, 5.09Hz /// NH_Asp, βH_Asp 
DKP_NH1 8.32, s ///  
DKP-H9 
3.92, ddd, 15.27/6.73/3.22Hz – 3.57, ddd, 
15.27 – 4.10Hz (J2=J3) 
39.4 DKP_NH10 
DKP-H3 4.37, sb 58.9  
DKP-H7 3.19 -2.85, dd overlapped 36.8 NH_Arg 
DKP-H6 4.48, sb 51.5  
CH2-Bn 4.67, deleted by water 48.9  
H-Ar 7.30 128  
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Table 2.2S 1H and 13C chemical shifts (δ in ppm) of compound 2 in H2O/D2O solution at T=298 K. 
Table 2.3S 1H and 13C  chemical shifts (δ in ppm) of compound 3 in H2O/D2O solution at T=298 K. 
 
 
 
Compound 2 1H(δ,ppm) 298 K 13C n.O.e. contacts 
Arg-NH 8.57, d, 7.20 Hz /// NH_Gly, DKP_H7 
Arg-Hα 4.21, m -  
Arg-Hβ 1.70-1.63, m -  
Arg-Hγ 1.61, m -  
Arg-Hδ 3.15, m 40.5  
Guan-NH 7.12, t, 5.48 Hz ///  
Gly-NH 8.18, d, 9.6 Hz /// NH_Arg 
Gly-Hα 4.17-3.54, d, 18 Hz 41.7 NH_Asp 
Asp-NH 8.29, d, 7.6 Hz /// αH_Gly 
Asp-Hα 4.68, influenced by water 52  
Asp-Hβ 2.82 – 2.75, dd, 17.0 – 7.0 Hz 35.3  
DKP_NH10 8.79, s br /// αH_Asp 
DKP_NH1 8.35, s ///  
DKP-H9 4.31 – 3.34, d, 16.9 Hz 38.7  
DKP-H3 4.30, m 55  
DKP-H7 2.88 – 2.39, m, 14.8 Hz 40 NH_Arg 
DKP-H6 4.55, m 52  
CH2-Bn 5.01 – 4.13, d, 16.4 Hz 47.9  
H-Ar 7.36 – 7.29, m 128.1  
Compound 3 1H(δ,ppm) 298 K 13C n.O.e. contacts 
Arg-NH 8.8, d, 8.29 Hz /// NH_Gly, DKP_H7, DKP_H6 
Arg-Hα 4.1, m -  
Arg-Hβ 1.89 – 1.71, m 25.7  
Arg-Hγ 1.53, m 24.6  
Arg-Hδ 3.12, q, 6.9 Hz 40.5  
Guan-NH 7.09, t, 5.76 Hz ///  
Gly-NH 8.06, dd, 7.98 – 4.14 Hz /// NH_Arg, αH_Arg 
Gly-Hα 4.20 – 3.55, dd, 17.6 – 8.17/5.76 Hz 42.6  
Asp-NH 7.94, d, 13.87 Hz /// αH_Gly, DKP_H6 
Asp-Hα 4.76, influenced by water 49.5  
Asp-Hβ 2.80 – 2.66, dd, 16.8 – 7.0/6.8 Hz 34.8 DKP_NH10 
DKP_NH10 8.4, t, 6.12 Hz /// αH_Asp, βH_Asp 
DKP_NH1 8.1, s ///  
DKP-H9 3.89, dd, 15.3 – 7.5 Hz – 3.49, dt, 15.3 – 5.7 Hz 39.2  
DKP-H3 4.05, d, 5.52 Hz 59.8  
DKP-H7 2.79 – 2.58, dd, 14.23 Hz – 8.35/5.34 Hz 37.9 NH_Arg 
DKP-H6 4.48, d 52.0  
CH2-Bn 5.02- 4.03, d, 15.9 Hz 47.9  
H-Ar 7.4 – 7.2, m 128.0  
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at T=298 K. 
Table 2.4S 1H chemical shifts (δ in ppm) of compound 5 in H2O/D2O solution at T=298 K. 
Table 2.5S 1H chemical shifts (δ in ppm) of compound 5 in H2O/D2O solution at T=298 K. 
 
 
 
Compound 4 1H(δ,ppm) 298 K 13C n.O.e contacts 
Arg-NH 8.30, s - DKP-H7 
Arg-Hα 4.24, s 53.4 - 
Arg-Hβ 1.77-1.67, m 27.9 - 
Arg-Hγ 1.56, m 24.4 - 
Arg-Hδ 3.12, q, 6.66 Hz 40.4 - 
Guan-NH 7.11, t, 5.97 Hz - - 
Gly-NH 8.27, t, 5.69Hz - Arg-Hα 
Gly-Hα 3.94-3.61 42.6 - 
Asp-NH 8.86, s - Gly-Hα 
Asp-Hα 4.33,  52.4 - 
Asp-Hβ 2.81-2.76, dd, 17.2 -  5.00 Hz 34.8 - 
DKP_NH10 7.57, s (broad) - - 
DKP_NH4 8.20, s - - 
DKP-H9 3.64-3.31,  40.5 - 
DKP-H3 3.88 52.0 - 
DKP-H7 2.91-2.73,  36.3 Arg-NH 
DKP-H6 4.18,  57.6 CH2-Bn 
CH2-Bn 5.09-(influenced by water)- - - 
H-Ar 7.33-7.23 128.4 DKP-H7 
Compound 5 1H (δ,ppm) 13C n.O.e contacts 
Arg-NH 8.47, d, 6.98 Hz - DKP-H7,  Gly-NH 
Arg-Hα 4.09 55.5 - 
Arg-Hβ 1.73-1.62, m - - 
Arg-Hγ 1.55, m - - 
Arg-Hδ 3.08, q, 6.55 Hz 40.3 - 
Guan-NH 7.05, t(broad) - - 
Gly-NH 8.22, d, 9.92 Hz - Arg-Hα, Arg-NH 
Gly-Hα 
4.21, dd, 15.87 Hz- 10.01 Hz 
-3.40, d, 15.87Hz 
41.8 - 
Asp-NH 8.41, d, 8.08 Hz - Gly-Hα 
Asp-Hα 4.64 50.2 - 
Asp-Hβ 2.84-2.67, dd  17.13 Hz- 8.03/7.23 Hz 35.2 - 
DKP_NH10 8.58, t(broad) - Asp-Hα 
DKP-H9 4.32-3.32 39.5 - 
DKP-H3 4.33 - - 
DKP-H7 2.53 (overllapped) 39.0 - 
DKP-H6 4.41 - - 
CH2-Bn(1) 5.11-4.35, d
, 16.56 Hz 49.6 - 
CH2-Bn(2) 4.13-5.00, d, 15.53-15.87Hz 48.3 - 
H-Ar(1) 7.72-7.19 128.7 Arg-Hα,  DKP-H7 
H-Ar(2) 7.72-7.19 128.7 - 
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Table 2.6S 1H chemical shifts (δ in ppm) of compound 6 in H2O/D2O solution at T=298 K. 
 
Table 2.7S 1H chemical shifts (δ in ppm) of compound 7-A in H2O/D2O solution at T=298 K. 
 
 
 
Compound 6 1H (δ,ppm) 298 K 13C n.O.e contacts 
Arg-NH 8.33 - DKP-H7 
Arg-Hα 4.30, broad 53.4 Gly-NH 
Arg-Hβ 1.77-1.69, m 28.1 - 
Arg-Hγ 1.57, m 24.7 - 
Arg-Hδ 3.13, dd, 6.91 Hz 40.2 - 
Guan-NH 7.10, t, 5.76Hz - - 
Gly-NH 8.34 - Asp-Hα 
Gly-Hα 3.85-3.69, dd, 15.55 Hz - 5.53Hz 42.9 Asp-NH 
Asp-NH 8.86, s - DKP_NH10, Gly-Hα 
Asp-Hα 4.37, broad 52.0 DKP_NH10 
Asp-Hβ 2.82-2.61, dd, 16.76 Hz - 6.23 Hz 35.7 - 
DKP_NH10 7.93, t, 6.18 Hz - Asp-Hα,  DKP_NH4 
DKP_NH4 8.01, s - DKP_NH10 
DKP-H9 3.78-3.55, dd, 14.49 Hz - 4.49 Hz                                                                        - - 
DKP-H3 3.94, d, 8.29 Hz 55.1 - 
DKP-H7 2.75-2.71, dd 34.8 Arg-NH 
DKP-H6 4.24, broad 57.6 H-Ar 
CH2-Bn 5.07-4.22, d, 16.06 Hz 47.7 - 
H-Ar 7.33/7.27 128.4 DKP-H6,  DKP-H7,  Gly-Hα 
Compound 7-A 1H (δ,ppm) 298 K 13C n.O.e contacts 
Arg-NH  8.66, d, 8.03 Hz - Gly-NH,  DKP-H7,  DKP-H6 
Arg-Hα 4.11 Under water Gly-NH 
Arg-Hβ 1.93-1.64, m 25.4 - 
Arg-Hγ 1.50, m 24.4 - 
Arg-Hδ 3.11, q, 6.62Hz 40.86 - 
Guan-NH 7.07, t, 6.10Hz - - 
Gly-NH 7.93, broad - Arg-NH, Asp-NH,  Arg-Hα 
Gly-Hα 4.37-3.56, dd, 17.38 Hz - 2.48 Hz 43.2 - 
Asp-NH 7.76, d, 9.14 Hz - Gly-NH,  Gly-Hα 
Asp-Hα 4.89, influenced by water Under water - 
Asp-Hβ 2.83-2.63, dd, 4.97 Hz - 17.38 Hz 36.94 - 
DKP-NH10 8.04, t, 6.34 Hz - Asp-Hα,  Asp-Hβ 
DKP-H9 3.92-3.66, dd, 14.90 Hz - 6.62 Hz 39.7 - 
DKP-H3 4.34 Under water - 
DKP-H7 2.55-2.81, dd, 11.59 Hz - 14.07Hz 37.7 Arg-NH, H-Ar 
DKP-H6 4.69, influenced by water Under water - 
CH2-Bn(1) 5.03-4.04, d, 15.73Hz 48.0 DKP-H3,  DKP-H9 
CH2-Bn(2) 4.57-4.80, influenced by water Under water - 
H-Ar(1-2) 7.39/7.19, m 128.1 DKP-H7 
v 
 
 
Table 2.8S 1H chemical shifts (δ in ppm) of compound 7-B in H2O/D2O solution at T=298 K. 
 
The n.O.e contacts reported in the Table were used for the investigation of the ligands 
conformation. The NH-/NH- n.O.e. contacts are reported in bold. They are used to determine the 
conformation and as constraints for the MC/SD simulations. 
 
 
 
 
 
 
 
 
 
 
Compound 7-B 1H (δ,ppm) 298 K 13C n.O.e contacts 
Arg-NH 8.34, d, 5.85 Hz - DKP-H7 
Arg-Hα 4.15, d, 7.79 Hz 53.59 - 
Arg-Hβ 1.77, m 27.81 - 
Arg-Hγ 1.61, m - - 
Arg-Hδ 3.16, q, 6.91 Hz 40.55 - 
Guan-NH 7.13- - - 
Gly-NH 8.45, t, 5.47Hz - DKP-H7 
Gly-Hα 3.80, d, 16.06 Hz -3.67, d, 16.06 Hz 43.45 - 
Asp-NH 8.55, d, 7.55Hz - DKP-NH10,  Gly-Hα 
Asp-Hα 4.52 51.37 - 
Asp-Hβ 2.77-2.61, dd, 7.12 Hz - 16.50 Hz 36.69 - 
DKP-NH10 7.72, dd, 2.83 Hz - 8.19 Hz - Asp-NH,  Asp-Hα 
DKP-H9 3.74-3.33, broad 39.3 H-Ar 
DKP-H3 4.10, dd, 1.94 Hz - 7.58 Hz 60.74 - 
DKP-H7 2.93-2.85, dd, 6.37 - 3.0 Hz 35.63 - 
DKP-H6 4.44, d 56.78 - 
CH2-Bn(1) 
5.22-4.20, d, 14.63 Hz 47.51 - 
CH2-Bn(2) 5.17-4.32, d, 16.46 Hz 49.63 - 
H-Ar(1-2) 7.42/7.17, m ~128.4 DKP-H6, DKP-H9,  Gly-Hα 
vi 
 
S2.2 NOESY SPECTRA FOR DKP-RGD COMPOUNDS (1 – 7) 
NOESY spectra of the compounds 1 - 7 performed with mixing time = 700 ms in H2O/D2O (9:1) 
solution at 298 K. Dipolar correlation of amidic protons (Figure 2.2S). 
Compound 1                                                                           Compound 2 
                  
 
 
 
 
 
 
 
 
 
Compound 3                                                                      Compound 5 
  
 
 
 
 
vii 
 
Compound 6  
 
 
 
 
 
 
 
 
 
 
Compound 7-A                                                                  Compound 7-B 
 
Figure 2.2S NOE contacts for DKP-RGD compounds 1 – 7. 
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S2.3 WORKFLOW AND DISTANCE RESTRAINTS USED FOR THE CALCULATIONS 
In a conformational equilibrium, NMR observables - such as NOEs - reflect the average 
properties of the individual conformations of a molecule. Thus, the area of cross peaks in a NOESY 
spectrum is a function of both the distance between the interacting protons and the molar 
fraction of each conformation at the equilibrium. For this reason, as the contribution of either 
factor cannot be clearly determined, all significant NOE long range interactions between amide 
protons have been assumed to produce the same distance restraint information. Therefore, in 
order to investigate the conformational features fitting a specific experimental NH-NH contact, a 
single restraint has been applied in each MC/SD run by imposing the same distance value of 
2±0.5Å with a force constant of 100 kJ/mol·Å2. At least two 10 ns MC/SD simulations (three on 
average) were conducted for each cyclo[DKP-RGD] peptidomimetic, using different starting 
conformations. When two mutually exclusive long-range NOE contacts are present (see ligands 
DKP-1, DKP-6 and DKP-7-A), only one restraint at a time was applied for each 10 ns run.  
 
Structure 
Distance restraints = 2±0.5 Å 
(in the case of two mutually 
exclusive NOE contacts, only 
one restraint at a time was 
used for each 10 ns run) 
cyclo[DKP-1-RGD] 
NHAsp-NH10 
NHAsp-NHGly 
cyclo[DKP-2-RGD] NHArg-NHGly 
cyclo[DKP-3-RGD] NHArg-NHGly 
cyclo[DKP-4-RGD] -- 
cyclo[DKP-5-RGD] NHArg-NHGly 
cyclo[DKP-6-RGD] 
NHAsp-NH10 
NH4-NH10 
cyclo[DKP-7-RGD]-A 
NHArg-NHGly 
NHAsp-NHGly 
cyclo[DKP-7-RGD]-B NHAsp-NH10 
Table 2.9S List of distance restraints used for each cyclo[DKP-RGD] peptidomimetic during MC/SD 
simulations. 
 
 
 
ix 
 
S2.4 CHARACTERIZATION OF DKP-isoDGR COMPOUNDS 8 AND 9 IN THE FREE STATE 
 
 
 
 
 
 
 
 
 
 
Table 2.10S 1H and 13C chemical shifts (δ in ppm) of compound 8 in H2O/D20 at T=298 K. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.11S 1H and 13C chemical shifts (δ in ppm) of compound 9 in H2O/D20 at T=298 K. 
 
 
 
 
Compound 8 1H (δ, ppm) 298 K 13C 
Asp-NH 8.25 (s overlapped) /// 
Asp-Hα 4.66 (influenced by water) 50.9 
Asp-Hβ 2.80, dd, 9.1 – 3 Hz 37.6 
Gly-NH 7.90, t, 6.35 Hz /// 
Gly-Hα 4.03-3.83, dd, 16.94 – 5.93 Hz 41.6 
Arg-NH 8.27 (s overlapped) /// 
Arg-Hα 4.15, d, 6.77 Hz 54.0 
Arg-Hβ 1.69, m 27.1 
Arg-Hγ 1.58-1.51, m 24.1 
Arg-Hδ 3.13, q, 6.73 Hz 40.4 
Guan-NH 7.11 /// 
DKP-NH10 8.44, t, 6.56 Hz /// 
DKP-NH1 8.35, s /// 
DKP-H9 4.01-3.46, dm 39.0 
DKP-H3 4.02 (s overlapped) 59.3 
DKP-H7 2.78-2.60, dd, 15.15 – 10.77 Hz 41.1 
DKP-H6 4.83 (influenced by water) 51.2 
CH2-Bn 5.09-4.12, d, 15.91 Hz 47.1 
H-Ar 7.38-7.25, m 128.2 
Compound 9 1H (δ, ppm) 298 K 13C 
Asp-NH 8.62, d, 8.57 Hz /// 
Asp-Hα 4.84 (influenced by water) 49.1 
Asp-Hβ 2.95-2.63, dd, 14.82Hz - 12.12 Hz 37.0 
Gly-NH 8.16, t, 5.71 Hz //// 
Gly-Hα 4.17-3.71, dd, 17.90Hz - 7.29/5.30 Hz 40.8 
Arg-NH 8.27, d, 6.75 Hz /// 
Arg-Hα 4.13 53.4 
Arg-Hβ 1.73-1.64, m 27.3 
Arg-Hγ 1.55, m 23.9 
Arg-Hδ 3.10 39.8 
Guan-NH 7.1 /// 
DKP-NH10 8.45, t, 6.49 Hz /// 
DKP-NH1 7.60, s /// 
DKP-H9 3.88-3.59, dd 15.25 - 6.63 Hz 38.3 
DKP-H3 4.04 58.8 
DKP-H7 3.07-2.30, dd, 14.82 - 12.12Hz 37.5 
DKP-H6 4.34, d, 12.43 Hz 50.5 
CH2-Bn 5.15-4.10, d, 16.08Hz 46.9 
H-Ar 7.35-7.22, m 128.0 
x 
 
S2.5 NOESY SPECTRA FOR DKP-isoDGR COMPOUNDS (8 – 9) 
NOESY spectra of the compounds 8 - 9 performed with mixing time = 700 ms in H2O/D2O (9:1) 
solution at 298 K. Dipolar correlation of amidic protons. 
    Compound 8                                                                                  Compound 9 
 
Figure 2.3S NOE contacts for DKP-isoRGD compounds 8 – 9. 
 
 
 
 
 
 
 
 
 
 
The n.O.e contacts reported are maintained in the three cell lines; when there is a selection 
between two conformations at the equilibrium, the observations about the n.O.e contacts 
selected are discussed in Chapter 2 (“Results and Discussion”). 
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S2.6 CHARACTERIZATION OF COMPOUNDS 1, 2 AND 3 WITH PLATELETS AT 298 K 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.12S 1H chemical shifts (δ in ppm) of compounds 1 – 2 - 3 in buffer solution in presence of 
human platelets suspension at T=298 K. 
 
       Compound 1 
 
Protons 
1H(δ,ppm) 298 K 
NH_Arg 8.40 (s overlapped) 
αH-Arg 3.98 (s overlapped) 
βH-Arg 1.76-1.62 (m) 
γH-Arg 1.57 (m) 
δH-Arg 3.14 (s overlapped) 
NH_guan 7.14 (m br) 
NH_Gly 8.69 (t, 6.23 Hz) 
αH-Gly 4.00-3.64 (dd, 17.26-5.52 Hz) 
NH_Asp 8.04 (d, 8.28 Hz) 
αH-Asp 4.38 (br) 
βH-Asp 2.59-2.40 (dd, 17.26-9.66 Hz) 
DKP_NH1 8.38 (s overlapped) 
DKP_NH10 7.49 (m br) 
DKP_H9 3.91-3.47 (dt, 15.19-4.14 Hz) 
DKP_H3 4.29 (br) 
DKP_H7 3.14-2.82 (dd, 17.26-4.14 Hz) 
DKP_H6 4.45 (br) 
CH2-Bn /// 
H-Ar 7.32-7.26 
         Compound 2 
 
Protons 
1H(δ,ppm) 298 K 
NH_Arg 8.60, d, 6.65Hz 
αH-Arg 4.19, m 
βH-Arg 1.78-1.69, m 
γH-Arg 1.62, m 
δH-Arg 3.14, q, 7.00 Hz 
NH_guan 7.12, t, 5.68 Hz 
NH_Gly 8.18, d br 
αH-Gly 4.14-3.51, d br 
NH_Asp 8.27, d, 8.29 Hz 
αH-Asp /// 
βH-Asp 2.60-2.54, dd, 16.2 – 7.7 Hz 
DKP_NH1 8.34, s 
DKP_NH10 8.64 (br) 
DKP_H9 4.30-3.32, br 
DKP_H3 /// 
DKP_H7 2.88-2.38, dd, 14.0 – 10 Hz 
DKP_H6 /// 
CH2-Bn 5.01-4.13, d, 16.6 Hz 
H-Ar 7.38-7.28 
           Compound 3 
 
Protons 
1H(δ,ppm) 298 K 
NH_Arg 8.72 (br) 
αH-Arg 4.26, dd, 9.10 – 6.26 Hz 
βH-Arg 1.89-1.72, m 
γH-Arg 1.57, m 
δH-Arg 3.16, td, 7.96 – 1.14 Hz 
NH_guan 7.14 (br) 
NH_Gly 8.03, s overlapped 
αH-Gly 4.21-3.62, d 
NH_Asp 8.03, s overlapped 
αH-Asp Under water 
βH-Asp 2.80-2.65, dd, 14.3 – 8.53 Hz (2.55) 
DKP_NH1 8.03, s overlapped 
DKP_NH10 8.16, t br 
DKP_H9 3.94-3.55, dd, 15.9 – 5.7 Hz 
DKP_H3 4.07, s overlapped 
DKP_H7 2.80-2.65, dd, 14.3 – 8.53 Hz (2.55) 
DKP_H6 Influenced by water 
CH2-Bn 5.08-4.08, d, 16.5 Hz 
H-Ar 7.36-7.26 
xii 
 
S2.7 CHARACTERIZATION OF DKP-RGD COMPOUNDS WITH ECV-304 AT 298 K AND 282 K 
Table 2.13S 1H chemical shifts (δ in ppm) of compound 1 in buffer solution in presence of ECV-304 
cancer cells suspension at T=298 K and at 282 K. 
Table 2.14S 1H chemical shifts (δ in ppm) of compound 2 in buffer solution in presence of ECV-304 
cancer cells suspension at T=298 K and at 282 K. 
                     Compound 1 
 
Protons  
1H(δ,ppm) 298 K 1H(δ,ppm) 282 K 
NH_Arg 8.45 (s br) 8.55 (s br) 
αH-Arg 4.04 (s) 4.04 (s) 
βH-Arg 1.82 -1.66 (m) 1.80-1.66 (m) 
γH-Arg 1.62 (m) 1.61 (m) 
δH-Arg 3.18 (s) 3.18 (dd,15.4-5.8Hz) 
NH_guan 7.23 (br) 7.25 (s br) 
NH_Gly 8.72 ( br) 8.83 (t, 6.0Hz) 
αH-Gly 4.03-3.68 (d, 20 Hz) 4.04-3.68 (d, 17.80 Hz) 
NH_Asp 8.08 (d, 8.1 Hz) 8.13 (d, 4.31Hz) 
αH-Asp 4.40 (br) 4.39 (s br) 
βH-Asp 2.59 (dd, 15-4 Hz)-2.40 (dd, 15-4 Hz) 2.59 (dd,16.0-9.9 Hz)-2.40 (dd,16.0-9.9 Hz) 
DKP_NH1 8.45 (s br) 8.55 (s br) 
DKP_NH10 7.54 (s br) 7.57 (s br) 
DKP_H9 3.95-3.50 (dd, 16-3 Hz) 3.95 (d, 18.0 Hz)-3.50 (d, 18.0 Hz) 
DKP_H3 4.32 (br) 4.33 (s) 
DKP_H7 3.16-2.86 (dd, 18.7-5.3 Hz) 3.16 (d,18.5Hz)-2.89 (dd,17.5-3.9 Hz) 
DKP_H6 4.51 (s br) 4.51 (s) 
CH2-Bn - (deleted by water saturation) - (deleted by water saturation) 
H-Ar 7.38-7.30 7.36-7.31 
       Compound 2 
 
Protons  
1H(δ,ppm) 298 K 1H(δ,ppm) 282 K 
NH_Arg 8.62 (s br) 8.72 (d,7.1Hz) 
αH-Arg 4.19 (m) 4.18 (m) 
βH-Arg 1.80-1.70 (m) 1.79-1.70 (m) 
γH-Arg 1.63 (m) 1.64 (m) 
δH-Arg 3.15 (t, 6.2 Hz) 3.15 (m) 
NH_guan 7.12 (s br) 7.18 (s br) 
NH_Gly 8.18 (s br) 8.26 (d, 10.0 Hz) 
αH-Gly 4.09-3.50 (m) 4.10 (m) -3.48 (d, 18.8Hz)   
NH_Asp 8.27 (s br) 8.40 (d, 8.5Hz) 
αH-Asp - (deleted by water saturation) 4.63 (m) 
βH-Asp 2.58 (dd, 15.9-7.5 Hz)-2.50 (dd, 15.9-7.5 Hz) 2.60 (dd, 15.4-6.8 Hz)-2.49 (dd, 15.4-6.8 Hz) 
DKP_NH1 8.60 (s br)  8.50 (s) 
DKP_NH10 8.62 (s br) 8.79 (m) 
DKP_H9 4.24 (br)-3.32  3.32 (m) 
DKP_H3 4.30 (br) 4.33 (dd, 17.10-6.8 Hz) 
DKP_H7 2.90 (dd, 15.7- 6.8 Hz)-2.38 (d, 15.7 Hz) 2.87 (dd,14.5-10.3Hz)-2.39 (d,14.5 Hz) 
DKP_H6 4.60 (br) 4.65 
CH2-Bn 5.03(d, 16.56 Hz)-4.10 - (deleted by water saturation) 
H-Ar 7.38-7.28 7.41-7.33 
xiii 
 
Table 2.15S 1H chemical shifts (δ in ppm) of compound 3 in buffer solution in presence of ECV-304 
cancer cells suspension at T=298 K and at 282 K. 
Table 2.16S 1H chemical shifts (δ in ppm) of compound 4 in buffer solution in presence of ECV-304 
cancer cells suspension at T=298 K and at 282 K. 
 
 
                Compound 3 
 
Protons  
1H(δ,ppm) 298 K 1H(δ,ppm) 282 K 
NH_Arg 8.74 (d, 8.4 Hz) 8.83 (d, 8.5 Hz) 
αH-Arg 4.30 (br) 4.30 (q, 9.1 Hz) 
βH-Arg 1.93-1.74 (m) 1.92-1.74 (m) 
γH-Arg 1.60 (m) 1.61 (m) 
δH-Arg 3.19 (br) 3.19 (m) 
NH_guan 7.16 (br) 7.20 (t, 5.4 Hz) 
NH_Gly 8.11 (s br) 8.15 (dd,4.6-7.8 Hz) 
αH-Gly 4.24(dd, 15.5-7.1 Hz)-3.65 (d, 15.5 Hz) 4.24 (dd, 18.0-7.9 Hz)-3.65(dd, 18.0-3.6 Hz) 
NH_Asp 8.07 (s br) 8.09 (d, 8.3 Hz) 
αH-Asp - 4.71 (s br) 
βH-Asp 2.59(dd, 16.2-6.5 Hz)-2.56 (dd, 16.2-6.5 Hz) 2.59 (dd, 16.5-6.4Hz)-2.56 (dd, 16.5-6.4Hz) 
DKP_NH1 8.11 (s br) 8.18 (s) 
DKP_NH10 8.18 (t, 6.5 Hz) 8.30 (t, 6.8Hz) 
DKP_H9 3.97(dd, 17.5-7.8 Hz)-3.57 (dd, 17.5-7.8 Hz) 3.97 (dd, 15.7-7.3 Hz)-3.58(m) 
DKP_H3 4.05 4.05 (s br) 
DKP_H7 2.81(dd, 14.2-8.4 Hz)-2.68 (dd, 14.2-8.4 Hz) 2.82 (dd, 13.9-8.5 Hz)-2.69 (dd, 13.9-8.5 Hz) 
DKP_H6 - (deleted by water saturation) - (deleted by water saturation) 
CH2-Bn 5.10(d, 16.2 Hz)-4.10 (d, 16.2 Hz) 5.12 (d,17.1Hz)-4.10 (d, 17.0Hz) 
H-Ar 7.41-7.28 7.38-7.29 
               Compound 4 
 
Protons  
1H(δ,ppm) 298 K 1H(δ,ppm) 282 K 
NH_Arg 8.35 (s br) 8.47 (s br) 
αH-Arg 4.29 (s br) 4.30 (s br) 
βH-Arg 1.82 (m)-1.72 (m) 1.82(m)-1.72(m) 
γH-Arg 1.62 (m) 1.62 (m) 
δH-Arg 3.17 (quintupletto, 6.5 Hz) 3.17 (s br) 
NH_guan 7.16 (t, 5.6 Hz) 7.20 (m) 
NH_Gly 8.29 (t, 5.7 Hz) 8.44 (t, 5.7 Hz) 
αH-Gly 4.00 (s br)-3.65 (s br) 3.99-3.66 
NH_Asp 8.77 (s br) 9.04 (s br) 
αH-Asp 4.27 (s br) 4.31 (s br) 
βH-Asp 2.66 (dd, 16.4-4.1 Hz)-2.56 (dd, 16.4- 10.0 Hz) 2.80 (s br) 
DKP_NH4 8.22 (s) 8.35 (s) 
DKP_NH10 7.56 (s br) 7.58 (s br) 
DKP_H9 3.89 (s br)-3.71 (s br) Not clearly visible 
DKP_H3 Under water Not clearly visible 
DKP_H7 2.99 (d, 16.0 Hz)- 2.78 (d, 15.4 Hz) 3.00 (m)-2.80 (m) 
DKP_H6 4.73 (under water) - 
CH2-Bn 5.17 (s br)-4.18 (s br) 5.17 (s br)- 4.16 (d, 14.6 Hz) 
H-Ar 7.38-7.29 7.35-7.26 
xiv 
 
 
Table 2.17S 1H chemical shifts (δ in ppm) of compound 5 in buffer solution in presence of ECV-304 
cancer cells suspension at T=298 K and at 282 K. 
Table 2.18S 1H chemical shifts (δ in ppm) of compound 6 in buffer solution in presence of ECV-304 
cancer cells suspension at T=298 K and at 282 K. 
 
                        Compound 5 
 
Protons  
1H(δ,ppm) 298 K 1H(δ,ppm) 282 K 
NH_Arg 8.39 (s br) 8.39 (d,6.7 Hz) 
αH-Arg 3.88 - 
βH-Arg 1.54 (m)- 1.42 (m) 1.57 (s br)-1.44 (s br) 
γH-Arg 1.37 (m) 1.38 (s br) 
δH-Arg 2.91 (s br) 2.91 (s br) 
NH_guan 6.94 (s br) 6.95 (s br) 
NH_Gly 8.08 (m) 8.08 
αH-Gly 4.06 (m)- 3.17 (m) 3.22 (d, 17.3 Hz) – 4.06 (dd, 16.1-9.7 Hz) 
NH_Asp 8.25 (m) 8.26 (d, 8.7 Hz) 
αH-Asp 4.36 (s br) 4.42 (d, 8.6 Hz) 
βH-Asp 2.29 (s br) 2.38-2.27 
DKP_NH10 8.45 (s br) 8.46 (dd, 9.1- 4.3 Hz) 
DKP_H9 4.1 (s br)- 3.11 (s br) 4.14 (m)-3.15 (dd, 14.9-3.7 Hz) 
DKP_H3 4.10 (s br) Not clearly visible 
DKP_H7 2.32 (m) 2.30 (m) 
DKP_H6 Not clearly visible 4.16 (s br) 
CH2-Bn Influence by water 4.99 (d, 17.4 Hz) -4.17 (d, 17.4 Hz) 
H-Ar 7.22-7.04 7.22-7.00 
                Compound 6 
 
Protons  
1H(δ,ppm) 298 K 1H(δ,ppm) 282 K 
NH_Arg 8.33 (d, 8.0 Hz) 8.46 (d, 7.9 Hz) 
αH-Arg 4.32 (m) 4.27 (s br) 
βH-Arg 1.79 (m)-1.70 (m) 1.80 (m)-1.71 (m) 
γH-Arg 1.57 (m) 1.59 (m) 
δH-Arg 3.15 (q, 6.9 Hz) 3.15 (s br) 
NH_guan 7.14 (s br) 7.20 (s br) 
NH_Gly 8.37 (t, 4.6 Hz) 8.48 (s br) 
αH-Gly 3.95 (d, 8.6 Hz)-3.85 (s br) 3.85 (s br)- 3.70 (dd,  15.8-6.2 Hz) 
NH_Asp 8.80 (d, 5.2 Hz) 8.92 (s br) 
αH-Asp 4.37 (m) 4.34 (m) 
βH-Asp 2.76 (s br)- 2.59 (dd, 16.2- 8.6 Hz) 2.74 (m)- 2.59 (dd, 16.2-8.8 Hz) 
DKP_NH4 8.12 (s) 8.21 (s) 
DKP_NH10 7.91 (t, 5.8 Hz) 7.99 (t, 5.8 Hz) 
DKP_H9 3.70 (dd, 15.3-5.5 Hz) 3.88(s br)-3.50 (m) 
DKP_H3 Not clearly visible Not clearly visible 
DKP_H7 2.79 (dd, 14.3-5.1 Hz)- 2.74 (m)  2.79 (dd, 13.8-4.5 Hz)- 2.73 (m) 
DKP_H6 4.26 (s br) 4.25 (s br) 
CH2-Bn 5.07 (d,13.7 Hz)-4.26 (s br) 5.08 --4.26 (s br) 
H-Ar 7.37- 7.28 7.37-7.28 
xv 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.19S 1H chemical shifts (δ in ppm) of compound 7-A in buffer solution in presence of ECV-
304 cancer cells suspension at T=282 K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Compound 7 A 
 
Protons  
1H(δ,ppm) 282 K 
NH_Arg 8.65 (d, 8.4 Hz) 
αH-Arg 4.27 
βH-Arg 1.96-1.64 
γH-Arg 1.52 
δH-Arg 3.15 (calibrato con  quello a 298 K) 
NH_guan 7.15 (m) 
NH_Gly 8.05 (s br) 
αH-Gly 3.58 
NH_Asp 8.04 (s br) 
αH-Asp 4.85 (under water) 
βH-Asp 2.63 (dd, 16.4-7.5 Hz)-2.54 (dd, 16.4-5.7 Hz) 
DKP_NH10 8.10 (t, 6.9 Hz) 
DKP_H9 3.92 (m)-3.71 (m) 
DKP_H3 4.35 (s br)  
DKP_H7 2.90 (d, 15.2 Hz)-2.48 (dd, 14-12 Hz) 
DKP_H6 Under water  
CH2-Bn 5.08 (under water)-4.06 (s br) 
H-Ar 7.41-7.20 
xvi 
 
 
Table 2.20S 1H chemical shifts (δ in ppm) of compound 7-B in buffer solution in presence of ECV-
304 cancer cells suspension at T= 298 K and at 282 K. 
 
 
 
 
 
 
 
 
 
 
         Compound 7 B 
 
Protons  
1H(δ,ppm) 298 K  1H(δ,ppm) 282 K  
NH_Arg 8.31 (d, 6.37 Hz) 8.42 (d, 6.09 Hz) 
αH-Arg 4.12 (q, 6.97 Hz) 4.11 (q, 7.39 Hz) 
βH-Arg 1.72 (m)-1.59(m) 1.71(m)-1.59 (m) 
γH-Arg 1.54 (m) 1.53 (m) 
δH-Arg 3.12 (m br) 3.12 (m br) 
NH_guan Overlapped with H_Ar Overlapped with H_ar 
NH_Gly 8.44 (t, 5.57 Hz) 8.54 (s br) 
αH-Gly 
3.76 (dd, 15.74-4.41 Hz)-3.64 (dd, 15.74 Hz-
6.61 Hz) 
3.76 (dd, 15.9-4.61 Hz)-3.64 (15.9-6.63 Hz) 
NH_Asp 8.48 (d, 7.43 Hz) 8.56 (s br) 
αH-Asp 4.48 (d, 7.54 Hz) 4.47 (d, 8.13 Hz) 
βH-Asp 2.65 (dd, 16.41-6.94 Hz)-2.49 (dd, 16.41-7.87 
Hz) 
2.65(dd, 16.7-7.5 Hz) -2.49(dd, 16.7-7.6 Hz) 
DKP_NH10 7.67 (dd, 8.65-3.24 Hz) 7.72 (dd, 8.94-3.09 Hz) 
DKP_H9 
3.71 (ddd, 14.53-8.89-3.25 Hz)- 3.29 (ddd, 
14.53-7.37-3.25 Hz) 
3.27 (dd, 7.42-2.73 Hz)-3.25(dd, 7.42-3.32 
Hz) 
DKP_H3 4.07 (dd, 7.54-2.26 Hz) 4.04 (m) 
DKP_H7 
2.79 (dd, 14.55-6.14 Hz)- 2.90 (dd, 14.55-2.54 
Hz) 
2.90 (dd, 14.8-6.36 Hz)-2.78 (dd, 14.8-2.07 
Hz) 
DKP_H6 4.41 (d, 6.03 Hz) 4.41 (dd br) 
CH2-Bn (1) 5.20 (d, 15.6 Hz)-4.17 (d, 15.5 Hz) 5.20 (d, 15.51 Hz)-4.17 (d, 15.5 Hz) 
CH2-Bn (2) 5.17 (d, 17.15 Hz)-4.29 (d, 17.25 Hz) 5.16 (d, 16.17 Hz)-4.29 (d, 16.99 Hz) 
H-Ar (1) 7.37-7.14 7.34 
H-Ar (2) 7.37-7.14 7.25-7.14 
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S2.8 CHARACTERIZATION OF DKP-RGD COMPOUNDS WITH MDA-MB-231 AT 282 K 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.21S 1H chemical shifts (δ in ppm) of compound 2 in buffer solution in presence of MDA-
MB-231 cancer cells suspension at T= 282 K. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.22S 1H chemical shifts (δ in ppm) of compound 3 in buffer solution in presence of MDA-
MB-231 cancer cells suspension at T= 282 K. 
                   Compound 2 
 
Protons  
1H(δ,ppm) 282 K 
NH_Arg 8.68 (d, 6.6Hz) 
αH-Arg 4.18 (m br) 
βH-Arg 1.76 (m)-1.67 (m) 
γH-Arg 1.60 (m) 
δH-Arg 3.13 (t, 5.23 Hz) 
NH_guan 7.16 (s br) 
NH_Gly 8.22 (d, 9.67 Hz) 
αH-Gly 4.18 (q, 7.0 Hz)-3.45 (d, 15.6 Hz) 
NH_Asp 8.36 (d, 8.14 Hz) 
αH-Asp 4.60 (s br) 
βH-Asp 2.57 (dd, 16.5-8 Hz)- 2.47 (dd, 16.5-7.4 Hz) 
DKP_NH1 8.45 (s) 
DKP_NH10 8.75 (dd, 9.7-4.1 Hz) 
DKP_H9 4.15 (m)-3.29 (d, 16.8 Hz) 
DKP_H3 - 
DKP_H7 2.84 (dd, 14.2 – 9.7 Hz)-2.35 (d, 14.2 Hz) 
DKP_H6 Under water 
CH2-Bn 5.05 (under water)-4.14 (m br) 
H-Ar 7.36-7.27 
                Compound 3 
Protons  
1H(δ,ppm) 282 K 
NH_Arg 8.79 (d, 8.44 Hz) 
αH-Arg 4.26 (q, 7.70 Hz) 
βH-Arg 1.87 (m)-1.69 (m) 
γH-Arg 1.57 (m) 
δH-Arg 3.13 (m) 
NH_guan 7.16 (t, 5.50 Hz) 
NH_Gly 8.12 (dd br) 
αH-Gly 4.19 (dd, 17.80-8.15  Hz)  -3.60 (dd, 17.80- 4.34 Hz) 
NH_Asp 8.05 (d, 8.61 Hz) 
αH-Asp 4.66 (near water) 
βH-Asp 2.54 (d, 6.60 Hz)  
DKP_NH1 8.15 (s) 
DKP_NH10 8.28 (t, 6.36 Hz) 
DKP_H9 3.93 (dd, 15.48-7.23Hz)  -3.53 (dt, 15.48-6.42 Hz) 
DKP_H3 4.03 (s overlapped) 
DKP_H7 2.76 (dd, 14.29-8.80 Hz)  -2.63 (dd, 14.29-5.28 Hz) 
DKP_H6 4.67 (near water) 
CH2-Bn 5.70 (d, 7.94 Hz) – 3.88 (d, 13.86 Hz) 
H-Ar 7.33-7.23 
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Table 2.23S 1H chemical shifts (δ in ppm) of compound 4 in buffer solution in presence of MDA-
MB-231 cancer cells suspension at T= 282 K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.24S 1H chemical shifts (δ in ppm) of compound 5 in buffer solution in presence of MDA-
MB-231 cancer cells suspension at T= 282 K. 
               Compound 4 
 
Protons 
1H(δ,ppm) 282 K 
NH_Arg 8.42 (d, 5.92 Hz) 
αH-Arg 4.23 (s sovrapposto) 
βH-Arg 1.78 (m)-1.68 (m) 
γH-Arg 1.58 (m) 
δH-Arg 3.11 (t, 5.96 Hz) 
NH_guan 7.16 (br) 
NH_Gly 8.35 (t, 5.92 Hz) 
αH-Gly 3.96 (d, 19.59 Hz) -3.59 (d, 19.59 Hz) 
NH_Asp 8.84 (s br) 
αH-Asp 4.21 (s overlapped) 
βH-Asp 2.60 (dd, 16.71-4.05 Hz)-2.51(dd, 16.71-10.38 Hz) 
DKP_NH4 8.29 (s) 
DKP_NH10 7.49 (d, 9.86 Hz) 
DKP_H9 3.67 (m br)-3.23 (t, 11.08 Hz) 
DKP_H3 3.81 (d br) 
DKP_H7 2.99 (d, 17.04 Hz)-2.74 (17.04 Hz) 
DKP_H6 4.16 (s) 
CH2-Bn 5.16 (d, 18.7 Hz)-4.10 (d, 18.7 Hz) 
H-Ar (2) 7.31-7.23 
                   Compound 5 
 
Protons  
1H(δ,ppm) 282 K 
NH_Arg 8.37 (d, 6.91 Hz) 
αH-Arg 3.90 (m) 
βH-Arg 1.54 (m)- 1.42 (m) 
γH-Arg 1.36 (m) 
δH-Arg 2.92 (m) 
NH_guan 6.93 (s br) 
NH_Gly 8.06 (d, 9.92Hz) 
αH-Gly 4.04 (dd, 16.00-10.18 Hz) - 3.20 (d, 16.00 Hz) 
NH_Asp 8.23 (d, 8.42 Hz) 
αH-Asp 4.48 (near water) 
βH-Asp 2.39 (dd, 15.93-7.54 Hz)- 2.25 (dd, 15.93-7.75 Hz) 
DKP_NH10 8.44 (dd, 9.32- 4.51 Hz) 
DKP_H9 4.14 (s overlapped)-  3.14(dd, 14.54-3.64 Hz) 
DKP_H3 4.42 (not clearly visible) 
DKP_H7 2.30 (m overlapped) 
DKP_H6 4.18 (s overlapped) 
CH2-Bn 4.96 (d, 17.45 Hz) -4.16 (s overlapped) 
CH2-Bn 4.83 (near water) -3.99 (d, 15.27 Hz) 
H-Ar (1) 7.23 -7.10  
H-Ar (2) 7.18 -7.04  
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Table 2.25S 1H chemical shifts (δ in ppm) of compound 6 in buffer solution in presence of MDA-
MB-231 cancer cells suspension at T= 282 K. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.26S 1H chemical shifts (δ in ppm) of compound 7-B in buffer solution in presence of MDA-
MB-231 cancer cells suspension at T= 282 K. 
                       Compound 6 
 
Protons  
1H(δ,ppm) 282 K 
NH_Arg 8.46 (d, 7.9 Hz) 
αH-Arg 4.27 (s br) 
βH-Arg 1.80 (m)-1.71 (m) 
γH-Arg 1.59 (m) 
δH-Arg 3.15 (s br) 
NH_guan 7.20 (s br) 
NH_Gly 8.48 (s br) 
αH-Gly 3.85 (s br)- 3.70 (dd,  15.8-6.2 Hz) 
NH_Asp 8.92 (s br) 
αH-Asp 4.34 (m) 
βH-Asp 2.74 (m)- 2.59 (dd, 16.2-8.8 Hz) 
DKP_NH4 8.21 (s) 
DKP_NH10 7.99 (t, 5.8 Hz) 
DKP_H9 3.88(s br)-3.50 (m) 
DKP_H3 Not visible 
DKP_H7 2.79 (dd, 13.8-4.5 Hz)- 2.73 (m) 
DKP_H6 4.25 (s br) 
CH2-Bn 5.08 (near water)-4.26 (s br) 
H-Ar 7.37-7.28 
                  Compound 7 B 
 
Protons  
1H(δ,ppm) 282 K 
NH_Arg 8.43 (d, 6.24 Hz) 
αH-Arg 4.13 (q, 6.66 Hz) 
βH-Arg 1.72 (m) 
γH-Arg 1.60 (m) - 1.54 (m) 
δH-Arg 3.12 (m br) 
NH_guan 7.16 (s overlapped) 
NH_Gly 8.56 (s sovrapposto) 
αH-Gly 3.75 (dd, 15.73- 4.75 Hz overlapped)-3.64 (dd, 15.73-6.89 Hz) 
NH_Asp 8.57 (s overlapped) 
αH-Asp 4.48 (d, 7.95 Hz) 
βH-Asp 2.66 (dd, 16.54-7.33 Hz) -2.49 (dd, 16.54 - 7.80 Hz) 
DKP_NH10 7.73 (dd, 8.93- 3.28 Hz) 
DKP_H9 3.72 (m overlapped)- 3.26 (ddd, 14.55-8.60-2.99 Hz) 
DKP_H3 4.04 (m br) 
DKP_H7 2.91 (dd, 15.02-6.38 Hz) - 2.78 (dd, 15.02-1.91 Hz) 
DKP_H6 4.43 (m) 
CH2-Bn (1) 5.16 (d, 17.32 Hz ) - 4.29 (d, 17.32 Hz) 
CH2-Bn (2) 5.21 (d, 15.97 Hz)- 4.18 (d, 15.97 Hz) 
H-Ar (1) 7.37-7.16 
H-Ar (2) 7.37-7.16  
xx 
 
S2.9 STD SPECTRA OF COMPOUNDS 2 – 7 WITH MDA-MB-231 at 282 K 
 
Figure 2.4S STD spectrum of compound 2 in buffer solution in presence of MDA-MB-231 cancer 
cells suspension at T= 282 K. 
 
Figure 2.5S STD spectrum of compound 3 in buffer solution in presence of MDA-MB-231 cancer 
cells suspension at T= 282 K. 
 
Figure 2.6S STD spectrum of compound 4 in buffer solution in presence of MDA-MB-231 cancer 
cells suspension at T= 282 K. 
 
xxi 
 
 
Figure 2.7S STD spectrum of compound 6 in buffer solution in presence of MDA-MB-231 cancer 
cells suspension at T= 282 K. 
 
Figure 2.8S STD spectrum of compound 7-B in buffer solution in presence of MDA-MB-231 cancer 
cells suspension at T= 282 K. 
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∗Supplementary information for Chapter 3∗ 
S3.1 CHARACTERIZATION OF THE COMPOUND 1c IN THE FREE-STATE AT 298 AND 283 K 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1S 
1
H and 
13
C chemical shifts (δ in ppm) of compound 1c in buffer solution at 298 K and 
283 K. 
 
 
Compound 1c 
1
H(δ,ppm) 298 K 1H(δ,ppm) 283 K 13C 
NH_isoLeu 7.98 d, 8.21 Hz 8.16 d, 7.91 Hz /// 
αH_isoLeu 4.02 t, 8.19 Hz 4.01 t, 8.19 Hz 58.2 
βH_isoLeu 1.81 m 1.81 m, 8.47 Hz 35.6 
γH_isoLeu 1.47 – 1.17 m 1.49 m overlapped 24.9 
CH3_isoLeu 0.89 d, 7.31 Hz 0.89 d, 7.16 Hz 14.2 
CH3_isoLeu 0.82 t, 7.69 Hz 0.80 t, 7.63 Hz 9.8 
NH10 8.44 s broad 8.61 s broad /// 
αH_Asp 4.18 dd, 7.82 – 5.55 Hz 4.17 dd, 8.00 – 5.84 Hz 50.8 
βH_Asp 2.72 dd, 17.14 – 5.55 Hz 2.71 dd, 17.32 – 5.74 Hz 37.0 
2.66 dd, 17.14 – 8.07 Hz 2.66 dd, 17.32 – 8.00 Hz 
H7 5.05 dd, 12.45 – 5.49 Hz 5.07 influenced by water 51.0 
H6 
2.92 m overlapped 2.93 m 
57.5 
2.82 t, 11.85 Hz 2.84 t, 11.77 Hz 
H11 4.49 m 4.48 m 59.7 
H10 
2.32 m 2.33 m 
27.2 
1.88 dd, 14.62 – 7.60Hz 1.89 dd, 14.59 – 7.53 Hz 
H9 
2.11 m 2.12 m, 6.59 Hz 
30.6 
1.67 dd, 13.36 – 6.81 Hz 1.67 dd, 13.08 – 6.68 Hz 
H2 Under water 4.51 m Under water 
H3 1.55 – 1.51  1.58 – 1.54 m, 6.78 Hz 35.5 
H4 Overlapped with H6 Overlapped with H6 /// 
CH2_Bn 
3.77 d, 13.49 Hz 3.82 d, 13.37 Hz 
61.2 
3.67 d, 13.49 Hz 3.73 d, 13.37 Hz 
H_Ar 7.35 – 7.29 /// 7.35 – 7.31 /// 129.4 
-NH2 7.55 – 7.04 s 7.68 – 7.15 s /// 
N
O NH
NH2
O
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H3C
O
N
H
N
O
NH3+
O
OH
Ph
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S3.2 CHARACTERIZATION OF THE COMPOUND 2c IN THE FREE-STATE AT 298 AND 283 K 
 
 
 
 
 
 
Table 3.2S 
1
H and 
13
C chemical shifts (δ in ppm) of compound 2c in buffer solution at 298 K and 
283 K. 
 
 
 
 
 
Compound 2c 
1
H(δ,ppm) 298 K 1H(δ,ppm) 283 K  13C 
NH_tBu 7.65 s 7.78 s /// 
CH3_tBu 1.23 s 1.23 s 28.0 
NH_isoLeu 8.11 d, 8.96 Hz 8.23 d, 8.96 Hz /// 
αH_isoLeu 3.94 t,8.58 Hz 3.93 t, 9.37 Hz 58.5 
βH_isoLeu 1.69 q, 7.93 Hz 1.69 q, 8.84 Hz 36.1 
γH_isoLeu 1.40, 1.12 m, 8.36 Hz 1.41, 1.13 m, 7.80 Hz 24.6 
CH3_isoLeu 0.84 d, 7.29 Hz 0.85 d, 7.42 Hz 14.3 
CH3_isoLeu 0.79 t, 7.93 Hz 0.79 t, 8.02 Hz 9.3 
NH10 
Not 
observable 
/// 8.64 s broad /// 
αH_Asp 4.05 dd, 10.28 – 3.91 Hz 4.06 dd, 10.73 – 3.80 Hz 51.0 
βH_Asp 2.60 dd, 17.92 – 3.94 Hz 2.61 dd, 18.11-3.58 Hz 37.5 
2.40 dd, 17.92-10.33 Hz 2.39 dd, 18.11-10.73 Hz 
DKP_H6 4.45 m 4.44 t broad 51.2 
DKP_H7 
3.06 dd, 17.43-4.84Hz 3.10 dd, 18.21-4.68Hz 
37.7 
2.83 dd, 17.43-4.34Hz 2.82 dd, 18.21-4.16Hz 
DKP_NH1 
Not 
observable 
/// 8.56 s /// 
DKP_H9 
3.74 d, 14.87Hz 3.73 d, 16.31Hz 
40.9 
3.52 dd, 14.87-5.29Hz 3.50 d 
DKP_H3 4.29 m 4.33 s 59.1 
CH2_Bn 
Under water /// 4.57 d broad 
/// 
Under water /// Under water /// 
H_Ar 7.28 /// 7.31 /// 128.6 
H2N
H
N
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H
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S3.3 CHARACTERIZATION OF THE COMPOUND 3c IN THE FREE-STATE AT 298 AND 283 K 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3S 
1
H and 
13
C chemical shifts (δ in ppm) of compound 3c in buffer solution at 298 K and 
283 K. 
 
 
 
 
 
Compound 3c 
1
H(δ,ppm) 298 K 1H(δ,ppm) 283 K 13C 
NH_tBu 7.49 s 7.65 s /// 
CH3_tBu 1.23 s 1.23 s 27.7 
NH_isoLeu 7.93 d, 8.26 Hz 8.10 d, 8.86Hz /// 
αH_isoLeu 3.92 t, 8.51 Hz 3.92 t, 8.51Hz 58.8 
βH_isoLeu 1.71 q, 8.99 Hz 1.70 m 35.6 
γH_isoLeu 1.40, 1.08 m, 7.49 Hz 1.41-1.07 m, 7.87Hz 24.7 
CH3_isoLeu 0.78 t, 7.74 Hz 0.78 t, 7.77Hz 9.8 
CH3_isoLeu 0.83 d, 7.28 Hz 0.83 d, 7.19Hz 14.6 
NH10 Not visible /// 8.65 s broad /// 
αH_Asp 4.09 dd, 7.36-5.52 Hz 4.13 dd, 7.73 -5.52Hz 50.9 
βH_Asp 2.67 dd, 17.50-5.79Hz 2.70 dd, 17.30-5.52Hz 37.2 
2.61 dd, 17.50-8.18Hz 2.63 dd, 17.30-8.10Hz 
DKP_H6 4.45 m 4.48 t broad 51.0 
DKP_H7 
3.05 dd, 17.17-3.98Hz 3.07 dd, 17.22-3.88Hz 
36.7 
2.79 dd, 17.17-5.03Hz 2.78 dd, 17.22-5.01Hz 
DKP_NH1 Not visible /// 8.49 s broad /// 
DKP_H9 
3.82 dd, 15.00-5.14Hz 3.83 dd, 15.08-5.00Hz 
39.1 
3.72 dd, 15.00-3.11Hz 3.73 d, 15.00Hz 
DKP_H3 4.01 m 4.02 s broad 59.0 
CH2_Bn 
5.14 d, 16.12Hz 4.24 d, 15.82Hz 
47.3 
4.20 d, 16.12Hz 5.18 d, 15.82Hz 
H_Ar 7.39-7.34 /// 7.36 /// 128.7 
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S3.4 REFERENCE COMPOUNDS 
NMR experimet of ADH-1 with EC1-EC2 fragment of E-cadherin 
Preliminary NMR experiments were performed on the reference compound ADH-1 and E-
cadherin EC1-EC2 domain. However, we were not able to find a suitable irradiation frequency for 
the STD experiments
5
 since the STD signals in the presence of E-cadherin were the same observed 
for the ligand in the absence of protein (control experiment).  
 
NMR experimet of tripeptide AWA with EC1-EC2 fragment of E-cadherin 
For this reason, we used other compounds to set up the experimental conditions. 
Unfortunatly, the natural DWVI sequence was not soluble in the phosphate buffer used for our 
experiment. We then performed NMR experiment using a commercially available tripeptide 
containing a Trp residue in position 2, i.e. AWA. In docking calculation into E-cadherin model, the 
peptide was able to satisfy the key binding requirements placing the indole ring into the 
hydrophobic pocket and forming the salt bridge between N-terminal NH3
+
 group and receptor 
Glu89 side chain. The NOESY spectra both at 298 K and 282 K did not give evidences of preferential 
conformation and in the tr-NOESY spectra the NOE contacts were the same that characterized the 
compound in the free state. STD-NMR experiments at 283K showed a signal for the indole NH 
(Figure 3.1S). The other aromatic protons signals overlap to the STD spectrum performed in the 
absence of protein (control experiment). 
 
 
 
 
 
 
 
Figure 3.1S Low field region (amidic and aromatic region) of the STD and 
1
H of AWA at 283 K.  
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S3.5 CHARACTERIZATION OF THE COMPOUND AWA IN THE FREE-STATE AT 283 K 
 
 
Protons 
1
H(δ,ppm) 283 K 13C 
NH2_Ala1 /// /// 
αCH_Ala1 3.70, q, 7.28 Hz 49.1 
CH3_Ala1 1.20, d, 7.58 Hz 16.9 
NH_Phe /// ///// 
αCH_Phe 4.42, s broad 54.7 
CH2_Phe 
3.08, dd, 14.83-5.59Hz 
2.98, dd, 14.83-8.39Hz 
26.8 
HAr-Phe (b) 7.02, (d, 1.72Hz) 124.7 
HAr-Phe (e,f) 
6.98, t, 7.79Hz 
6.91, t, 8.09Hz 
121.7 
119.33 
HAr-Phe (g, d) 
7.42, d, 8.49 Hz 
7.24, d, 8.49 Hz 
118.31 
111.92 
NH_Ala3 7.59, d, 6.86 Hz //// 
αCH_Ala3 3.77, q, 7.28 Hz 51.0 
CH3_Ala3 1.02, d, 7.58 Hz 17.9 
NH_indol 9.89, s ///// 
Table 3.4S 
1
H and 
13
C chemical shifts (δ in ppm) of AWA in buffer solution at 283 K. 
 
H2N CH C
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N
H
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CH3
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1 2 3
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